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FUNCTIONALISED MACROCYCLES FOR TUMOUR TARGETING 
ABSTRACT 
Monoclonal antibodies which recognise tumour-associated antigens 
~rovide a means of targetinrr radionuclides selectively to tumour cells. 
9mTc and 64Cu are potentially useful isotopes for radioimmunoimaging; 
goy and 67Cu may be suitable for radioimmunotherapy. 
The synthesis of functionalised macrocycles for binding these four 
radioisotopes to antibodies is described. In each case, a macrocycle 
has been selected to provide a complex which is kinetically inert, 
thereby preventing dissociation of the radiolabel in vivo. 
A novel strategy for conjugating a C-alkylated cyclam derivative 
(for binding Tc and Cu) to an antibody is described. This method 
facilitates the selective acylation of an exocyclic primary amino group 
in the presence of the secondary ring nitrogens. 
Unfortunately, the labelling of antibody-bound cyclam with 99mTc 
required conditions (pH 11) which produced extensive binding of the 
radiolabel to the protein backbone. "Non-specific" 99mTc Has 
subsequently found to dissociate in vivo. Pre-labelling the macrocycle 
with 99 mTc solved the "non-specifics" problem but required a pH Hhich 
meant that the conjugation step was too sloH for sufficient specific 
activity to be bound. A phenol-pendent derivative of cyclam Has found 
to incorporate 99 mTc at a lmver pH than cyclam itself. 
The "non-specific" binding of copper to the protein was minimised 
~~~~~~~~~~H~~~!t~~~l~~~9--~~:~~e~~L~~,:~nJ~n:~~~n-~it~ a che~~t~ Hash. 
mu.vJ.V'-'J'-'.L'-' U.llu.LUVUJ \..VHJUC,CLu~i::l .!.CLU~.l..l.CU .l.H ull.l.i::l lllCLHllCl. !'l.VV.l.UCU VCJ.Y 
promising biodistribution profiles in normal mice. 
A labelling buffer was selected to enhance the rate of uptake of 
copper by the macrocycle at loH pH. ~[acrocycle-antibody conjugates 
containing 13N4 , Hhich was found to provide faster association kinetics 
than cyclam, have been prepared and a\vai t radio labelling studies. 
A derivative of 13N4 , containing 4 carboxylic acid donor sites, has 
been functionalised for conjugation to an antibody to act as a 90 Y 
binder. 
J.R. MORPHY (1988) 
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CHAPTER ONE 
INTRODUCTION 
1 -
1 .1 CANCER. - 'll'lliE NEED FOR. THERAPY IMPROVEMENT 
1.1.1 Uhat is Cancer?1 
Cancer is a disorder of cells which normally appears as a tumour (a 
swelling), made up of a mass of cells. The visible tumour is the end 
result of a whole series of changes which may have taken many years to 
develop. Tumours contain cells which are capable of abnormal growth, 
since they no longer respond to normal growth-control mechanisms; 
thereby invading and damaging surrounding normal tissues. Strictly 
speaking a cancer is a malignant tumour (there are also benign types) 
capable of shedding cells which are carried to distant organs where they 
may produce secondary tumours (metastases). 
Carcinogenesis is a multistage process - after an initiation step 
involving the carcinogen, another substance is required to promote 
growth of the tumour. The initiated cell may lie dormant for many years 
before its activation by the promoting agent. Carcinogens damage or 
destroy, as yet unknown, sequences of genes in the cellular DNA of the 
i:uitia.t.:;d c.:;ll. Tiley ma.y ue physicai e.g rad1at10n and UY light, or 
chemical e.g nicotine, benzene, chlorinated hydrocarbons etc. Animal 
experiments suggest that viruses may be associated with the initiation 
of some forms of cancer (mainly leukaemias). There is considerable 
evidence that increased susceptibility to various forms of cancer may be 
inherited, although in the end environmental factors (e.g diet, tobacco, 
UV exposure etc.) usually determine whether or not the disease develops. 
- 2 -
1.1.2 The Incidence of Cancer 
Cancer is a common disease In the developed world, responsible for one 
death in every five. Most cancers develop late in life. Hence the 
elimination of the common diseases of childhood and of infectious 
diseases, since the middle of the 19th century, has dramatically 
increased the proportion of older people at risk. 
Cancers can occur in any tissue of the body. The most common in 
the USA in 1984 Here those of the lung, lmver intestine (colon/rectum) 
and breast (Figure 1.1 top). In Japan, stomach cancer is a much more 
common cause of death (almost certainly diet-associated). These cancers 
are also amongst the most difficult to treat; the 5 year survival rates 
being relatively lmv (Figure 1.1 bottom) . Improving the treatment 
available for these four types of cancer is the aim of this research 
project. 
1.1.3 An Outline of the Project. 
Although the exact nature of carcinogenesis remains largely unknown, it 
appears that potential cancer cells arise constantly within us 
("initiation"). llmvever the change in the character ("antigen 
complement") of these cells is usually sufficient to alert the immune 
system, whose white cells and natural antibodies seek out and destroy 
the mutinous cells. When the immune system fails to recognise these 
cells, cancer develops. This project aims to fight cancer by providing 
antibodies which the body itself has failed to produce. If these 
antibodies can be tagged with radioactive isotopes, it may be possible 
to detect and destroy tumour cells in situ, with minimal damage to 
normal tissue. 
- 3 -
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Since the project is multidisciplinary in nature, there are a 
number of research groups involved. Celltech Ltd. (of Slough) have 
expertise in the production and genetic engineering of monoclonal 
antibodies. The MRC Radiobiology Unit at Han.;ell provides wide 
experience of the use of radioisotopes in nuclear medicine. The Durham 
branch of the project aims to develop appropriate methods for attaching 
radioisotopes to monoclonal antibodies. 
1.2 ANTIDODIES1-5 
-----------------------------------------------
1.2.1 What are antibodies ? 
Antibodies are proteins, called Immunoglobulins, produced by vertebrates 
in response to infection by pathogens and other foreign substances. 
They invoke a response by the immune system which ultimately leads to 
the elimination of that substance from the body. Antibodies are 
produced by the white blood corpuscles called B-lymphocytes. B-cells 
are manufactured in the bone marrow but migrate soon afterwards to the 
lymphatic system, especially the lymph nodes and spleen. There they 
remain dormant until alerted to the presence of foreign substances by 
another group of white cells called T-lymphocytes. Once alerted they 
proliferate rapidly and produce huge quantities of antibodies which 
recognise the invading substance as foreign, stimulating its destruction 
by a third group of white cells, the macrophages. 
Antibodies recognise a foreign material, the antigen by binding 
with partial structures (determinants) on its surface in a highly 
specific manner. Each B-lymphocyte produces a single type of antibody 
with specificity for one determinant on one antigen - a monoclonal 
- 5 -
antibody. The specificity of monoclonal antibodies is generally so 
precise that higher animals can produce antibodies to a wide range of 
foreign molecules \vhich differ only slightly from the animal's own 
molecules. The key to this specificity lies in the highly complex 
three-dimensional structure of the protein. 
1.2.2 The Structure and Specificity of Antibodies 
Antibodies are symmetrical molecules and consist, in the case of 
Immunoglobulin G (IgG - the most common type in the bloodstream) of two 
identical "heavy" chains (50000 daltons) and tHo identical 11 light 11 
chains (25000 daltons). The four polypeptide chains are linked by 
disulphide bonds, the light chains to the heavy chains and the heavy 
chains to one another in the 11 hinge region". Although the overall 
effect is a complex three-dimensional structure, it can be approximated 
to a two-dimensional 11Y11 form (Figure 1.2). 
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domains 
constant 
domains 
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~ J 
ligh;\. 
chain '\)P.,-"'" 
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'tl..._ complement binding 1 EFFECTOR 
v--- monocyte binding \ FUNCTIONS 
Figure 1.2 The structure of IgC 
Each heavy chain consists of a variable domain and three constant 
domains; the light chain contains a variable domain and a single 
constant domain. The variable and constant domains of one light chain 
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fold over the variable and first constant domain of a heavy chain to 
give a ''Fab'' arm (Fab = fragment antigen binding) which contains a 
single antigen binding site. Each antibody molecule is therefore 
bivalent, having two identical binding sites. The other constant 
domains of the heavy chain form the stem of the molecule, the "Fe" 
portion (Fe= fragment crystallisable), which interacts with the immune 
system through its effector functions. 
It is principally the spatial arrangement of amino acid residues 1n 
the variable domains which determines the individual antigen-binding 
specificity of an antibody molecule. These antigen-binding sites 
constitute unique 3D structures called "idiotypes" and are complementary 
in shape to that of the determinant. 
1.2.3 Antibodies for Cancer Treatment 
The development of monoclonal antibodies in recent years has revitalised 
the search for a so-called "magic bullet" treatment for cancer. The 
theoretical basis of this concept is a simple one. Tumour cells have 
upon their surfaces specific molecules, termed "tumour-associated 
antigens", which are not found, or at least are less numerous, on the 
surfaces of normal cells. Pressman was the first to realise that an 
antibody with the relevant specificity for these antigens could be used 
to carry radioactivity to the site of a tumour, where it would 
accumulate preferentially. The main obstacle to the development of this 
approach was the difficulty of raising antibodies with sufficiently high 
specificity for the target antigen. 
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1.2.4 Polyclonal Antibodies 
Antibodies are raised by injecting the tumour-associated antigen into 
mice and collecting the antibody-producing B-cells from the spleen. 
However the normal antibody response of an animal to a foreign antigen 
is to produce an enormous diversity of antibody structures directed 
against different antigens, different determinants of a single antigen 
and even different antibody structures against the same determinant -
these are polyclonal antibodies. Since individual antibody molecules 
are extremely similar chemically, once mixed in a polyclonal serum, they 
cannot be separated from one another. l~ere these polyclonal antibodies 
to be tagged with radioactivity and injected into a patient, they ,.;ould 
bind non-specifically to tissue not associated with the tumour, damaging 
normal as well as malignant cells. 
1.2.5 Monoclonal Antibodies 
It was not until the development of "hybridoma" technology by Kohler and 
Milstein6 in 1975 that antibodies with sufficiently high specificity for 
tumour targeting (monoclonal antibodies) were available. B-lymphocytes 
from the spleen of mice, immunised against a sheep antigen, were 
immortalised by fusion with mouse myeloma cells (X63-Ag8), in the 
presence of a fusion-promoting agent (Sendai virus; polyethylene glycol 
4000; dimethylsulphoxide), to produce hybrid cells called hybridomas 
(Figure 1. 3). 
A myeloma is a malignant B-lymphocyte tumour whose cells normally 
secrete immunoglobulins but X63-Ag8 was specifically selected for its 
inability to produce Ig. 
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Figure 1.3 Production of a monoclonal antibody 
The hybridoma inherits both the capacity of the myeloma cell-line for 
continuous proliferation and the capacity of the B-lymphocyte to 
synthesise and secrete a single specific antibody. 
In the second stage of the protocol, the so-called "HAT" selection, 
hybridoma cells are separated from unfused myeloma cells by growing the 
cell mixture 1n a culture containing nutrients which are useful in the 
synthesis of hybridomal DNA but not myelomal DNA. Finally the mixture 
of purified hybridoma cells is screened to identify and isolate those 
hybridoma clones which secrete the antibody of interest. This is usually 
done by diluting the suspensions of hybridoma cell mixtures into 
individual wells of plastic microtitre plates such that each well 
contains, on average, less than one cell. The clones are allo~ed to 
grow and the content of each well is assayed for the presence of the 
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desired antibody. The dilution procedure is repeated until the cell-
line producing this antibody is truly monoclonal. Virtually unlimited 
quantities of highly specific anti body can be produced in this \·lay. 
1.2.6 Human Monoclonal Antibodies 
One factor which limits the usefulness of mouse monoclonal antibodies 
(murine Mab's) for cancer treatment in humans is that they are 
inherently immunogenic. Human Mab 1 s \VOuld be less immunogenic since they 
possess the same constant domains as normal human Ig. Unfortunately the 
production of human Mab's by the hybridoma method is much more difficult 
than that of murine Mab's. Human B-lymphocytes are necessarily more 
difficult to obtain since tumour-associated antigens can hardly be 
injected into humans. In some cases, they may be recovered from the 
blood of individuals already exposed to the antigen, such as cancer 
patients who have the ability to make antibodies against tumour 
antigens. Furthermore human B-cells are more difficult to fuse with 
suitable human myeloma cell-lines, of which there are few. 
Other ways of immortalising human antibody-forming cells are being 
sought; in the meantime, two other methods for reducing immunogenicity 
in humans are being explored - antibody fragments and chimaeric 
antibodies. 
1.2.7 Antibody Fragments 
Since the antigen-binding site lies within the variable region of the 
antibody, the remaining portion, the Fe region, is not necessary for 
targeting radioisotopes. Moreover, the appreciation that the Fe region 
of murine Mab's could be immunogenic in humans, and reduce the 
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specificity of the antibody for the tumour, led to the use of antibody 
fragments rather than the whole molecule. 
Where the first and second constant domains of the heavy chain 
meet, there is a short mobile polypeptide piece ("s1vitch region") 
containing the functionally important hinge region where the tHo heavy 
chains are joined by disulphide bonds. This region is particularly 
susceptible to attack by protease enzymes. The enzymes plasmin and 
papain cleave the IgG molecule into Fe and t1w monovalent Fab fragments 
(Figure 1.4 left). Pepsin cleaves IgG into Fe' and one F(ab') 2 fragment 
(Figure 1.4 right). 
Fo PORTION I \~o/ 
papain / 
digestion/ A 
\\ II 
\Y 
Fab fragments 
+ Fe (digested) 
I Fab ARM 
F(ab') z fragment 
+ Fe' 
Figure 1.4 Proteolytic fragments of IgC 
The use of Fab and F(ab') 2 fragments may have other advantages besides 
reducing immunogenicity. Their smaller size should improve access to 
more hindered sites within the tumour. Since they are cleared more 
rapidly from the circulation than intact Ig, the radiation background 
and whole body dose may be minimised. 
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1.2.8 Chimaeric Antibodies7 
Using recombinant DNA technology, it is noH possible to combine portions 
from one antibody gene Hith segments from another to produce completely 
novel types of antibody. Chimaeric antibodies contain the variable 
region of a murine Mab joined to the constant regions of a human Mab. 
Chimaerics may be less likely to trigger an immune response in humans 
than all-mouse Mab's provided that the immune attack is primarily 
directed against the constant region. 
1.2.9 Tumour-Associated Antigens 
mwn a normal cell becomes malignant it can express antigens lvhich are 
not produced by the parent cell such as altered carbohydrates and 
proteins and oncofoetal antigens Hhich reflect the tendency of tumour 
cells to become more primitive (Figure 1.5). These antigens may be 
tumour specific or, more commonly, highly selective for certain types of 
tumour cells. 
altered carbohydrate mutant protein 
proliferation-linked virally-coded 
determinant protein 
oricofoetal antigen normal tissue antigen 
Figure 1. 5 Target Ant igen.s 
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It is actually quite rare for an individual Mab to bind exclusively to 
the target cell since normal tissue may express either the same antigen 
or a strncturally indistinguishable molecule. Since a tumour cell 
membrane expresses a large number of antigens, the key to successful 
targeting is to identify those Hhich are most characteristic of that 
individual cell-type. 
Consideration must also be given to the tendency of certain 
antigens to be shed from the tumour into the bloodstream. In addition 
many tumours have regions ''hich are devoid of a particular antigen. The 
importance of these "cold regions" will be discussed in section (6.1). 
Judicious choice of the target antigen, and its complementary Mab, is 
therefore crucial for the overall success of this approach. 
1.3 RADIOISOTOPES FOR TUMOlm TARGETING 
1.3.1 General Criteria for the Selection of Radioisotopes8-11 
The primary consideration governing the choice of a suitable radio-
isotope is the purpose for which the antibody is to be radiolabelled. 
The desired physiological effect of the radiation is markedly different 
depending upon ~~hether the primary aim is diagnostic (radioimmuno-
irnaging) or therapeutic (radioirnmunotherapy). 
For imaging purposes, minimal interaction of radiation is desired 
with the tissues of the patient and maximum interaction Hith a detector 
located outside the body. Gamma emitters may be suitable in this respect 
if they deliver photons of appropriate energy to escape from the body 
and with sufficient density to achieve the necessary resolution for 
tumour imaging. 
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In radioimmunotherapy, the intention is to deliver as much energy 
as possible at the target site, thereby delivering a sterilising dose of 
typically 500-2000 rads. Suitable sources emit largely particulate 
radiation, a particles or, more commonly, (J particles, with little or no 
gamma component. The contrasting radiation requirements for imaging and 
therapy are summarised belmv': 
Therapy 
Beta rays are useful since they deliver ionizing 
radiation to the limited are:1 that is to be treated. 
Gamma rays are of little therapeutic value 
(except those of very low energy) since they 
distribute the radiation exposure over a wide 
area. 
There may be a role for longer lived radio-
nuclides if the radiation has to be delivered over 
a period of time. 
Diagnosis 
Beta rays can not be visualized externally and 
only increase tissue radiation exposure. 
Gamma rays are of primary importance in 
imaging (except those of low energy. which do 
not penetrate the tissue). 
Short-lived radionuclides are preferred since 
they do not have to be present after the initial 
images are obtained. 
Another important factor which differs for imaging and therapy is the 
physical half-life of the radioisotope, usually being longer for therapy 
than for imaging. The physical t 1 of an imaging radioisotope is the 
2 
minimum time necessary for localisation of the radiolabelled Mab in the 
tumour, followed by the diagnostic procedure itself, in order to limit 
the radiation dose to the patient. For therapy, the desire is to 
maximise the radiation dose to the tumour. Providing the Mab is 
sufficiently specific towards the target tissue and has a suitably long 
biological half-life, it is useful to deliver sterilising radiation over 
a period of several days from a longer-lived radioisotope. 
In addition to the aforementioned criteria, there are also a number 
of additional factors governing the choice of radionuclide which are 
common to both imaging and therapy. 
The decay of the radioisotope should ideally produce a stable 
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daughter product in order to reduce the hazard to the patient. The 
recoil produced by particulate emissions, especially of a particles, may 
rupture the bond bet1-1een the radionuclide and the a.nt i.body allm>ing it 
to diffuse randomly throughout the body. In addition, radioactive decay 
usually produces a different element with different chemical properties 
for '"hich the mode of attachment to the antibody may be less sui table, 
alloHing it to become detached from the protein. If active daughter 
products are produced, they should be rapidly eliminated from the body. 
The method of production of the radionuclide should be straight-
fon.;ard and relatively economical, such that the radioisotope is readily 
available for medical use. Its chemical properties must be sufficiently 
different from those of the nuclide from which it is prepared (the 
''carrier" material) to permit its purification by chemical means. The 
use of "carrier-free" material is particularly important for therapy, 
since a sterilising dose can only be delivered if a substantial amount 
of active material is attached to each antibody molecule. 
Finally the chemical properties of the radionuclide must allow its 
attachment to the antibody by a stable radionuclide-protein bond, and in 
sufficient quantity to provide the specific activity necessary to 
produce the desired effect, whilst retaining the the immunoreactivity of 
the antibody. Metals are usually better than non-metals in this respect 
since they allmv more flexibility for the chemist and usually form 
stronger radionuclide-antibody bonds. 
Suitable radionuclides for therapeutic applications are discussed 
further in section (6.2). For now, the emphasis will be placed on the 
select ion of radioisotopes for imaging and their attachment to ~lab's. 
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1 3 2 I . I . 12 . . n vzvo mag1ng 
Often the life-threatening nature of cancer arises not from the primary 
tumour but from the spread of the disease to other critical organs. The 
development of in vivo imaging as a means of detecting a broad spectrum 
of cancerous growths within a patient, including smaller secondary 
growths called metastases, is crucial to the success of antibody-based 
cancer therapy. Large accessible tumours are probably best removed by 
surgery, smaller less accessible metastases by radioimmunotherapy1 
(Figure 1.6). As well as providing useful information about the size, 
morphology and location of tumour deposits, in vivo imaging is vital for 
prognosis and for monitoring the effect of therapeutic radiation upon 
the tumour during the course of the treatment. 
patient with 
primary tumour 
radioactive 
antibody injected 
into patient 
metastasis 
detected 
surgical removal 
of primary tumour 
and metastasis 
Figure 1.6 The Principle of radioimmunoimaging 
Electromagnetic radiation of suitable energy for in vzvo imaging, to 
which the human body is "transparent", has a frequency of either less 
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than 1010 Hz or greater than 1018 Hz. Nuclear medicine exploits the 
high energy gamma ray "windmv". At the lmv energy side of the spectrum, 
imaging techniques based upon nuclear magnetic resonance are being 
developed. 
m1R imaging13 ,16 exploits the differences in the relaxation times 
of water protons depending upon their location within the body. If a 
superparamagnetic nucleus can be targeted to a tumour site, the 
relaxation times of tumour-associated protons will be sufficiently 
shorter than those of protons in the surrounding tissue to allaH the 
tumour to be imaged by NMR. Unlike gamma radiation, radiofrequency 
waves are thought to be completely harmless to the patient. Hmiever the 
field of NMR imaging is still in its infancy and it may be several years 
before it can compete with gamma ray imaging in terms of cost, 
sensitivity and resolution. 
Gamma rays sui table for radio imaging can be produced in t1w 
different 1vays. Either they result directly from the nuclear decay of 
the isotope - single photon emitters - or the isotope emits a positron 
(p+) and creates two opposing 511 keV gamma rays by electron-positron 
annihilation. The two techniques are completely different in terms of 
the method of detection of the gamma ray and the type of image thereby 
obtained. 
1.3.3 Single Photon Emission 
A static Anger camera is required to provide an image of the tumour 
(Figure 1.7). In vieH of the random direction of emission from single 
photon-emitting isotopes, a collimator is required to localise the 
radiation upon the detector. The detector is a Nai (Tl) crystal which 
produces a flash of light when struck by a gamma particle. These light 
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flashes are amplified with photomultipliers and counted as electrical 
pulses. The resolution of an Anger camera is typically 1-2 em, hhich is 
much coarser than that obtainable using X-ray techniques. 
Preamplifiers 
Photomultiplier 
tubes 
Signal processing 
' - .•. -.. . ~ . 
Collimator 
Figure 1.7 The Anger camera layout 
1.3.4 Tomography1,12 
1 
A two-dimensional image of a tumour on a plate often contains artefacts 
and false positive regions. It is preferable to assemble a three-
dimensional picture of the tumour by recording the activity from a 
series of slices taken across the body of the patient - this process is 
called tomography. Tomography can be carried out by mounting the Anger 
camera on a rotating gantry, recording multiple images at different 
angles of the patient and reconstructing the activity distribution 
through a back-projection process. The need for physical collimation, 
which reduces the count-rate at the crystal surface 1000 fold, makes 
single photon emitter computerised tomography (SPECT) a much less 
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sensitive and accurate technique than positron emission tomography 
(PET). 
1.3.5 Positron Emission Tomography14 
The data provided by positron emitters can be processed to give 
tomographic information without the need for physical collimation, by 
virtue of the directional nature of the emission ("electronic 
collimation''). The annihilation of a positron "at rest 11 by a standstill 
electron implies the emission of two perfectly anti-parallel quanta. 
Due to the relative motion of positron and electron, the distribution is 
actually gaussian about 180° (± 0.5°). 
{~ 
--- --~---0 0--- -~ ----
}~ 
In PET, the two gamma rays are detected at each side of the source. 
This confines the annihilation event to a single line joining the two 
detectors (Figure 1.8). 
Figure 1.8 Schematic drawing of the first PET scanner 
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In conventional PET, a distribution plot of the radioisotope throughout 
the tumour is constructed from the pattern of coincidences as the t'vo 
scanners are rotated around the patient. More modern detector 
configurations are shmm in Figure 1.9; a planar annular ring of 
scintillators, a large area planar detector and the most recent 
development, multiring configurations. 
p) bl 
c) d) 
Figure 1.9 Examples of PET camera configurations: a) two 
opposite Anger cameras; b) single ring; c) hexagon 
planar camera; d) multiring 
In "Time-of-Flight" PET, the position of the isotope can be found very 
precisely by calculating the difference in the time of arrival of the 2 
photons (t1-t2) onto opposite detectors 1 and 2, using the relation: 
(d1-d2)/c = t 1-t2 
where d is the distance from the detector and c is the speed of light. 
Generally PET techniques produce very high resolution images, 
theoretically down to 3-4 mm, which are vastly superior to those given 
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by SPECT. The main disadvantage of PET is that the special camera 
presently required is very expensive, typically ten times the cost of an 
Anger camera. This will remain the main obstacle to the widespread 
application of PET as a routine tool for in vivo imaging until cheaper 
equipment becomes available. 
1.3.6 Choice of Single Photon Emitters8' 9' 10 
In addition to fulfilling the general criteria outlined in section 
(1.3 .1), single photon emitters suitable for radio imaging are 
characterised by 
(1) a half-life of bet1~een 6 hours and 8 days 
(2) a gamma energy of bet1~een 80 and 240 keV 
(3) high energy single gamma abundance per decay 
( 4) zero or small abundances of 101~-energy particulate radiations 
(5) chemical properties 1~hich facilitate their attachment to 
antibodies 
Examples of radionuclides which fulfill some or all of these criteria 
are given in Table 1.1 
Nuclide tl Emax (J Ephoton Source 
2 (MeV) (keV %) 
99m 6.02h 141(89) Tc generator 
123 
I 13h 159(83) cyclotron 
125 
I 60.00d 27(138) cyclotron 
1 3 l 
364(82) I 8.05d 0.188 reactor 
1 1 1 
In 2.83d 171 (88) reactor 
Table 1.1 Radionuclides used or useful for radioimmunoimaging 
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Technetium15 -18 
99IDrct has been the most widely used radioisotope in nuclear medicine 
for many years for two principal reasons. 
Firstly it delivers gamma rays of an almost ideal energy (140 keY) 
for detection by the Nai (Tl) crystal of an Anger camera. 99~c is 
relatively safe - there are no particulate emissions and the abundance 
of single energy gamma rays allows a lmv- specific activity to be used. 
Secondly, since 99mTc is obtained from a 99Mo generator, it is 
readily available in a "carrier-free" form. It can be transported 
easily from the production to the application site and is cheap and 
convenient to use. Radioactive generators are column-chromatographic 
devices which can separate the components of a radioactive decay chain. 
In this case, the daughter isotope 99mTc (t 1 = 6h) can be separated from 
2 
its parent isotope 99Mo (t 1 = 66h) by eluting an alumina/silica column, 
2 
onto which the parent is absorbed, with an isotonic (0.9%) saline 
solution (Figure 1.10). The eluate, a saline solution containing 99"Tc, 
is collected with a lead-shield evacuated vial. Since 99Mo continuously 
decays to 99"Tc, after a suitable time delay further batches of 99mTc 
may be eluted from the column. One major benefit of the generator 
system is that it provides supplies of the daughter isotope for much 
longer than its own half-life allows. For example a single 99Mo 
generator provides a supply of 99"~c for a period of up to 7 days. 
Iodine isotopes2,15 
Three isotopes of iodine, 1231, 1251 and 1311, have been investigated 
for diagnostic use. 123I shares with 99mTc the benefit of abundant, 
single energy gamma emissions particularly suitable for detection using 
t"m" stands for "metastable" and signifies an excited nuclear state with 
an unusually long life-time. 
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an Anger camera. However unlike 99mTc, 123I is a cyclotront product and 
is consequently much more difficult and expensive to produce in a 
"carrier-free" form. 125I is much less suitable for diagnosis by virtue 
of its long half-life (60 days) and the low energy of its gamma 
emissions. 
99mrc 
GENERATOR 
(alumina column) 
Figure 1.10 Technetium-99m generator 
131I was the first isotope to be used for radiolabelling antibodies 
with the intention of imaging tumours, but has noH fallen into 
disfavour. Its gamma energy (364 keV) is rather too high to be detected 
efficiently using a Anger camera and its particulate (jJ) emissions 
increase the absorbed radiation dose to the patient unnecessarily. 
Iodine isotopes also suffer from the disadvantage of rapid de-
iodination from the Mab in vivo, releasing the radioisotope to circulate 
randomly through non-target tissue and to accumulate in the thyroid 
gland. 
tA cyclotron is a type of particle accelerator in Hhich a target 
material is bombarded Hith projectiles e.g protons accelerated under the 
influence of magnetic and electrical fields. 
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Indium 
An isotope of indium, 111In, is the only serious competitor to 99~c as 
a gamma source for scintigraphy. Although its gamma emissions are less 
well matched to an Anger camera than those of 99mTc, 111rn has the 
advantage of a longer half-life (2.83 days) which allows more time for 
the radiolabelled antibody to accumulate in the tumour and clear from 
the bloodstream. Often useful tumour : background relationships are 
only available after 2 days2, less than one half-life for 111In. For 
99~c, less than 0.5% of the original activity will remain after 2 days, 
probably insufficient for imaging purposes unless a high initial 
specific activity is used. If the accumulation/clearance time can be 
reduced by use of antibody fragments 2, Fab and F(ab 1 ) 2 (section 1.2.7), 
990Tc will be less disfavoured. On the grounds of cost and availability, 
99mm . h . . b b . d f 1111 1c IS t e easy winner - It can e o taine rom a generator, n 
cannot. 
Cl 1 . 1 99IDm 111r I . d 1 1 . . ear y neitler 1c nor n 1as I ea nuc ear properties 1n 
every respect. Their relative merits and drawbacks are summarised In 
Table 1.2. Also included in the table are a number of other 
considerations, largely influenced by the chemical rather than the 
nuclear properties of the isotopes. Some of these factors only came to 
light during the course of our work and will be discussed in more detail 
in subsequent chapters. For the time being, suffice it to say that 
either one of these isotopes is worthy of serious consideration for zn 
vivo imaging. 
1.3.7 Choice of Positron Emitters 
The positron emitters 82Rb and 68Ga are widely used in PET studies since 
they are readily available from 82sr and 68Ge generators respectively14 . 
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However their physical half-lives, 1.4 and 1.1 minutes, are too short 
for our purposes; there being insufficient time for localisation of the 
radiolabelled antibody in the tumour. 
TECHNETIUM 
Merits 
1. Abundant single E gamma 
emissions 
2. Ideal E (141 keV) for 
detection 
3. Cheap and readily available 
from a generator 
Dra\vbacks 
l.Very short t 1 /2 (6.0 h) 
2.Difficult and largely 
unknmm tracer level 
chelation chemistry 
3. 11 Non-specific 11 binding 
to antibodies 
INDIUM 
Merits 
1. No "non-specific 11 
labelling of antibodies 
2. Lon~er half-life (2.83 
days) than 99mTc 
DraHbacks 
1. Lmver abundance of 
suitable energy gamma 
rays than 99mTc 
2.Existinu chelating 
agents ~or binding lllin 
to antibodies are 
unsatisfactory esp.EDTA 
3.Hydrolyses easily to 
form colloids which 
increase the non-target 
..l~~~ 
uvuv .. 
4.Not available from a 
generator - lOx more 
expensive than 99mTc 
Table 1.2 Advantages and disadvantages of 99mTc and 111 Jn 
for radioimmunoimaging 
64cu is more suitable for antibody-based PET imaging by virtue of 
its longer half-life (12.8 hours). It has t\vO modes of decay, the 
dominant one being positron emission (see diagram overleaf). 64cu also 
has a very small gamma component (0.6%; 1.34 MeV). It is made from 64zn 
by a (n,p) reaction (section 4.1.1). The major disadvantage of 64cu is 
its cost, 100 times that of 99mTc and 10 times that of 111rn. 
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e 
(f 0.57 MeV 
tl 0.66 MeV 
2 gamma 0.51 MeV 
1.4 THE BINDING OF METALLIC RADIONUCLIDES 
Metallic radionuclides e.g 99Inrc, 64cu, 111In must be attached to 
monoclonal antibodies using a strong binding ligand. The donor atoms of 
the chelate may form part of the antibody itself or, more usually, 
belong to a separate chelating agent, selected for its high affinity for 
the radiometal, which is suitably attached to the Mab. 
1.4.1 Direct Labelling of Antibodies15 ' 19 
Direct labelling exploits the functional groups of the amino acids, 
which constitute the protein, to complex the metal. The great advantage 
of this method is its experimental simplicity, an important factor 1n 
the preparation of any radiopharn~aceutical. Unfortunately, direct 
protein-radiolabel bonds are usually labile if the stereochemistry of 
the donor groups does not match the preferred coordination geometry of 
the metal. 99mTc has been used to directly label Mab' s but the in vivo 
stability of the majority of the protein-metal bonds thus formed is low. 
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There are however a limited number of sites within the antibody, thought 
to be associated with thiol groups, which bind 99IDrc more avidly20 
(section 3 .1. 5). 
1.4.2 Use of Bifunctional Chelating Agents 
By far the most successful strategy for attaching radiometals to Mab's 
employs bifunctional chelating agents. The advantage of chelators is 
that they form bonds to metals which are generally much more stable than 
those formed by direct labelling. It is possible to tailor the choice 
of chelating group to match the distinctive coordination requirements of 
the radiometal which must be bound, optimising the "hardness" and number 
of donor atoms and the coordination geometry such that the complex is 
sufficiently stable for use in vzvo. 
Suitable chelating agents are bifunctional in the sense that they 
possess one site, containing a number of donor atoms, which binds the 
metal and another site through which the chelator can be linked to the 
antibody. The preferred form of the latter functionality will be 
discussed 1n section (1.7). The metal-binding functionality forms the 
basis of the current discussion. 
1.4.3 Thermodynamic and Kinetic Stability of Chelate Complexes for 
In Vivo Applications 
It is well knmm that complexes formed between metals and chelating 
ligands are generally more thermodynamically stable than those involving 
monodentate donor groups - this is the so-called "chelate effect". The 
strong driving force for complexation is often cited to be the large 
increase in translational entropy which accompanies the displacement of 
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a given number of solvent molecules by a smaller number of ligand 
molecules, e.g. 
M(H20) 6 + 31 ---1 M13 + 6II20 
M(H20) 6 + 21 ---1 M12 + 6H20 
The greater the denticity of the ligand, the larger the positive entropy 
contribution and the more thermodynamically stable the complex (assuming 
that enthalpy effects are minor!). 
Although thermodynamic stability provides a useful bench-mark by 
which we can judge the suitability of a particular chelate for zn v2vo 
use, it is not the major consideration. No matter hm~ high the stability 
constant of the complex may be, the establishment of equilibrium inside 
the body will encourage dissociation of the metal. This is a consequence 
of the extremely low concentration of radioactive chelates in vivo 
compared to the relatively high concentrations of competing chelatable 
metals (e.g Zn2+, Ca2+) and competing chelating ligands, notably the 
metal-binding proteins, albumin and transferrin21 . 
Dissociation of metals from chelating agents occurs by either an 
acid-catalysed or an acid-independent mechanism. Since the former 
process is much more rapid, the majority of the flux of the dissociation 
reaction occurs via this route. As a general rule, a metal-chelate 
complex becomes progressively less thermodynamically stable as it is 
more highly protonated (M1 > M1H > M1H2 > M1H3 etc): 
Kt K2 K3 
kt k2 k3 
M1 ~ MLH ~ MLH2 ~ MLH3 etc. k-1 k_ 2 k_ 3 
A more important factor governing in v2vo stability than the stability 
constant of M1 is therefore the kinetic inertness of the complex towards 
protonation (k1, k2, k3 etc should be slow). Additionally, the 
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protonation constants (K1, K2, K3 etc) should be low, such that the pH 
at which ML becomes extensively protonated and seriously destabilised is 
lowered. 
1.4.4 EDTA and DTI)A Chelating Agents 
The first chelate-protein conjugates which were considered sufficiently 
stable for in vivo use were based upon the polyaminocarboxylate ligands: 
ethylenediaminetetraacetic acid (EDTA) and diethylene tri-
aminopentaacetic acid (DTPA): 
EDTA DTPA 
These ligands form complexes with a huge number of different metal ions; 
:ll EDTA being a chelator for at least 70 different elements . However, 
many of these complexes are insufficiently stable for use in vivo. The 
very fact that EDTA forms complexes with so many elements, with a great 
range of chemical properties, implies that it is not tailored to satisfy 
the often distinctive coordination requirements of individual elements -
it is "jack-of-all-trades and master-of-none"! 
For some metals the particular combination of N and 0 donor atoms 
found in EDTA and DTPA is ideal, for others a combination containing 
"harder" or "softer" donors may be preferred. In some cases, there are 
insufficient donor sites for the metal to be coordinatively saturated, 
for other metals there are too many and carboxylate arms hang free. 
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The carboxylic acid arms of EDTA and DTPA are deprotonated when 
bound to metals, often resulting in anionic complexes. Inside the body, 
anionic complexes attract protons and other metal cations e.g Ca2+ and 
Zn2+. Since the main pathHay for cleavage of metal-nitrogen bonds 
involves acid (or metal) catalysis, metal complexes of EDTA and DTPA 
normally have low kinetic stability in vivo. This problem is 
particularly serious in those regions of the body where the pH is 101~. 
In the stomach and liver, the pH may be as low as 2. Under such acidic 
conditions, the metal-chelate complex is protonated and the overall 
species has a much reduced thermodynamic stability and a strong tendency 
to dissociate. 
1.4.5 Macrocycles for Metal Binding22 ,23 
In order to bind labile metal ions in such a manner that they are stable 
in vivo, nature often uses macrocyclic ligands; for example, the iron-
and magnesium-porphyrins of haemoglobin and chlorophyll and the cobalt-
corrin complex of vitamin B12 . The basic skeleton of the porphyrin ring 
contains 16 atoms. 
Figure 1.11 Basic skeleton of natuTally occuTTing poTphyTins 
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The metal sits in the plane of the four nitrogen donors which are 
arranged to give a sequence of 6-membered chelate rings (Figure 1.11). 
The corrin ring has a total of 15 atoms and a sequence of three 6- and 
one 5-membered chelate rings. In view of their unique chelation 
properties, many synthetic analogues of naturally-occurring tetraamine 
macrocycles have been synthesised during the last 3 decades and have 
been found to form complexes with a wide variety of metal ions. To 
fully encircle a first-row transition metal ion, a macrocyclic ring size 
of between 13 and 16 members is appropriate, providing that the nitrogen 
donors are arranged to give five-, six- or seven-membered chelate rings 
(Figure 1.12). Smaller rings e.g 12N4 can only be accommodated if the 
macrocyclic folds and does not completely encircle the metal ion on 
coordination. 
n 
[
NH HNJ 
NH HN 
I I 
~
(] 
~H HNJ 
LNH HN 
I I 
(I (I (I 
[ 
NH HN\ [NH H~ CNH HN\ 
NH HN_/ NH HN_j NH HN_/ 
I I V lJ 
5 6 
Figure 1.12 Tetraamine Jlacrocycles 1}12N4 ; 2}13N.t; 3) cyclam; 
4) isocyclam; 5) 15N4 ; 6} 16N4 
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Larger rings must be sufficiently conformationally mobile to achieve a 
favourable coordination geometry about the central transition metal ion. 
Ligands with more than 4 donors may be able to accommodate more than one 
metal ion. 
1.4.6 The Macrocyclic Effect 
Macrocyclic complexes are, almost without exception, more stable 
thermodynamically and kinetically than their corresponding open-chain 
analogues. Termed the "macrocyclic effect" by its discoverers, Margerum 
1 C bb . 24 . . f d f f 1 . 1 anc a mess , 1t 1s a more pro oun eature o macrocyc 1c camp exes 
than simply an increased "chelate effect" arising from the presence of 
an additional chelate ring. 
The high thermodynamic stability of macrocyclic complexes may be 
attributed to either a favourable enthalpy or entropy contribution or to 
a combination of both. For example, Margerum et al. 25 found that the 
enthalpy term is dominant when the formation of the Ni(II) complex of 
the [14]-membered tetraamine macrocycle ("cyclam") and its non-cyclic 
analogue are compared. However, for other complexes, the entropy term 
is primarily responsible for the increased thermodynamic stability 
(section 1.5.6). 
The enhanced thermodynamic stability associated with the 
"macrocyclic effect" was attributed to the kinetic inertness of the 
macrocycle versus acyclic complexes. Open-chain ligands can undergo 
successive SN1 displacement steps. and in acidic media, the dissociated 
groups are rapidly protonated. HO\.'ever, dissociation of a macrocyclic 
complex requires distortion of the ligand to minimise electrostatic 
repulsion between the first dissociated and protonated site and the 
central metal, and to allow the approach of the incoming ligand. The 
- 32 -
requirement for rearrangement of the ligand upon protonation raises an 
energy barrier to decomplexation, imparting higher kinetic stability 
upon the complex (section 1.5.3). 
The reasons for the slmv association kinetics of tetraamine 
macrocycles are discussed in section (5.1.2). 
It is popular to ascribe the enhanced stability of macrocyclic complexes 
to the "fit" betHeen the metal ion diameter and the size of a relatively 
rigid cavity in the centre of the macrocycle. Although this may be a 
valid concept for explaining the selectivity of crmm-ether ligands for 
alkali metal ions26 , the correlation between stability and "fit" is less 
certain for tetraamine macrocycles and is metal-dependent. 
27 f . 2+ 2+ Hancock et al. ound that the larger cat1ons, Ph and Cd , 
formed their most stable complexes with a [12]-membered tetraamine 
ligand. For the smaller Cu2+ cation, larger [13]- and [14]-membered 
ligands were preferred. The first observation may be explained in terms 
of the metal lying outside the "cavity" with the ligand in a folded 
("cis") conformation. This type of ligand conformation is usually more 
strained so, as for acyclic complexes, the overriding stability factor 
is the sequence of chelate ring sizes. HoHever the overall stability of 
the complex may still be higher than the open-chain analogue due to a 
more favourable entropy factor. In cases where the metal ion precisely 
"fits" the macrocyclic cavity, the metal-nitrogen bond distances are 
optimised, the ligand conformation is unstrained and the overriding 
stability factor is usually the enthalpy. The factors determining 
enthalpy and entropy contributions to thermodynamic stability are 
assessed in section (1.5), for complexes of Cu2+ with a series of 
tetraamine macrocycles. 
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1.5 COPPER RADIOISOTOPE BINDING 
1.5.1 Dasic Copper Chemistry28 
The dipositive state is the most important one for copper. The d9 
electronic configuration makes Cu(II) complexes subject to Jahn-Teller 
distortiontt if placed in cubic (octahedral or tetrahedral) environments 
and this profoundly affects the stereochemistry and stability of its 
complexes. When six-coordinate, the "octahedron" is severely distorted 
along one 4-fold ~~is, such that there is a planar array of four short 
equatorial Cu-1 bonds and two long axial Cu-1 bonds. In fact copper(II) 
forms many complexes in which the elongation is so pronounced that the 
coordination environment is essentially square planar. Usually the 
cases of tetragonally distorted "octahedral" coordination and square 
coordination are not easily differentiated. 
There are few tetrahedral complexes containing copper(II), examples 
being the chloro complex CuCl~- and the bis(salicylaldiminato) complex 
(Me3C-N=CH-(C6H4)-0-) 2Cu. Most copper(II) complexes have distorted 
"octahedral" or square planar symmetries. 
In aqueous solution, Cu(II) salts give the aqua ion [Cu(H20) 6]
2
+ in 
which two of the water molecules are further from the metal than the 
other four. Addition of nitrogen-containing ligands to aqueous 
solutions leads to successive displacement of water ligands since 
transition metal ions such as Cu2+ prefer "softer'' nitrogen donors to 
"harder" oxygen donors. Ho1,rever the addition of the fifth and sixth 
nitrogen donors is difficult due to the Jahn-Teller effect. For 
ttThe Jahn-Teller theorem predicts that the unsymmetrical occupancy of a 
degenerate energy level will be unstable and the system Hill undergo 
distortion so as to remove the degeneracy. The driving force for the 
distortion is a reduction in the overall energy of the occupied "d" 
orbitals. 
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example, [Cu(NH3)6]
2
+ can only be formed in liquid ammonia and 
[Cu(en) 3]
2
+ is formed only at extremely high concentrations of ethylene 
diamine. Amine complexes of Cu(II) are much more intensely blue than 
the aqua ion because amines produce a stronger ligand field which causes 
a high frequency shift in the position of the 11 d-d 11 absorption band. 
1.5.2 Copper Binding using EDTA, DTPA and TETA 
Meares et al. 29 ,30 reported that 67cu complexes of EDTA or DTPA, whether 
in the free-form or antibody-bound, were extensively decomposed by human 
serum Hithin 24 hours. In contrast copper chelates made from the 
macrocyclic ligand 11 TETA 11 and its antibody conjugates Here found to be 
much more stable in serum, 94-98% remaining intact after 5 days (Table 
1.3). 
CHELATE DAY 
0 3 5 
67cu-DTPA-N-butylamide 100 35 33 
67cu-DTPA-antibody 100 6 5 
67 (1,_1\rn_ p,.,..,~ .. l vnrrA I'll"" ~0 
...,u. .1.1\J.:'.- L#VJ..L~J ..1. Lil./,L,U, 
"" 
.l(J .10 
67cu-Benzyl-EDTA-antibody 94 4 5 
67 Cu-N02-Benzyl-TETA 100 98 98 
67cu-Benzyl-TETA-antibody 100 96 94 
Table 1.3 Vecomposition of Cop%er Chelates in Serum. Intact 
Chelate Remaining ( o) at Various Times 
These results are surprising on the basis of the relative thermodynamic 
stabilities of the chelates - Cu-TETA is actually less stable than Cu-
EDTA or Cu-DTPA at pH 7 (Table 1.4). Moreover the EDTA complex of 
cobalt(II) has a higher serum stability than Cu-EDTA even though it is 
less thermodynamically stable31 . This Has explained in terms of the high 
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rate of ligand exchange characteristic of Cu(II) relative to Co(II) 
complexes and the high concentration of competing ligands (e.g albumin) 
in serum. The enhanced in vivo stability of Cu-TETA must be explained 1n 
terms of the "macrocyclic effect" and the kinetic inertness which it 
conveys upon copper(II) complexes of [14]-membered macrocyclic 
tetraamines. 
LIGAND STRUCTURE log KcuL 
EDTA 18.7 
DTPA 21.4 
TETA 18.6 
Table 1.4 Stability constants of Aminocarboxylate Ligands; 
(\ 
20C; 1=0.1 
1.5.3 The Macrocyclic Effect for Copper(II) Cyclam Complexes 
The role of the "macrocyclic effect 11 in accounting for the observed 
thermodynamic and kinetic stabilities of copper-tetraamine complexes is 
well-illustrated by considering the parent 14N4 cycle "cyclam" and its 
acyclic analogue, 1,4,8,11-tetraazaundecane (2,3,2-tet), as examples 
32 (structures overleaf). Kimura and Kodama found the copper complex of 
cyclam to be 2000 times more stable than that of the linear tetraamine 
(Table 1.5). 
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cyclam 2,3,2-tet 
LIGAND log KcuL -~H ~s (kcal mol- 1 ) (cal K-lmol- 1 ) 
CYCLAM 27.2tt 30.4 22.4 
2,3,2-TET 23.9 27.7 16.5 
Table 1.5 (25° C; 1=0.2 mol dm-3) 
They proposed that the observed "macrocyclic effect'' was due to a 
combination of favourable enthalpy (ca 60%) and entropy (ca 40%) 
contributions. Earlier the Ni(II)-cyclam complex had been found to 
exhibit a solely enthalpy-governed 11 macrocyclic effect". 
Hinz and Margerum25 explained the enthalpy contribution for Cu(II) 
cyclam in terms of decreased free ligand solvation; less energy being 
required for desolvation prior to complexation. Fabrizzi and 
Paoletti33 ,34 prefer to explain the effect in terms of the conformation 
of the free ligand being perfectly pre-orientated for copper 
complexation. In the acyclic system, energy must be expended for the 
required conformational change. Indeed this represents the popular 
notion of a relatively rigid macrocycle cavity (cyclam) accommodating a 
metal ion of "best fit" with strong planar Cu-N bonds and a large heat 
of formation (-~H). 
ttCu(II) cyclam is thought to be a mixture of tlm isomers, a blue isomer 
and a more thermodynamically stable red isomer. The reported formation 
constant would then be a composite of the values for the individual 
isomers. 
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Another manifestation of the "macrocyclic effect" for Cu(II) cyclam 
is its kinetic inertness, especially towards acid-catalysed 
dissociation. In fact it is so inert that decomplexation only occurs to 
an appreciable extent in very strong (5-6M) acid35 . The dissociation of 
copper from tetraamines occurs in two steps for cyclam but one step for 
the linear tetraamine, 1,5,8,12-tetraazadodecane (3,2,3-tet): 
2+ kt 3+ k2 2+ 4+ Cu(cyclam) ~ Cu(Hcyclam) ------1 Cu + (H4cyclam) k-1 
I 
2+ kt 2+ ( 4+ Cu(3,2,3-tet) ------1 Cu + H4tet) 
The cleavage of the first Cu-N bond in Cu(cyclam) 2+ requires distortion 
of two stable chelate rings (Figure 1.13 left) and is via a protonation 
pathway. Similar cleavage in Cu(3,2,3-tet) 2+ requires distortion of a 
single chelate ring only (Figure 1.13 right) and is via a solvation 
pathway. 
c 
...J 
--~~~ N~- ---N N ( ,, /' , '- , ,' / M, ,' 
N --- --s 
s 
Figure 1.13 Species resulting from first Cu-N bond cleavage 
Thus the cleavage of the first Cu-N bond of Cu(3,2,3-tet) 2+ is much more 
rapid (104 - 105 times) than that for Cu(cyclam) 2+. Since solvation of 
(1) is hindered by the steric constraints of the macrocyclic ligand, k_ 1 
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is larger than k2 and the cleavage of the second Cu-N bond is rate-
determining for Cu(cyclam) 2+. 
1.5.4 Crystal Structures of Copper(II) Cyclam Complexes 
The X-ray structure36 of the perchlorate salt of Cu(II) cyclam is sh01m 
in Figure 1.14. The 4 N donors lie in the same plane as the metal with 
all four Cu-N bonds of equal length (2.02 A). The tetragonally distorted 
"octahedron" is completed by the oxygen atoms of perchlorate in the t1vo 
axial positions (Cu-0 = 2.57 A). The ligand adopts a least-strained 
"trans-III" conformation in which the six-membered chelate rings are in 
a stable chair form on opposite sides of the N4 plane. The five-membered 
chelate rings adopt a stable gauche form. 
In the crystal structure37 of Cu- Nbz TETA (Figure 1.15), the 
expected tetragonal distortion is also observed. However in this case 
the equatorial positions are occupied by 2 N and 2 0 donors, with Cu-
donor bond lengths of 2.0 A. The remaining two Cu-N bonds are elongated 
and occupy axial positions (2.428 and 2.367 A). The strong interaction 
of the carboxylate oxygens is surprising in view of the usual preference 
of Cu2+ for N donors. 
It is interesting that the crystal structure38 of the copper(II) 
complex of the 1,8-diacetic acid derivative of cyclam is similar to that 
of [Cu(cyclam)] 2+(Cl04) 2, in that the four strongest bonds are to 
nitrogen with relatively weak Cu-0 axial bonds (Figure 1.16). Thus it 
would appear that the N202 coordination of Cu-TETA is unique amongst the 
known copper complexes of cyclam derivatives, resembling more closely 
the copper complexes of EDTA and DTPA. 
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Figure 1.14 Crystal Struct1tre of {Cu(cyclam)J.ClD4 
Figure 1.15 Crystal Structure of Cu {6-(p-N02C6n4cH2TETA} 
Figure 1.16 Crystal Structure of Cu {1,8-N,NJ-bis(carboxy-
methyl)-cyclam 
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1.5.5 Comparison of TETA and cyclam for copper binding 
Since the structure of a copper-tetraamine complex in solution is 
expected to resemble that in the solid-state, Meares et al. 37 proposed 
that the unusual N202 donor set conveyed upon Cu-TETA a special kinetic 
inertness over and above that expected for a cyclam complex from the 
"macrocyclic effect". The complex was said to have a structural rigidity 
which shields the copper ion from attacking ligands. The assertion that 
N2o2-coordinated Cu-TETA is more kinetically stable than than N4-
coordinated Cu-cyclam is highly controversial. Peralkylated cyclams are 
generally accepted to have faster metal-dissociation kinetics than the 
parent cycle (section 2.2.4). In addition, the anionic nature of Cu-
TETA will attract protons and other metal ions into the vicinity of the 
complex. As noted earlier for EDTA and DTPA, these species catalyse 
dissociation of metal ions. Although Cu-TETA was shown by Meares et al. 
to be inert in serum at pH 7 (section 1.5.2), its weak axial Cu-N bonds 
will be particularly susceptible to acid-catalysed cleavage in the more 
acidic parts of the body. 
Cationic .complexes e.g Cu(cyclam) 2+ forming strong Cu-N bonds 
should be more kinetically stable in vivo. Unfortunately the rate of 
dissociation of copper from cationic macrocyclic tetraamine complexes 1s 
so slow that it has proved difficult to measure rate constants through 
which we can compare the suitabilities of a series of macrocycles for in 
vivo copper binding (only a value for Cu-cyclam has so far been 
measured) 35 . It is therefore necessary at present to consider the 
thermodynamic stability and rate of association of a Cu(II) complex as a 
rough guide to its suitability. 
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1.5.6 Thermodynamic Stabilities of Copper(II) Polyamine Complexes 
The stability constants of the copper(II) complexes of a series of 
macrocyclic ligands (Figure 1.12) are given in Table 1.1632 . 
LIGAND 
Cu-12N4 
Cu-13N4 
Cu-15N4 
Cu-cyclam 
Cu-isocyclam 
log K 
24.8 
29.1 
24.4 
27.2 
22.4 
Table 1.16 Stability constants for a series of tetraamine 
. 0 
macrocycles at 25 0 and !=0.2 mol dm-3 
With increasing r1ng size, the stability of copper-tetraamine complexes 
reaches a maximum value (29.1) for 1,4,7,10-tetraazacyclotridecane 
(''13N4"), then decreases again. It is notmvorthy that the copper 
complex of iso-cyclam is significantly less stable than Cu(II) cyclam. 
The unsymmetrical arrangement of 5- and 6-membered rings introduces 
steric strain into the conformation of the bound ligand34 . 
Interest in.e;ly, the origin of the 11 m::J.r.ror.yr.l i r pff Prt." ~'~ ri ~3 fry: 
different ring sizes. Kimura et az. 39 found that the increased 
stability of Cu-12N4 was primarily due to a more favourable entropy 
contribution. This arises from the free ligand being more "rigid" and 
more highly solvated than the acyclic ligand, giving rise to favourable 
configurational and translational entropy changes on complexation. For 
the Cu-13N4 system
40
, the entropy contribution is l01{er but it is more 
than offset by a more favourable enthalpy factor giving a larger 
stability constant overall. The enhanced enthalpy contribution arises 
from stronger Cu-N bonds, a less strained ligand conformation for a 
larger cycle and possibly lower solvation in the free ligand. As 
discussed previously (section 1.4.3), the "macrocyclic effect'' for Cu-
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cyclam is predominantly enthalpy-driven. 
In view of their high thermodynamic stabilities, the tetraamine 
macrocycles, cyclam and 13N4 were shortlisted for further investigation 
as potential bifunctional chelating agents for 64cu and 67cu. 
1.5.7 Phenolic Macrocycles as Copper Binders 
In a series of papers41 -45 , Kimura et al. reported the metal-binding 
potential of tetraamine macrocycles bearing phenolic side chains. The 
[14]-membered phenolic cycle (2) forms complexes with Ni(II) and Fe(II) 
in which the phenol is bound to the metal as an axial phenolate donor 
(Figure 1.17). 
Cl9 
Cl8 
Cl7 
Cl6 
ow 
@ 
Figure 1.17 J/olecular Structure of a Nickel{II) Complex 
with Phenol-pendent cyclam (g) 
Cl3 
The pKa values for the phenols in the NI(II) and Fe(II) complexes of 
(2), a measure of the strength of the axial interaction, are 6.30 and 
6.8 respectively, compared to 8.86 for the free ligand. Incidentally, 
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the phenol in the free ligand is more acidic than phenol itself (pKa 10) 
due to stabilisation of the phenolate by intramolecular electrostatic 
attraction with the dipositively charged ring (pK1 11.75; pK210.84). 
When bound, the phenolate imparts special properties upon the chelate, 
stabilising complexes which are not normally formed by the parent cycle 
e.g Fe111-(2) and Niiii_(2). 
The phenol pKa for the Cu(II) complex (9.2) is high indicating that 
axial interaction is weak (Jahn-Teller distortion). The stabilising 
influence of an axially bound phenolate donor is therefore likely to be 
irrelevant for the Cu(II) complex except at higher than physiological pH 
(Table 1.7). 
log K (25°C; 1=0.2 mol dm-3) 
Cu-cyclam 27.2 
CuL 29.2 
pKa ll 9.2 
CuH_ 1L 32 
·Table 1. 7 Stability constants of Cu{II} complexes of 
n •• n 7 n ~ N ~ ,J ~ 7. ~- ~ 7 - ~ - ,J ~ - .l -' • • J -- • r i\) 
v t:J V U Utili Ut IU U1 f' I~ V '" V (I jJ V Ill Ul V Ill IJ (.., !:Jl..- (.. f.(! III J JJ- /:J 
Nonetheless, the suitability of phenol-pendent derivatives of cyclam and 
13N4 for binding copper (and technetium) will be discussed in more 
detail in Chapters 2,3,4 and 5. 
1. 6 TECONETIUM RAIHOISOTOPE BINDING 
1.6.1 Basic Technetium Chemistry18 ,46 
Despite the widespread use of 99"1'c in nuclear medicine, the chemistry 
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of technetium is still poorly developed. However the ready availability 
in recent years of macroscopic amounts of a longer-lived radionuclide 
99Tc, a P-emitter (t 1 = 2.13 x 105 yr), has encouraged much effort to 
2 
elucidate basic technetium chemistry. It appears that technetium has an 
extensive coordination chemistry, with a variety of inorganic and 
organic ligands, exhibiting oxidation states from -1 (d10) to +7 (d0) 
displaying coordination numbers from 4 to 9. 
Those Tc complexes most relevant to nuclear medicine contain the 
metal in the oxidation state +1, +3, +4 or +5. Since 99mTc is obtained 
as the pertechnetate (TeO 4J ion from a 99Mo generator, it must be 
reduced from the +7 oxidation state to a lmver oxidation state. For 
example a tin(II) salt is normally used for the t1w-electron reduction 
of Tc(VII) to Tc(V): 
+ -
Tcviio- 2H ,2e "TcvO-" 4 (- H2 0) 3 
1 2H+ (-H20) 
"Tcvo3+11 
2H+ 
"TcVO+" 
(- H2 0) 2 
Only one oxo group is removed in the reduction step; others being 
removed by protonation and loss of water. 
In general Tc(IV) and Tc(V) complexes have technetium-oxo cores in 
order to satisfy their high-charge requirements. In particular, Tc(V) 
can be satisfied by one oxo group and four good ~-bonding ligands (e.g 
Tc03+ core in Tc0Cl4J or by two oxo groups and one u-donating ligand 
(e.g trans-Teo; core in [Tc(py)402]+). Technetium-oxygen bonds have 
been found by X-ray analysis to be sufficiently short to be formulated 
as (u +~)double bonds (Tc=O). The Tc=O bond length 1n complexes with 
a Tco3+ core is usually shorter (by about 0.1 A) than that in complexes 
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containing trans-Teo; groups. The former can be 5-, 6-, or 7-coordinate, 
the latter are ahvays 6-coordinate. The TeO group demonstrates a 
powerful trans effect and influence. In complexes containing "hard" or 
~-acidic ligands in the cis-position, solvent molecules (water or 
alcohol) occupying the sixth position will subsequently be deprotonated 
to give a trans-Teo; core (Figure 1.18). 
0 
l\ll;l 
-X-+ ROH 
Tc 
/1 ' -ROH+X-
'L L X 
where L =cis ligar.ds, R =Me • 
For R = H the reaction can proceed further 
Figure 1.18 Formation of trans-TcOi species in aqueous solution 
In Tc(I) and Tc(III) complexes, there are no oxo groups ie. TcLn, Tc2Ln 
etc. Low valent complexes of technetium most often contain ~-acceptor 
ligands which can accept electron density from the metal e.g phosphines, 
arsines, carbon monoxide etc. Technetium at the "carrier-added" level 
(ie. 99Tc) also forms a variety of polynuclear species, containing for 
example Tc2o~+ cores. In contrast "carrier-free" 99mTc rarely forms 
polynuclear species since its molar concentration is so low. It is 
important to recognise that the chemistry of technetium may differ 
between "carrier-free" and "carrier-added" levels. 
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1.6.2 99IDrc radiopharmaceuticals 
A wide variety of tissues can be imaged using 99mTc radiopharmaceuticals 
which localise passively within these regions by virtue of their size, 
lipophilicity, charge etc., rather than by antibody targeting16 ,18 . An 
enormous number of chelators for 99IDrc have been synthesised in an 
attempt to achieve the required selectivity for the target tissue, a feH 
of which are described below. 
B . 47,48 razn 
In order to penetrate the highly lipophilic blood-brain barrier, 
technetium complexes must be n_eutral with small hydrophobic ligands. 
Three 99nLrc complexes designed for SPECT brain imaging (99mTc-BAT, 
99mTc-GTS and 99mTc- PnAO) are given in Figure 1.19. 
Heart 
The first heart imaging agents49 containing Tc(I) had the structure 
Tc[D2X2]+ where D = ditertiary arsine or phosphine and X= Cl-, Br-, or 
r. Hmvever they shmved disappointing uptake in human myocardium and 
have been superceded by second generation isonitrile-Tc(I) complexes 
[99mTc(CNR) 6]+, developed by Davison et al. (Figure 1.20). 
Kidney 
99mTc-DTPA has been widely used for glomerular filtration imaging. 
Davison et al. 50 complexed 99mTc with N,N-bis-(mercaptoacetamido)-
ethylene diamine (DADS) to produce an imaging agent for renal tubular 
secretion. However another complex 99mTc-MAG3 (MAG3 = mercaptoacetyl-
glycylglycylglycine) was found51 to be more effective than 99mTc-DADS 
(Figure 1.21). 
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99
'"Tc-BAT SSmTc-GTS 99 '"'fc-PnAO 
Figure 1.19 99mTc complexes designed for SPECT brain imaging; 
BA T=b is- ami noe thane th i o l j OTS=g l ucob is- th i osemi carb-
azonej PnAD=propyleneamine oxime. 
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Figure 1.21 Structures of 99mTc kidney-imaging agents. 
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Figure 1.22 Structure of diphosphonate ligands for 99mTc 
bone imaging; J/IJP: Rt =R2 =II; JIEIJP: Rt =DII, R2 =Cfh 
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Bone 
Bone-scanning using 99~c-phosphate complexes is the most common 
application of 99~c in diagnostic medicine. The use of diphosphonate 
ligands provides particularly high resolution images; methylene 
diphosphonate (MDP) and hydroxyethylidene diphosphonate (HEDP) being 
especially popular (Figure 1.22). 
1.6.3 Antibody-bound Technetium Chelators 
Some workers have attempted to adapt some of the acyclic ligands 
developed for conventional 99mTc-radiopharmaceuticals for use as 
antibody-bound chelators-, particularly DTPA52 . Although 99mTc-DTPA 
gives better results than "direct-labelling" of the antibody (section 
1.4.1), there are still the problems of excessive re-oxidation to Tc04 
and transchelation to serum components. 
Other workers53 have employed acyclic ligands containing nitrogen 
and sulphur donors to produce more stable 99mTc chelates than 99mTc-
DTPA. Another approach is to replace DTPA with a tetraamine macrocycle, 
the advantages of which have been discussed vide ante in connection with 
copper binding. 
1.6.4 99IDrc Complexes of Macrocyclic Ligands 
In 1980, Volkert et a l. 54 reported that the macrocyclic tetraamine, 
cyclam, formed a kinetically inert chelate with 99~c. Complexes could 
be formed from pertechnetate in higher than 95% yield at pH 11 in 10-3 M 
cyclam using 5 x 10-6 M stannous chloride as the reducing agent. The 
yield of complex was decreased at more acidic pH, and with decreasing 
concentrations of ligand and reducing agent. The 99mTc-cyclam complex 
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was resistant to oxidation (air, 02, H202) and exposure to 0.05 M NaOH, 
although there was slight decomposition in 0. 05 M HCl. In a later 
paper55 , the overall charge of 99Inrc-cyclam was reported to be +1, with 
technetium in oxidation state +5, consistent with the structural formula 
[Tc02(cyclam)]+. Since the longer-lived isotope 
99Tc formed identical 
complexes with cyclam in comparable yield to 99mTc, sufficient complex 
was isolated to grm.,r an X-ray quality crystal 56 . 
The 99mTc-cyclam complex was isolated as the perchlorate salt, 
trans-[Tc(cyclam)02] .Cl04.H20. There are no bonding interactions 
between cation and anion or \vater molecules. The cation consists of a 
trans-OTcO+ core with the ligand in the favoured trans-III conformation. 
The structure has a centre of symmetry at the metal, which sits in the 
N4 plane with the axial oxo donors completing a near-perfect octahedron 
(Figure 1.23). The Te-O distance (1.751 A) is greater than that found 
in a mono-oxo complex and the Te-N distance (average 2.125 A) is the 
longest observed for any cyclam complex (cf. Cu(II) 2.02 A). It is 
suggested that the donor distance might impose a small amount of steric 
strain upon the conformation of the ligand. 
Figure 1.23 ORTEP drawing of the cat ion trans- {Tc( cyclam)02 /. 
Probability ellipsoids are shown at the 50% level. 
Hydrogen atoms are not included. 
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In conclusion, cyclam binds ggn~c rapidly at pH 11, forming a 
kinetically inert complex suitable for in vivo applications. One 
problem which will be addressed in Chapters 2 and 3 is the slow rate of 
complexation of 99mTc by cyclam at neutral pH (preferred by antibodies). 
At low pH, electrostatic repulsion between the protonated ligand and 
cationic Tc(V) species is an important factor determining rate. One 
possible solution is to employ an axial anionic donor in an attempt to 
reduce electrostatic repulsion and enhance the rate of uptake. In 
particular, the phenol-pendent cyclam (1) will be investigated as a 
potential Tc- binder at lm~er pH. 
1.7 CONJUGATION OF CIIELATING AGENTS TO ANTIBODIES 
1.7.1 Use of Acylating Agents 
Practically all reported methods of conjugation employ a reaction 
between an electrophilic group on the chelating agent and a nucleophilic 
group on the antibody. The most useful nucleophilic residues on the 
antibody are amines: the terminal amino groups, the isoindoles of 
histidine but more particularly the c-amino group of lysine. The most 
commonly-used chelating ligand, DTPA, is easily converted to more 
reactive acy lat ing agents e.g anhydrides, car bod iimides or activated 
esters. 
Anhydrides 
There are two anhydride methods for conjugating DTPA to antibodies. 
Originally, Krejcarek and Tucker57 used a mixed anhydride (MA-DTPA) 
prepared from DTPA and isobutylchloroformate. However this anhydride 
- 51 -
was found to be so unstable that a second route based on a cyclic 
dianhydride (CA-DTPA), prepared from DTPA and acetic anhydride, was 
devised58 ,59 . It was presumed that the site of attachment of DTPA was 
the lysine E-amino group (Figure 1.24). Although the CA-DTPA is more 
stable than MA-DTPA and less easily hydrolysed in the aqueous reaction 
medium, there is a greater probability of loss of antibody immuno-
reactivity by internal or external cross-linking since CA-DTPA has t1~0 
reactive groups. 
DTI?A 
Dianhydrida 
~t 
P-./\,/NH2~P /v'N-C'-..,/N) 
HO~N 
~~ 
HO\ 1 
DITA ~
formed o 
Figure 1.24 Conjugation of ETPA Eianhydride (CA-ETPA) to 
lusine E-NH? orouvs of an antihnd11. 
. . - - - . .... 
Carbodiimide method 
A water soluble carbodiimide, 1-ethyl-3(3-dimethyl-aminopropyl) carbo-
diimide (EDC) has been used to conjugate the carboxy groups of DTPA to 
amino groups on Mab's60 . The reaction mechanism involves an intermediate 
0-acylisourea species. This method apparently produces an even higher 
level of Mab deactivation than CA-DTPA. 
N-hydroxysuccinimide ester method 
Najafi et az. 61 synthesised an N-hydroxysuccinimide pentaester of DTPA 
from CA-DTPA and N-hydroxysuccinimide which was more stable than CA-DTPA 
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and therefore gave a higher DTPA conjugation yield. However the 
presence of 5 active ester groups causes considerable cross-linking and 
deactivation of Mab's. 
The main advantage of using acylating agents for conjugating chelates is 
the simplicity of the protocol since the chelate itself is the starting 
material. HOI,'ever in the case of DTPA, the main disadvantage is the 
loss of a potential binding site. The loss of denticity makes DTTA, a 
less efficient binder of 111rn and other radionuclides than DTPA itself, 
h h h d. 1 b 1 . l . dl . . 62 sue t at t e ra 10 a e 1s ost more rap1 y ~n vzvo . 
1.7.2 Use of Aromatic Amine-Derived Reagents 
Historically, the first chelate-protein conjugates to be stable enough 
for in vivo use were derived by reaction of azophenyl-EDTA with Mab 
amines63 . However the complexity of the synthesis of chelate side-
chains, such as azophenyl, hindered the further development of this 
approach until Meares et al. 64 developed a shorter procedure using amino 
acids and aromatic amine intermediates (Figure 1.25). 
Unfortunately azophenyl-EDTA, derived by diazotisation of 
aminophenyl-EDTA, proved to be non-specific for lysine residues, 
reacting instead with tyrosine (OH) and histidine (NH) 15 . 
The use of thiocyanate groups (R-N=C=S) for coupling fluorescent 
probes, spin labels etc. to proteins is well known. They are mild 
reagents obtained by reacting aromatic amines with thiophosgene and are 
specific for amino groups. Both Meares e t a l. 65 and Gansow e t a l. 62 
have used thiocyanate groups ("CITC") extensively and effectively for 
conjugating EDTA and DTPA to antibodies (Figure 1.26). 
Another class of coupling agents derived from aromatic amines, by 
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Figure 1.25 Synthesis of functionalised EETA derivatives 
(azophenyl-, "BABE" and "CITC" from amino acids. 
Figure 1.26 
coo-
( coo-1\r N~ NH____!()\--CHz -eN® N=> 
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0 
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Protein conjugates of azo-phenyl EET,4 (top), "CITC" 
(middle) and a-bromoacetamido-TETA {bottom), thro1tg!t 
a C4S spacer group to lys. f.-Nih. 
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reaction with a-bromoacetyl bromide, are the a-bromoacetamides ("BABE"). 
These reagents were used by Meares et al. to couple EDTA65 and TETA29 to 
Mab amines for use as 111In and 67cu binders respectively. Although 
this method apparently worked well for the 111In binder, the 67cu binder 
was found to be effective only if the lysine side-chain was first 
extended with "Traut's reagent" to include a free thiol group (section 
2.4. 2). The a- bromoacetamide \-laS then conjugated via a thioether bridge 
(Figure 1.26). The effectiveness of this coupling method, as ~etermined 
by our own experiments, will be explored further in Chapter 2. 
The difficulty of the synthesis of functionalised chelates containing 
aromatic amine-derived coupling agents makes this strategy more complex 
~ 
than the anhydride method. However since the metal-binding site is 
unaffected by conjugation, the stability of the resulting radionuclide 
bond in vivo is greatly enhanced. An additional advantage is the 
greater selectivity of coupling reactions employing thiocyanates and a-
bromoacetamides; there being less deactivation of the antibody. 
1.7.3 Use of Maleimide-Based Reagents 
The use of maleimides as coupling reagents for proteins was first 
described by Kitagawa et az. 66 in 1976. The water soluble maleimide 
ester used in this initial work, N-maleimidobenzoyl-N-hydroxysuccinimide 
ester (MBS) is noH commercially available as a cross-linking agent. 
MBS was used to link the thiol groups of the enzyme P-D-galactosidase to 
the lysine residues of insulin, by reaction with the maleimide and N-IlS 
ester respectively. Several other maleimide cross-linkers have since 
been synthesised with the intention of improving the stability of the 
maleimide ring at higher pH (section 2.4.3). One of these, succinimidyl-
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4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (Q) is reported67 to be 
more stable than MBS. 
0 0 ~ 0 ~N-o-g-0-¢ 
0 0 
( MBSJ 
( 3 ) 
In addition to our own work involving maleimides (section 4.2), 
Volkert et al. 68 reported a coupling method using MBS to conjugate a di-
N-alkylated cyclam, with a thiol-containing side chain, to Mab lysine 
residues. A potential problem arises from the incorporation of highly 
reactive maleimide residues into the antibody itself, rendering the 
modified protein highly sensitive to changes in pH. It seems to us 
preferable to use maleimides on the chelate side chain and thiol groups 
on the Mab when using cross-linkers such as ~illS and (Q). 
1.7.4 Antigen-Site Binding 
A potentially very exciting method of conjugating chelates to Mab's is 
to raise an antibody which recognises the chelate as an antigen, binding 
it reversibly in the variable region. Meares e t a l. 69 developed an 
antibody which recognises 111In-benzyl-EDTA. Since, in this case, the 
antigen binding site is occupied and cannot recognise tumour associated 
antigens, the antibody must accumulate passively inside the tumour. A 
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solution to this problem is to develop a bifunctional antibody in which 
one Fab arm recognises the chelate, or preferably a cluster of chelates, 
and the other recognises the tumour associated antigen. This approach 
is far more complex than those described vide ante, and may take many 
years to develop to fruition, but in the long term, it could well prove 
to be a relatively simple method for conjugating large concentrations of 
chelates to Mab's without impairing immunoreactivity. 
1.8 THE SCOPE OF TlliS WORK 
The majority of this thesis is concerned with the development of novel 
functionalised macrocyclic ligands for binding isotopes of technetium 
and copper to antibodies, in a manner suitable for radioimmunoimaging 
and radioimmunotherapy. The most appropriate ligands for this purpose 
are derivatives of cyclam and 13N4. 
Chapter 2 contains a discussion of the factors influencing the 
choice of a suitable side-chain functionality for the macrocycles, 
cyclam and 13N4, their preferred methods of synthesis and the 
development of a novel conjugation procedure for attaching 
functionalised macrocycles to Mab's. 
Chapters 3 and 4 contain the results of 99~c and 64cu radio-
labelling experiments using the antibody-macrocycle conjugates described 
in Chapter 2. In Chapter 5, the kinetics of association of copper(II) 
with cyclam, 13N4 and derivatives thereof, are discussed. 
Chapter 6 includes a review of current progress in the field of 
radioimmunotherapy. Also discussed: the development of functionalised 
macrocycles for binding 90v and radiolabelling experiments involving 
67Cu; both isotopes being favoured for therapeutic applications. 
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Chapter 7 contains experimental procedures for the synthesis of 
tetraamine macrocycles, macrocycle-linker conjugates and macrocycle-
antibody conjugates. Non-synthetic experimental is reported at the end 
of the chapter in which it is discussed. 
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CHAPTER TWO 
THE SYNTHESIS OF MACROCYCLE-
ANTIBODY CONJUGATES 
- 62 -
PART A: SYNTHESIS ~F FUNCTIONALISED MACROCYCLES 
2.1 INTRODUCTI~N 
2.1.1 The Need for Functionality 
The preferred type of macrocycle for binding isotopes of technetium and 
copper, a [13] or [14]-membered tetraamine, must be functionalised with 
a side chain through which attachment to the antibody will take place. 
There are many factors which must be considered when deciding upon a 
particular type of side chain and many criteria must be fulfilled. 
Firstly, the side chain should render the ligand both soluble and 
stable in aqueous media over a wide pH range and it should be unreactive 
tmvards the secondary amines of the ring. Secondly the steric 
constraints imposed upon the ring should be minimised such that the 
binding characteristics of the functionalised and parent cycles are of 
the same order. Thirdly the synthesis of the functionalised cycle 
should be as straightforward as possible. Given the complexity of many 
macrocyclisation reaction mixtures, an ultraviolet active side chain, 
typically an aromatic group, would help in the monitoring and 
purification of the reaction products. Finally the functionality of the 
pendent group must allow the cycle to be linked selectively to the 
antibody without damaging the integrity of the tetraamine system of the 
nng. 
2.1.2 The Use of Aromatic Amine Side C.bains 
As discussed in section (1.7.2), Meares et al. reported in 19841 a 
- 63 -
method of conjugating chelates, such as EDTA, to antibodies using an a-
bromoacetamide side chain. In view of the apparent success of this 
method, it was decided to pursue in the first instance, the synthesis of 
macrocyclic tetraamines functionalised with aromatic amine side chains 
which could later be converted to a-bromoacetamides using a-bromoacetyl 
bromide. 
2.2 PI1ENOL-PENDENT TETRAAMINE MACROCYCLES 
2.2.1 The Use of Phenolic Side Chains 
As suggested in section (1.6.4), phenol-pendent macrocycles are 
potentially useful for binding technetium-99m. In particular, the effect 
of the phenol group on the kinetics of association and dissociation of 
the radiolabel is of interest. 
The decreasing rate of uptake of technetium(V) by cyclam at lmver 
pH is almost certainly due to electrostatic repulsion between the 
· · h · · r o3+ r o+ d h · · 1 cat1on1c oxo-tec net1um spec1es, c or c 2, an t e 1ncreas1ng y 
protonated ligand. Antibody-bound macrocycles should ideally be 
labelled at physiological pH (7.0-7.8) to avoid damage to the protein 
but the rate of complexation at this pH and at the "no carrier added"t 
level is slow. Negatively charged pendent groups could serve to reduce 
the charge density on the macrocycle thereby enhancing the kinetics of 
complexation. 
The pKa value for the phenol 1n Kimura's macrocycle (Z) IS 
t"No carrier added" material contains a single radioactive isotope only; 
since no "cold" isotopes are present, the molar concentration of metal 
in radiolabelling experiments is necessarily l01v. 
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significantly lower (8.8) than for the phenol itself (10) 2. At pH 9 the 
phenol will be substantially deprotonated reducing the net positive 
charge on the macrocycle by one unit (Figure 2.1). 
1+ 
Figure 2.1 /Jominant species at pll9 for cyclam and (g) 
Alternatively, or in addition to electrostatic effects, the phenol might 
serve to orientate the incoming technetium cation for rapid 
incorporation into the r1ng. There is even the possibility that the 
phenolic group might act as an axial donor for technetium, as was 
observed in the Ni 2+ and Fe2+ complexes of (2.) 2' 3, replacing one of the 
oxo donors and conferring extra thermodynamic or kinetic stability on 
the complex. These factors will ·be considered further in Chapter 3. 
2.2.2 Synthesis of p-Aminophenol-pendent Cyclams 
The attachment of a pendent group to cyclam containing both phenolic 
moieties is possible by way of Kimura's macrocyclisation of the linear 
tetraamine, 1,4,8,11-tetraazaundecane with 6-nitrocoumarin2. The 
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proposed scheme is given in full in Figure 2.2. The macrocyclic amide 
(1) may be reduced with diborane to give the tetraamine (Q). To 
facilitate selective acylation by a-bromoacetylbromide at the exocyclic 
aromatic amine, it would be necessary to protect, with methyl groups, 
the more nucleophilic secondary amines of the ring. In turn this would 
require prior protection of the phenol as a suitable ether. Finally the 
nitro group would be hydrogenated to give the aminophenol-pendent cyclam 
(§.) and converted to the a-bromoacetamide (1). 
It was found that the presence of an electron-withdrawing nitro 
group increased the reactivity of the coumarin ring, reducing the 
reaction time from 2 weeks to 5 days. The desired macrocyclic amide (1) 
was then separated by painstaking column chromatography on gravity 
silica. Providing the elution rate is not too fast (overall elution 
time 18 hours), the amide may be obtained in reasonable yield (21%) and 
of sufficient purity not to require recrystallisation. The yields of 
macrocyclic amides of this type were improved by using only anhydrous 
solvents for the cyclisation step. 
It became apparent that a solution of diborane-dimethyl sulphide 
complex in THF reduced both amide and nitro groups of (1), if the 
reaction time was 6 days. This was primarily established from the 13c 
NMR spectrum; the signal due to the aromatic carbon bearing a nitro 
group (ca. 140 ppm) was replaced by a signal attributable to an aromatic 
amine (118-127 ppm region). Aromatic nitro groups are not usually 
attacked by diborane4 but the presence of an electron-donating phenol in 
the para position apparently activates this system towards reduction. 
Selective reduction of the amide group to give cycle (Q) was 
subsequently achieved with a solution of diborane in TI!F by limiting the 
reaction time to 24 hours. 
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Figure 2.2 The Synthesis of para-Aminophenol-pendent Cyclams 
R =Tr 
X =CI 
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2.2.3 Redox reactions of p-Aminophenols 
It was apparent from the behaviour of the fully reduced cycle (B.) in 
aqueous solution that the p-arninophenol moiety was unstable, especially 
at alkaline pH. A solution of the free amine in water was found to 
darken on standing and in time an intractable dark brown solid 
precipitated. This instability was attributed to the propensity of p-
arninophenols to oxidise in basic solution to p-irninoquinones5: 
0 0 + 2Hz0 + ze-
NH 
The darkening of the solution may be explained by the formation of a 
charge-transfer complex involving the p-arninophenol as an electron donor 
and the p-irninoquinone as an electron acceptor. The redox reactions of 
p-arninophenols clearly make them less than ideal for conjugating 
rnacrocycles to antibodies and alternative side chains were required. 
Two further problems carne to light regarding the use of aromatic 
arnines as pendent groups for tetraarnine rnacrocycles. The necessity for 
peralkylation of the secondary arnines and the lack of selectivity in the 
reaction of bromoacetyl bromide with aromatic amines. These subjects 
will be considered in sections (2.2.4) and (2.2.5) respectively. 
2.2.4 Binding Characteristics of Per-N-Alkylated Cyclams 
The methyl groups of N-tetramethylcyclam (~) impose steric constraints 
upon the structure of its metal complexes. The metal is displaced from 
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the plane of the four nitrogen donors. Barefield et al. 6 used space-
filling models to show that a metal in the coordination plane forces the 
methyl groups into positions close to possible axial donors. This 
finding is supported by our own molecular modelling studies on a dioxo-
technetium (V) complex of (10) which shows steric crowding about the 
axial oxo groups due to the proximity of the methyl groups. Relief of 
steric strain would require the metal to sit outside the coordination 
plane, almost certainly weakening the Te-N bonds and reducing the 
stability of the complex. In his thesis7, J. Simon reported that tetra-
methylcyclam was a much less efficient technetium binder than cyclam 
itself which he attributed to steric hindrance by the methyl groups 
bonded to the nitrogens. 
(Q) (10) 
NC/"'-....~CN c J 
NC'-/ ~N""-./CN 
HO~n ./"o-...OH 
c J HO""-./~N"'-/OH 
(11) (12) 
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The ruthenium (VI) dioxo complex of N-tetramethylcyclam 
[RuV1o2(tmc)]+, which is isoelectronic with the technetium (V) complex 
[TcV02(tmc)]+, is rather unstable both in solution and in the solid 
state8 . This instability has been associated with steric interactions 
between the N-Me groups and the oxygen lone pairs. 
The presence of alkyl groups on all four nitrogens of cyclam is 
equally undesirable for copper binding. Barefield and \hgner9 shm.;ed 
that the copper complexes of N-tetramethylcyclam (.Q) are formed more 
rapidly than those of cyclam, but dissociation of the metal is also more 
facile. Subsequent studies by Hay et az. 10 ,11 using the ligands N-
tetrakis-(2-cyanoethyl)-cyclam (11) and N-tetrakis-(2-hydroxyethyl)-
cyclam (12) indicate that their copper complexes also dissociate readily 
in acid solution. 
2.2.5 Competitive Alkylation and Acylation of Aromatic Amines 
Some model reactions using cyclam and aromatic amines showed it was not 
possible to selectively acylate the amine with a-bromoacetyl bromide. A 
mixture of N-alkylated and N-acylated products was suggested by the 
appearance of two methylenic resonances in the 3.5-4.5 ppm region of the 
1H NMR spectrum (Figure 2.3). This observation was subsequently 
supported by the work of Gansow et az. 12 who reported that N-alkylation 
of the aromatic amine of aminobenzyl-EDTA, by a-bromoacetyl bromide, 
occurs to a greater extent than N-acylation (70% alkylation/30% 
acylation). The lack of selectivity of the amine towards acylation 
would cause intermolecular reaction of a pair of macrocycles to produce 
aggregates such as (13) destroying their potential to be linked to 
antibodies. 
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BrCH2COBr H H 
ArNCOCH2Br + ArNCH2COBr 
I I I ArNH2 
ArNHCOCH2NHAr (13) 
Figure 2.3 Competitive Alkylation and Acylation of aromatic amines 
by a-bromoacetyl bromide 
2.2.6 Synthesis of p-Aminomethylphenol-pendent Macrocycles 
By using a primary aliphatic amine group in place of the aromatic amine, 
it was hoped to overcome the problems outlined above. In addition to 
resisting oxidation in aqueous base, the p-aminomethyl phenol 
derivatives should prove easier to acylate selectively at the exocyclic 
amine by virtue of its enhanced nucleophilicity relative to the aromatic 
amine of cycle(~). This is illustrated by the difference in basicity 
between the two types: pKa ~ 10 for primary aliphatic amines; pKa ~ 5 
for primary aromatic amines13 . This type of cycle can be synthesised 
using an analogous two step route from 6-cyanocoumarin and a linear 
tetraamine. However unlike 6-nitrocoumarin, 6-cyanocoumarin is not 
commercially available and must be made by reducing the former to 6-
aminocoumarin followed by diazotisation in the presence of copper (I) 
cyanide (Figure 2.4). In the first step, the yield of 6-aminocoumarin 
was optimised by modifying the procedure of Micklethwaite et az. 14 such 
that the product is extracted into chloroform rather than crystallised 
directly from hot sodium bicarbonate solution. Unreacted 6-nitrocoumarin 
was removed by dissolving the mixture in aqueous acid and extracting 
exhaustively into chloroform. 
The standard diazotisation procedure outlined 1n Vogel's handbook15 
was fol101ved for the conversion of 6-aminocoumarin to 6-cyanocoumarin. 
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However to ensure complete dissolution of 6-aminocoumarin hydrochloride, 
3N, rather than 6N, hydrochloric acid was used. The 6-cyanocoumarin 
recovered from the chloroform layer was found to be sufficiently pure to 
be used in the next step. A small amount was recrystallised from hot 
water for analytical purposes. 
The duration of the cyclisations of the linear tetraamines (14) and 
(15) with 6-cyanocoumarin were of the same order as those observed for 
6-nitrocoumarin, in accord with the electron withdrawing effect of the 
nitrile group. The yield of the [13]-membered macrocyclic amide (16) 
was consistently lower than that of the [14]-membered analogue (11), 
possibly due to increased conformational strain arising from the 
replacement of a propylenic unit by an ethylenic unit. 
The macrocyclic amides (16) and (17) were isolated in a similar 
manner to (±) through column chromatography and reduced to pentaamines 
(18) and (19) using diborane-THF. Excess borane was consumed with 
methanol to give easily removed trimethylborate. The resulting penta-
aminoborane was hydrolysed to the pentahydrochloride salt with 6N HCl. 
It was possible to isolate cycles (18) and (19) as clear oils simply by 
dissolving the crude hydrochloride salt in aqueous base and extracting 
into chloroform. The poorer yield of the [13]-membered cycle (18) may 
result from either a less clean borane reduction or a less favourable 
partition of the cycle between chloroform and aqueous base. Attempts to 
recrystallise cycles (18) and (19) proved unsuccessful due to their high 
solubility but it was found, by cation exchange HPLC, that the material 
1n each case was sufficiently pure (~ 957.) to proceed with conjugation 
to the antibody. 
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Fe,HCl 
~['NH2 
(HzC)n 
~ NH2 
n=O; (14) \__/ 
n=1; (15) 
i) HN02j -5°C 
;o cJcN 
~CN 
o.J...o~ 
Figure 2.4 Synthesis of (13}- and [14}-membered para-
Aminomethylphenol-pendent Hacrocycles. 
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2.3 NON PHENOL-PENDENT TETRAAMINE MACROCYCLES 
2.3.1 The Use of Non-Phenolic Side Chains 
The synthesis of non-phenolic functionalised cyclam and 13N4 is equally 
important for two main reasons. Firstly it permits an investigation of 
the possible role of a phenol-pendent group in technetium binding; we 
require a non-phenolic analogue as a control. Secondly, Kimura et az. 16 
reported that the phenol is interacting very weakly (pKa 9.2) in the 
copper complex of (2) and stabilises the system only at high pH (section 
5.1.3). Non-phenolic cyclam and 13N4 should therefore suffice as 
64cu 
and 67cu binders. 
It is possible to conjugate the macrocycles either through a carbon 
or through a nitrogen atom of the ring. Each method has merits and 
dra\vbacks which will be considered in sections 2. 3. 2 and 2. 3. 3. 
2.3.2 Synthesis of N-functionalised Cyclams 
The main advantage of N-functionalised cyclam derivatives is their easy 
synthesis from cyclam itself, which is commercially available. Reaction 
of excess cyclam with a suitably substituted benzyl bromide, according 
to the method of Volkert et az. 17 , proceeds cleanly to give the mono-N-
alkylated derivative in high yield. Pendent groups attached through 
carbon must be introduced into the backbone before macrocyclisation. 
The synthesis of C-functionalised macrocycles is consequently more 
complex and much more expensive, in view of the costly starting 
materials, loH yielding reactions and time-consuming chromatography for 
their purification. 
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In the first instance, when our efforts were directed towards aromatic 
amine-based side chains, cyclam was alkylated using p-nitrobenzyl 
bromide in chlorofonn at room temperature. With cyclam in large excess, 
exclusively monoalkylated product (20) is obtained (Figure 2.5). 
Unreacted cyclam can be filtered off after extracting the product into 
diethyl ether and is easily recovered by sublimation. 
Selective reaction of a-bromoacetyl bromide at the exocyclic 
aromatic amine requires methylation of the three remaining secondary 
amines using the Eschweiler-Clarke method18 . The final step, hydrogen-
ation of the nitro group of (21) to give cycle (22) was never completed 
due to a shift 1n emphasis away from aromatic amines towards a new 
strategy based on aliphatic primary amines. It was noted previously 
(section 2.2.6) that the use of an aliphatic amine-based side chain 
should permit conjugation of a phenol-pendent macrocycle without the 
risk of acylation of the ring. Likewise cycle (24) should possess 
similar advantages over (22) and can be made simply, by monoalkylating 
cyclam with a-bromotolunitrile followed by reduction of the nitrile 
group using diborane-THF (Figure 2.6). Both reactions proceed in high 
yield to give the free amine form of (24), isolated as a clear oil by 
extracting a basic solution of the crude hydrochloride salt with 
chloroform. In accord with the behaviour of pentaamines (18) and (19), 
cycle (24) could not be recrystallised using a wide range of solvent 
systems but was deemed sufficiently pure for conjugation purposes, as 
determined by 1H NMR and DCI mass spectroscopy. 
2.3.3 llinding Characteristics of Mono-N-Alkylated Cyclams 
Although per-N-alkylated cyclams are unquestionably poorer technetium 
and copper binders than cyclam itself, there is uncertainty about the 
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BrCH2C6H4N02 
Pd/C 
(l 
CHN N]rOlo N N N02 
HUH (20) 
IHCOOH HCHO 
Figure 2.5 Synthesis of N-(aminobenzyl)-pendent Cyclams. 
OBr -...:::: ~ 
CN 
CHCI3 
Figure 2.6 Synthesis of N-(aminomethylbenzyl}-
pendent Cyclams. 
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binding efficacy of mono-N-alkylated cyclams. 
J. Simon7 recommended that, wherever possible, derivatisation of 
cyclams for technetium binding should be made through carbon rather than 
nitrogen. Technetium complexes of a series of mono-N-alkylated cyclams 
were prepared by Ketring et al. 17 in greater than 90-95% yield at pH 
11.5 but a temperature of 80-90°C was quoted. The same workers reported 
in an earlier paper19 that cyclam itself incorporates technetium in 
similar yield at room temperature (pH 11). If a temperature of 80-90 °C 
is required for complexation by mono-N-alkylated cycles, their use for 
binding technetium to antibodies, which denature above 40 °C, would be 
precluded. FeH copper complexes of mono-N-alkylated cyclams have been 
reported. Kaden et az. 20 prepared a series of copper (II) complexes of 
N-carboxyalkylcyclams, Hhich do not appear to differ appreciably 1n 
their binding characteristics from cyclam itself. 
It is conceivable that we would need to use protecting groups 
e.g benzyl,Z for conjugating certain types of macrocycle to the 
antibody. Hydrogenolysis of these protecting groups would probably 
cleave the side chain from the macrocycle in the same step. 
2.3.4 Synthesis of C-functionalised Macrocycles 
C-functionalisation appears to be preferable to N-functionalisation in 
view of the greater resistance of the carbon-carbon bond to cleavage and 
the superior binding characteristics of macrocycles with four secondary 
amines in the ring. 
The preferred route to C-functionalised [13] and [14]-membered 
tetraamines employs a double condensation reaction between a linear 
tetraamine and a functionalised malonate ester to form a macrocyclic 
diamide which can then be reduced to the tetraamine using diborane 
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(Figure 2.7). This route was first reported by Tabushi et al. in 197721 
and has since been used by Meares et az. 22 to functionalise TETA with an 
aromatic amine side chain. 
Diethyl p-cyanobenzylmalonate (25) can be made by alkylating the 
sodium salt of diethylmalonate with a-bromotolunitrile. A two fold 
excess of diethylmalonate prevents significant dialkylation occurring. 
Condensation between the functionalised malonate ester and the 
linear tetraamine requires several days under reflux in anhydrous 
ethanol. The [13]-membered diamide (26) conveniently precipitates from 
solution as it is formed and can be recrystallised from hot ethanol. The 
[14]-membered diamide (27) must be purified by lengthy chromatography on 
silica. The yield of (26) is again lm-1er than for (?.7), the yields of 
the diamides are broadly similar to those obtained for the corresponding 
phenolic amides (16) and (17), but the diamides are easier to purify in 
both cases. 
Reduction of the amide and nitrile groups proceeds smoothly with 
diborane, both pentaamines can be isolated in good yield by extracting 
from basic solution into chloroform. 
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Figure 2.7 Synthesis of C-functionalised {13}- and 
{14}-membered macrocycles. 
- 79 -
PART B: SYNTITESIS ~F CROSS-LINKING AGENTS AND ANTIBODY CONJUGATION 
2.4 INTR~DUCTI~N 
2.4.1 lleterobifunctional Linker Molecules 
The preferred form of the functionalised macrocycle, containing a 
nucleophilic aliphatic amine in the side chain, must be attached to 
nucleophilic residues on the monoclonal antibody. This requires the use 
of a heterobifunctional cross-linker with tHo distinct groups, one 
specifically reactive towards the macrocycle side chain, the other 
towards suitable groups on the antibody. 
2.4.2 Modification of the antibody with Traut's reagent 
It has been reported by Meares et al. 22 that labelling of the 
macrocyclic ligand TETA with 67 Cu is only effective if a ''spacer" group 
is employed between the macrocycle and the antibody. The conjugate 
obtained by reacting a-bromoacetamidobenzyl-TETA directly with amine 
residues on the antibody "Lym-1" could not be labelled successfully 
unless the copper was added to the macrocycle prior to conjugation to 
the protein. This observation implies that in the absence of a spacer 
group, the macrocycle is inaccessible to the radioisotope, possibly 
"buried" within the complex macrostructure of the protein. 
Similarly, Arana et a l. 23 reported that the efficacy of the 
labelling of bifunctional chelators with technetium-99m was related to 
the length and lipophilicity of the chain separating chelator and 
antibody. If the chain was too short or too lipophilic, the chelate was 
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11 buried 11 within the protein and was unavailable for radiolabelling. 
The spacer group employed by Meares et al. was introduced by 
reaction of lysine c-amino groups with 2-iminothiolane (11Traut's 
Reagent 11 ). For their purposes, the resulting thiol group was then 
reacted with the bromoacetamide of the functionalised TETA derivative 
(30) to form a thioether bridge (Figure 2.8). 
Figure 2.8 11 Trauting 11 of lysine residues produces thiol-containing 
11 spacer11 groups for attachment of functionalised 
macrocycl es. 
11Trauting 11 of the antibody also all01.rs us to control more precisely the 
number, but not the location, of macrocycles bound to each antibody. An 
excessive number of chelators bound to the antigen binding region, which 
also contains lysine, would reduce the immunoreactivity of the antibody 
and must be avoided. The conversion of a limited number of lysines, 
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typically five, to thiols would ~nable us to control the conjugation of 
macrocycles bearing thiol-specific functional groups. Normally, Immuno-
globulin G does not contain free thiol groups but its Fab fragments+ do, 
in which case the use of thiol-specific macrocycle conjugates would be 
equally applicable. 
2.4.3 Cross-Linking Agents of the Prior Art 
A suitable bifunctional linker molecule must provide a terminus which 
reacts with the exocyclic primary amino group of the functionalised 
macrocycle and another which reacts specifically with the antibody 
thiols. The use of activated esters e.g of p-nitrophenol, N-hydroxy-
succinimide, in place of acyl halides should allow greater selectivity 
and control in the acylation of the exocyclic amine. In addition 
hoHever, protection of the ring nitrogens with metal ions or by pH 
control will still be necessary. 
The use of a-bromoacetamides as thiol specific reagents, although 
favoured by Meares e~ al. 1,22 , is unsuitable for our purposes since 
reaction also occurs at the secondary nitrogens of unsubstituted 
macrocyclic tetraamines giving complex oligomeric mixtures. At higher 
pH a-haloacids are readily hydrolysed to a-hydroxyacids, of which the 
aldehyde tautomer is essentially non-specific for thiol groups, reacting 
with amine residues as well (Figure 2.9). 
Heterobifunctional cross-linkers which employ maleimides as the 
thiol-specific group are commercially available24 ,25 . Generally these 
are highly reactive and tend to hydrolyse readily at high pU (~ 7.5) to 
maleamic acid (Figure 2.9). It would appear that the less favoured 
tSee section (1.2) for a definition of the terms Immunoglobulin G and 
Fab fragments. 
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orbital symmetry of the ring-opened form renders it unreactive towards 
thiol residues. In addition maleimides generally show relatively poor 
selectivity for thiols over amines e.g lysine, histidine, especially at 
high dilutions and at higher pH i.e above 7.5. 
The use of cross-linkers which have low specificity for thiols, 
such as a-bromoacetamides and maleimides, would result in the formation 
of complex polymeric mixtures through reaction at amino groups on both 
the antibody and the unsubstituted macrocycle. 
0 
II 
RNC-CHzBr 
H 
HzO 
~-R 
0 
~ 9H 0 
RHNC-CHzOH o::::=~ RNC-C1" H }J 
H20 
pH>15 
0 
~OH 
YNHR 
0 
Figure 2.9 Hydrolysis reactions of a-bromoacetamides 
and maleimides. 
2.5 VINYL PYRIDINE LINKER MOLECULES 
2.5.1 Vinyl Pyridines as Thiol-Specific Reagents 
In 1970, Cavins and Friedman26 announced a new internal standard for 
amino acid analyses based on S-P~(4-pyridylethyl)-L-cysteine. The thiol 
group of cysteine was found to be 300 times more reactive towards 4-
vinylpyridine than the amino group and reacted selectively to give (31). 
In view of the superior thiol specificity of vinyl pyridines, compared 
to the reagents of the prior art, a new generation of bifunctional 
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linker molecules was developed in collaborative work with Celltech. 
Both 2- and 4-vinylpyridine derivatives were found to react selectively 
with thiols in the pH range 5 to 9. 
HOOC-CH-CH2 I I 
NH2 SH 
In separate experiments, both isomers were found to be unreactive 
tm~ards the amino group of the dipeptide, Ala-Pro-NH2 at pH 9. (Ala = 
Alanine; Pro= Proline). The relative rates of reaction of 2- and 4-
vinyl pyridines with N-acetyl-cysteine and Ala-Pro-NH2 are presented in 
Figure 2.10. 
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Figure 2.10 Reaction of 2- and 4-vinylpyridine with N-acetyl 
cysteine and A la-Pro-Nil2 
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Thiols react with a number of a,fi-unsaturated compounds at rates 
determined by the electron deficiency of the terminal position27 The 
~ orbitals of 2- and 4-vinyl groups have appropriate symmetry for 
conjugation with the ~ orbitals of the pyridine ring. The characteristic 
electron-deficiency of the pyridine ring is thus delocalised to the 
terminal position of the vinyl group (Figure 2.11). The more highly 
conjugated 4-vinylpyridine derivative is more electron deficient at the 
terminal position and therefore more reactive towards thiols than 2-
vinylpyridine. Ho,iever since heterobifunctional cross-linkers 
containing 2-vinylpyridine are considerably easier to synthesise from 
commercially available materials than their 4-vinyl analogues, they were 
preferred in the first instance . 
. ~,~ n· ~~ llr-..1  5-R N '/ I N + 
H -~ ~-R 
~ 
tlN~S-R ~ ~~~-R 
Figure 2.11 Valence bond structures of 2- and 4-vinylpyTidine; 
mechanism of the reaction of 2- VP with thiol groups. 
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2.5.2 Synthesis of a Vinyl Pyridine Cross-linker 
The linker molecule, 2-vinyl-6-methoxyacetic acid pyridine-p-nitrophenol 
ester, can be synthesised in six steps from commercially available 2,6-
bis(hydroxymethyl) pyridine (Figure 2.12). The synthetic route, devised 
primarily at Celltech, aims to convert one hydroxymethyl group to a 
vinyl group and the other to a p-nitrophenyl ester. Initially one of 
the hydroxy groups is protected as an acid-labile dimethoxytrityl ether 
whilst the other is alkylated to give a relatively stable methyl ester. 
Having removed the DMT group with either p-toluenesulphonic acid or 
zinc(II) bromide, the liberated alcohol (33) can be oxidised to an 
aldehyde (34) using an activated form of manganese dioxide28 (obtained 
from Fluka). The conversion of the aldehyde to a vinyl group was higher 
yielding when the Peterson reagent29 , trimethylsilylmethylmagnesium 
chloride, was used rather than a conventional Wittig reagent. The use 
of thionyl chloride to promote 1,2-elimination from the intermediate 
silyl alcohol gave satisfactory yields of product (35). The final step, 
exchange of methyl and p-nitrophenyl esters, requires that the lithium 
salt of the acid be converted to its pyridinium salt before condensing 
with p-nitrophenol. It is thought that the pyridinium cation is acting 
catalytically as a proton donor since neither lithium nor triethyl-
ammonium salts of the acid are reactive. The p-nitrophenyl ester (36) 
is highly reactive and must be stored at -18 °C under nitrogen to 
prevent rapid retro-hydrolysis to the acid. 
The synthesis of the more reactive 4-vinylpyridine linker molecules 
is more complex since 2,4-bis(hydroxymethyl)-pyridine is both 
commercially unavailable and more difficult to mono-protect selectively 
at the 2-position. 
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Figure 2.12 Synthesis of a 2-Vinylpyridine-active 
ester Linker Molecule. 
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2.6 SELECTIVE ACYLATION OF EXOCYCLIC AMINO GROUPS 
2.6.1 Strategies for Selective Acylation 
Since exocyclic primary amines are much more nucleophilic than aromatic 
amines, milder acylating reagents such as active esters can be used in 
place of acyl halides. However since secondary amines are also 
susceptible to acylation by activated esters, the ring must be 
protected. The most obvious answer would be to protect ·the ring with a 
metal ion which could be removed once acylation lvas complete. 
2.6.2 Metal Ion Protection 
Lithium and sodium are known to form weak complexes with cyclam. We 
have investigated the possibility of using alkali metal ions as 
protection for the tetraamine system of cycle (29) during acylation of 
its exocyclic primary amino group with a-bromoacetyl bromide. However 
the precipitation of oligomeric material from solution suggests that 
lithium and sodium ions cannot prevent acylation of the ring. 
Zinc forms complexes with cyclam30 which we hoped would be 
sufficiently stable (log K = 15.5) to protect the ring in aqueous 
solution, yet which allow removal of the metal under relatively mild 
conditions. However when a p-nitrophenyl ester was added to an aqueous 
solution containing (29) and zinc(II) bromide no reaction occurred. 
This suggests that the acidity of zinc(II) ions in water is promoting 
excessive protonation of the primary amine. The use of aprotic 
solvents, such as acetonitrile, would avoid protonation but the z1nc 
complex of (29) was found to be insufficiently soluble in such media. 
Copper and nickel form sufficiently strong complexes with cyclam to 
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protect the ring but subsequent removal of the metal ion requires such 
forcing conditions that their use is impracticable. Removal of 
nickel(II) ions requires the complex to be boiled in sodium cyanide 
1 . 31 SO UtlOn . Copper(II) ions cannot be removed even as the insoluble 
sulphide following treatment with H2S. They will eventually dissociate 
in boiling 6N HCl but cannot be separated from the free ligand under 
these conditions. If the pH is raised or the temperature dropped, 
copper is bound by the ligand again. 
2.6.3 Controlling pH 
In view of our failure to identify a suitable metal for protecting the 
ring, it was decided to investigate the role of pH in the relative rates 
of acylation at the primary and secondary centres. It was discovered 
that by buffering the reaction mixture to pH 7, acylation could be 
confined to the exocyclic amine of the functionalised macrocycle. The 
four successive protonation constants of cyclam itself are 11.5, 10.2, 
1.7 and 1.032 . At neutral pH, the ligand will bind two protons shared 
equally between the four equivalent nitrogens. As a result of the 
extensive hydrogen bonding and extremely rapid exchange of protons, each 
nitrogen will effectively "see" half a proton. It would appear that 2 
protons are sufficient to lock up all four nitrogen lone pairs and 
prevent acylation occurring in the ring (Figure 2.13). 
At pH 7 the benzylamine side chain of (29) will also be extensively 
protonated (pKa:::: 9.5), less than 1% existing as the free form. H01~ever 
this is much greater than the concentrations of monoprotonated and 
unprotonated cyclam, 0.04% and 0.002% respectively, and it is clearly 
sufficient to allow exocyclic acylation to occur. 
Another important factor could be the low intrinsic reactivity of 
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the diprotonated form of the ring. Although protons are exchanged 
rapidly within the r~ng, the loss of a proton will require a change 1n 
the conformation of the ring, imposing a kinetic barrier to deproton-
ation. If this is the case, the kinetic barrier for deprotonation of 
the exocyclic amine would almost certainly be lower, allowing more rapid 
deprotonation to occur. 
RAPID 
Figure 2.13 Hydrogen Bonding and Proton Exchange zn 
/)iprotonated Cyclam 
2.6.4 Synthesis of Macrocycle-linker Conjugates 
A solution of "Pipes" buffer (0.5M) provides a pH in the range 6.8 to 
7.0 for the condensation of the macrocyclic primary amine with the p-
nitrophenyl ester (36) (Figure 2.14). The macrocycle is dissolved in 
aqueous buffer and a 2 fold excess of ester is added in an equal volume 
of p-dioxane. Should the pH of the solution deviate significantly from 
6. 8 to 7. 0, it can be adjusted with either lN NaOII or lN HCl. 
The reaction is equally applicable to non-phenolic and phenolic 
macrocycles and is generally complete within 4 hours at 40 °C. The 
- 90 -
((~~ 
c: :3 
H~~ 
.. ~JJ 'NH2 
HO n= 0; (18) 
n= 1; (19) 
0 ~I OzN----\i-- O~O 'N ~ 136! I 
n=O; (371 
n=1;138l 
pH 6.8 
n = 0; 1281 
n = 1; ( 29) 
Figure 2.14 Selective Acylation of the Exocyclic Amino 
Croups of Functionalised {13}- and {14]-
membered Hacrocyclic tetraamines. 
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dicationic macrocycle-linker conjugate can be separated from unreacted 
macrocycle (charge +3) using cation exchange HPLC, by virtue of the 
charge difference. The HPLC profile for the reaction of the [13]-
membered phenol (18) is shown in Figure 2.15. 
i 
NT'-f\11 
N~~! 
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1: !I~ i I 
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\~ 
.'-...1 \_I 
Figure 2.15 Cation Exchange HPLC profile for reaction between 
(18) and (36), showing (37) at 12 minutes and 
(18) at 17.5 minutes 
Retention times vary between 11 and 14 minutes, being slightly earlier 
for the phenolic macrocycle conjugates. Isolated as diacetate salts, 
the non-phenols are colourless oils, the phenols slightly yellow solids. 
Yields varied from 807. for (40) to 507. for (37). The long term 
stability of the conjugates is good, both in the solid state and in 
aqueous solution. The conjugates were characterised by 1H NMR 
spectroscopy and FAn mass spectroscopy, the 3 methylenic resonances 1n 
the 4.7-4.1 ppm region being particularly diagnostic. Typical NMR and 
FAB spectra are presented in Figure 2.16. 
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Figure 2.16 Nti!R and FAB Spectra 
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2.7 ANTIDGDY CONJUGATION 
2.7.1 Choosing the Antibody 
Having made the macrocycle-vinyl pyridine conjugates (37) to (40), the 
next step is to attach them to a suitable monoclonal antibody. The 
antibody of first choice, "B72.3", binds to tumour-associated glyco-
protein (TAG-72) found in human colon and breast cancer33 ,34 . Monoclonal 
B72.3 is an attractive choice for research \YOrk since it is readily 
available, has a lm" affinity for normal tissue types and has a 
complement antigen (TAG-72) with a high incidence (> 80%) in colon 
carcinoma tissue. 
2.7.2 Introduction of Free Thiol Groups on the Antibody 
The need for derivatisation of the antibody with Traut's reagent35 has 
been discussed previously (section 2.4.2). 
A solution of antibody (2 mg) in 0.2M phosphate buffer (pH 7.4) was 
treated with 75 pl of 20 mM 2-iminothiolane in 50 mM triethanol-HCl (pH 
8) in the presence of 2-mercaptoethanol at 4 °C. After 60 minutes at 4 
°C, the conjugated antibody was separated from small molecules by 
filtration through Sephadex G-50 (0.1 M sodium phosphate buffer pH 8). 
Using Traut's method, the number of free thiols introduced per 
antibody was found to vary from 2 to 5, as determined by titration 
against Ellman's reagent, 6,6'-dinitro-3,3'-dithiobenzoic acid (DTNB) 36 . 
Antibody thiols cleave the disulphide bonds of DTNB to form a mixed 
disulphide (41) and, in the process, liberate a molecule of 6-nitro-3-
thiobenzoic acid (Figure 2.17). Since the titration is performed at 
high pH, the liberated thiol is deprotonated and the resulting thiolate 
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anion (42) has an intense yellow colouration. Knowing the Amax (412 nm) 
and extinction coefficient (13600) of its absorption band, the 
concentration of thiolate and, by extrapolation, the concentration of 
antibody thiols can then be calculated. 
1 
(42) 
Figure 2.17 Ellman's Assay for Free Thiol Cro·ups 
0 = antibody 
2.7.3 Conjugation of the Antibody 
A solution of "trauted" antibody in 0.1M phosphate hnffer (pH 8.0), 
containing 2 nilll EDTA to sequester trace metals, was divided into two 
equal fractions. Both fractions were then incubated for 18 hours at 4 °C 
under argon, one fraction containing excess macrocycle-vinyl pyridine 
conjugate, the other fraction acting as a control. The first fraction 
was centrifuged through Sephadex G-50 to separate the antibody-chelator 
conjugate from unreacted vinylpyridine. Doth fractions were then 
assayed for free thiols using Ellman's reagent. It was apparent that 
some thiols had been "lost" from the control antibody due to oxidation. 
However a greater number had been "lost" by the antibody exposed to the 
macrocycle-vinylpyridine conjugate. The difference in the number of 
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free thiols between the two fractions gave an indication of the number 
of thiols capped by macrocycles. 
Before radiolabelling studies were performed using these antibody-
chelator conjugates, those thiol groups which had oxidised were re-
reduced and all free thiols were then capped with a-iodoacetamide (or 4-
vinylpyridine) to prevent their participation in metal-binding (see 
section 3.1.5). 
2.8 MONITORING ANTIBODY CONJUGATION 
2.8.1 The Importance of Monitoring Conjugation 
It 1s important to quantify the number of macrocycles bound per antibody 
as accurately as possible. The number of bound chelators must be 
optimised to provide as large a chelator concentration as possible for 
rapid metal binding without compromising the immunoreactivity of the 
antibody37 . Additionally, quality control in the manufacture of a 
radiopharmaceutical dictates that we monitor the number of macrocycles 
per antibody to determine accurately the radiation dose to the patient. 
The Ellman's assay, described in section (2.7.3), gave an 
indication of the macrocycle:antibody ratio by relating the number of 
free thiols in the derivatised and control antibodies. However for 
greater accuracy we require a method which counts the number of bound 
chelators directly, rather than by inference from the number of "lost" 
thiol groups. A variety of techniques have been employed by other 
workers for this purpose, incorporating either radioactive or 
fluorescent markers. 
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2.8.2 Radioactive Assay 
In order to monitor the number of molecules of functionalised EDTA bound 
to 872.3, Gansow et al. 12 used 14c labelled bromoacetic acid in its 
synthesis. Knowing the concentration of protein, they could calculate 
the chelator:antibody ratio from the amount of specific activity bound 
to the antibody. 
The TLC assay developed by Meares et al. 1 uses a solution of 
radioactive cobalt (57Co) in citrate buffer to quantify the protein-
bound chelator. The antibody bound 57co-chelate remains at the origin 
whilst 57co-citrate moves with Rf > 0.2, in ammonium acetate/methanol. 
Although radio-assays allaH the quantification of very lo"' 
concentrations of antibody-bound chelator, they possess a number of 
disadvantages. The 14c labelling method is only useful at the research 
stage. If employed for quality control in the final product, its P-
emissions would increase the dose to the patient unnecessarily. 
The utility of Meares' method based on radioactive cobalt is 
limited by the presence in solution of trace metals which occupy a 
sizeable proportion of the ligands at low chelator concentrations. In 
addition, there is the prospect of cobalt binding non-specifically to 
the protein backbone. An EDTA wash needs to be performed to avoid over-
estimation of the true chelator concentration. 
2.8.3 Fluorescent Assay 
Alternative assays based on fluorescent markers have been used 
extensively in protein chemistry. Our initial line of approach was to 
incorporate a fluorescent 1-dimethylaminonaphthalene-5-sulphonyl or 
"dansyl" group38 into a prospective linker molecule based on a Z-
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protected lysine. It was planned to react the p-nitrophenyl ester of 
the functionalised lysine (43) with the exocyclic primary amino group of 
cycle (29), remove the Z group then attach the macrocycle-linker 
conjugate (44) to the antibody thiols using a-bromoacetyl bromide 
(Figure 2.18). However the poor solubility of the lysine derivative 
(43) in aqueous media, due to the lipophilicity of the dansyl residue, 
inhibited further development of this approach. Furthermore it is 
conceivable that the incorporation of a bulky fluorescent group, such as 
dansyl, into the chain linking macrocycle and antibody might trigger a 
greater immunogenic response to the modified antibody. It is 
intrinsically preferable to employ a fluorophore which need not be part 
of the linker molecule itself. 
2.8.4 Ortho-phthalaldehyde (OPA) Assay 
The reaction between o-phthalaldehyde and primary amines in the presence 
of 2-mercaptoethanol, produces highly fluorescent products39 . The 
isoindole product (45) exhibits greater sensitivity than either 
ninhydrin or fluorescamine (detection limit is ca. 10-11 M). The o-
phthalaldehyde adducts are completely soluble and stable in aqueous 
buffers and since they are considerably less expensive than alternatives 
based on fluorescamine, they may be used routinely for quality control. 
Exhaustive hydrolysis of the antibody conjugate with 6N HCl (16 
hours at 110 °C) gives a mixture of amino acids and protonated 
functionalised macrocycle. Reaction of the liberated primary amino 
groups with o-phthalaldehyde and 2-mercaptoethanol gives a series of 
isoindole adducts which may be detected spectrofluorimetricallv (-\ 
. . ~c 
334 nm; Afl 453 nm). uor Separation of the macrocycle-isoindole compound 
(45) from derivatised amino acids was achieved using cation-exchange 
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(CH2)4 
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ZHNC~H 
I 
C=OpNP 
II (43) 0 
1) ( 29) 
2) H2 
1) BrCH2COBr 
2) Ab-SH 
Z NMe2 DSL = 0 -s 2 
Figure 2.18 Synthesis of a linker Molecule containing 
a Fluorescent "Oansy l" Group. 
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HPLC, by virtue of its dipositive charge at pH 6.5 (Figure 2.19). 
Typically, the derivatised antibodies were found to contain, by the OPA 
method, between 2 and 3 macrocycles per antibody. This level of 
conjugation was consistent with that given by the previously described 
Ellman's assay. 
2.9 IMMUNOREACTIVITY - THE EFFECTS OF CONJUGATION 
The immunoreactivity of the derivatised B72.3 antibody was assayed by 
affinity chromatography. This technique measures the percentage of the 
total antibody which retains an affinity for the TAG-72 antigen, 
suitably attached to a chromatographic plate. The immunoreactivity was 
tested for levels of conjugation between 1 and 9 macrocycles per 
antibody. It was found that up to 3 macrocycles could be conjugated 
without unduly diminishing the immunoreactivity. However when the 
average number of chelators bound was increased from 3 to 9, the 
affinity of the antibody for TAG-72 was progressively reduced. 
Other workers also found an inverse relationship between the number of 
chelating groups per antibody and immunoreactivity. Meares et al~ found 
77-84% retention of immunoreactivity by the anti-lymphoma Mab, "Lym-1", 
when conjugated with 0.4 to 2.3 molecules of EDTA per antibody. In 
their experience, 3 or 4 chelators per antibody did not seriously 
degrade the immunoreactivity but this may depend upon the type of 
chelator, the method of conjugation and the type of antibody used. 
Using the macrocyclic ligand TETA as a copper-67 binder, Meares et 
al. 22 found a retention of 70-75% with 2.7 chelators bound per antibody. 
Paik et az. 37 noted retentions of 67% and 47% for 0.8 and 3.4 molecules 
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Figure 2.19 01'tho-phthalaldehyde Assay joT the Number of 
JfacTocyc l es bound peT anti body. 
of DTPA per antibody, bound using the carbodiimide method, and 100% 
retention for 2 molecules of DTPA per antibody, bound by the cyclic 
anhydride method (see section 1.7.1). Hnatowich40 reported that 
conjugation of 4.3 DTPA molecules per protein using the cyclic anhydride 
method gave a retention of immunoreactivity of 51%. 
Volkert et al. 41 attached up to 4.2 functionalised cyclam 
macrocycles to the Mab, anti-HSA IgG (HSA = human serum albumen), \·lith 
90% retention of immunoreactivity. Using the same Mab as ourselves, 
872.3, Gansow et az. 12 attached up to 1 molecule of EDTA or DTPA using 
the anhydride or isothiocyanate methods (section 1.7.2) without loss of 
antigen affinity. Hmvever when more than 3 ligand~ were attached, a 
serious deterioration was noted. The nature of the chelator was 
important; EDTA being \vOrse than ·DTPA with respect to loss of affinity: 
EDTA: 36% retention (2.8 per Mab); DTPA: 75% retention (2.7 per Mab). 
The inverse relationship between the level of conjugation and the 
immunoreactivity of an antibody is valid for a given chelator conjugated 
by a given technique. Hmvever Paik et az. 37 reported that antibodies 
bearing equal numbers of chelating groups can, under certain 
circumstances, be either active or inactive. There would appear to be a 
more subtle relationship between immunoreactivity and derivatisation, 
involving the positioning of the chelating groups with regard to the 
variable region. 
The method of conjugation outlined 1n section 2.7 introduces (at 
lys E-NH2) thiol groups and concomitant macrocycles with a completely 
random distribution along the protein backbone. It is intrinsically 
preferable to locate chelating groups specifically outside the immuno-
logically important variable region. In future, genetically engineered 
antibodies, developed by Celltech, will permit "site-specific" 
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attachment of the chelator outside the binding region. The chelator 
concentration on the antibody could then be increased, thereby enhancing 
its metal binding characteristics, without impairing its immunological 
integrity. 
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CHAPTER THREE 
RADIOLABELLING STUDIES USING TECHNETIUM-99m 
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3.1 THE LABELLING ijF MACR~CYCLE-ANTIB~DY CONJUGATES 
3.1.1 99IDrc for Radioimmunoimaging 
The suitability of 99mTc for imaging tumours has been discussed in the 
introduction (section 1.3.3). Its ideal gamma energy (140 eV) and 
availability from a 99Mo generator have made 99IDrc by far the most 
widely used radioisotope in diagnostic nuclear medicine (90% of all 
current applications involve 99mTc!). In addition, its ability to form 
"strong" complexes with macrocyclic ligands such as cyclam (section 
1.6.7) make 99IDrc an attractive choice for radiolabelling tumour-
specific Mab's. 
3.1.2 The Labelling of Cyclam-Antibody Conjugates with 99mrc 
In 1980, Volkert et al~ described the formation of thermodynamically and 
kinetically stable 99mTc-cyclam complexes (Figure 3.1) by reducing 
pertechnetate (Tc04) with stannous chloride in the presence of the 
macrocycle at pH 11. The yield of complex was reduced at lower pH due 
to electrostatic repulsion between an increasingly protonated ligand and 
the oxo-technetium cationic species. 
Hfo\H + C~~NJ NII'N H~H 
Figure 3.1 Structure of the 99mTc complex of cyclam 
The same workers later reported2 that the rate of incorporation of 
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technetium by cyclam at pH 7 could be improved dramatically if a weak 
anionic 99IDrc-citrate complex was used as a carrier species. This 
method appeared to be ideal for the labelling of cyclam-antibody 
conjugates since the use of a pH close to physiological pH (7-7.8) would 
reduce the risk of damaging the antibody. However our fellow workers at 
Celltech found that the citrate transfer method was ineffective for 
labelling cyclam-antibody conjugates at pH 7. It would appear that 
99IDrc-citrate is more stable at pH 7 than was reported by Volkert et al. 
and it is thought that these workers may have measured the pH of the 
buffer before addition of the highly basic macrocycle (this makes the 
buffer much more alkaline). 
The incorporation of 99IDrc into antibody-bound cyclam was 
sufficiently rapid only at pH > 10. It was hoped that the Mab would not 
be unduly affected by this alien pH. Pertechnetate was pre-reduced 1n 
phosphate buffer at pH 6.0 using stannous chloride since there was 
evidence that reduction at more alkaline pH produces a higher yield of 
99IDrc-colloids which cannot then be incorporated by the macrocycle. The 
reduced technetium was then added to a solution of cyclam-antibody 
conjugate in bicarbonate buffer at pH 10.8: 
Tc04, phosphate , 
pH 6/SnCb 
ab = antibody "872.3" 
"TeO+" 2 
1 cyclam-ab bicarbonate pH 10.8 
Tc02-cyclam-ab 
3.1.3 The Need for Biodistribution Studies 
Serum stability studies give a rough indication of the suitability of a 
99IDrc-labelled macrocycle-antibody conjugate for in vivo diagnosis. If 
transchelation to serum components is observed, the conjugate is 
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unequivocably unsuitable. If the conjugate is stable in serum it may be 
suitable; conclusive evidence of suitability can only be obtained by 
conducting a biodistribution study in normal (non-tumour bearing) mice. 
The conjugate is injected intravenously into the tail vein of the mouse 
and is evenly distributed throughout the cardiovascular system within a 
matter of seconds. The level of cardiovascular activity falls quite 
steeply initially as the radiolabelled Mab diffuses from the blood into 
the extracellular fluid (ECF) until an equilibrium is reached between 
the blood and the ECF (typically 50% in 24 hours, Figure 3.2). The 
activity in the blood-pool will then fall more slowly at a rate 
determined by the rate of antibody catabolism. 
blood 
activity 
:-----------1 I 
~: b 
time 
Figure 3.2 Decreasing cardiovascular activity with time 
after injection; a= equilibration (N 24 hours); 
b= catabolism (several days}. 
If the cardiovascular activity falls in a given time by more than the 
theoretical amount, the radiolabel may have dissociated from the 
antibody or the antibody may have been damaged and removed from the 
blood by the liver. 
Some accumulation of activity in the liver is inevitable as a 
result of its blood content (N 30% by mass) and the leakage of activity 
from blood capillaries into the extracellular spaces. Higher than 
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expected levels of activity in the liver may signify that the antibody 
has suffered damage during the radiolabelling procedure. The free thiol 
groups of "trauted" antibodies may form disulphide bonds which cross-
link individual IgG to form aggregates which would accumulate in the 
liver. Alternatively high liver activity may be due to dissociation of 
metal ions from the antibody to form complexes with other metal-binding 
proteins, e.g transferrin, albumin which are subsequently degraded in 
the liver. Although the exact nature of metal extraction by the liver 
is unknmm, it appears that there are receptors which can bind a variety 
of metals. In particular there are thiol receptors which seem to 
extract technetium avidly unless it is strongly chelated to a protein. 
It is also important to limit the accumulation of activity in other 
organs to that arising from their blood content and from the initial 
equilibration. The interpretation of the activity in the kidney is 
complicated by virtue of it being the organ of excretion. Small 
molecules (including proteins of mass < 60000 daltons) can be excreted 
rapidly into the urine. Several biodistribution time points are 
required to determine whether there is excessive accumulation in the 
kidney relative to the blood. 
3.1.4 Biodistribution of 99~c-cyclam-antibody conjugates 
The cyclam-antibody conjugate was labelled at pH 11 (section 3.1.2), 
then purified from small molecules e.g excess SnC12, using a PD10 column 
(Sephadex G-25). The biodistribution data at 4 and 24 hours is given in 
Table 3.1. Two indicators of tissue activity are given: %dose g- 1 and 
%dose. The former gives a direct indication of the relative activity in 
equal masses of different tissues and therefore measures any 
accumulation of activity in a particular organ over and above that 
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expected from its blood content and equilibration. However the total 
dose in that organ depends upon its total mass, which can vary between 
smaller and larger animals. It is therefore usual to quote the 
percentage of the total dose contained within an organ in addition to 
the %dose g- 1 . The quoted figures are mean values (typically 2 mice per 
time-point), corrected for decay to time zero (the standard deviations 
are also given). 
Tissue 
BLOOD 
KIDNEYS 
LIVER 
--- 4 Hours ---
%D g-1 %Dose 
16.0 ± 0.1' 
13.1 ± 1.3 
8.8 ± 0.1 
7.1 ± 0.9 
13.2 ± 1.0 
--- 24 Hours ---
%D g- 1 %Dose 
7.8 ± 0.4 
6.9 ± 3.0 
5.7 ± 1.1 
3.7 ± 1.8 
8.7 ± 1.4 
Table 3.1 Biodistribution data for pH 11 conventional 
labellingj 2 mice per time point. 
At both time-points, the level of activity in the blood is considerably 
lower than would be expected from equilibration alone. Together with 
the relatively high kidney levels, this suggests that most of the 
activity has been excreted within 24 hours. 99~c may have been 
dissociated from the protein as Tc04, which is rapidly excreted. 
Alternatively, the thioether bond linking macrocycle and antibody may be 
unstable in vivo (thiol-vinylpyridine additions are potentially 
reversible). The liberated 99~c-cyclam complex would be eliminated 
rapidly from the body. 
Technetium bound by the macrocycle is unlikely to dissociate in 
vivo due to its kinetic inertness. If the low levels of cardiovascular 
activity are due to dissociation of 99~c form the Mab, technetium must 
also be bound "non-specifically" by other chelating groups on the 
protein. 
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3.1.5 Non-Specific Metal Binding 
In addition to a small number of macrocyclic ligands (typically 2 or 
less), the derivatised antibody contains a multitude of other sites 
which are capable of binding transition metals, albeit less strongly. 
Thus cyclam-antibody conjugates contain two types of binding sites -
"specific" sites (the macrocycles) and "non-specific" sites (the protein 
itself). Non-specific binding sites can successfully compete with much 
''stronger" ligands such as macrocycles by virtue of their higher 
concentration on the antibody. 
It is knmm that non-specific binding sites which chelate 99mTc are 
of two different types: high capacity, lm-1 affinity sites and lmv 
capacity, high affinity sites. The addition of a 10 fold excess of DTPA 
can prevent the binding of technetium to low affinity sites but no 
amount of DTPA can prevent binding to high affinity sites. Paik et 
al. 3' 4 reported that high affinity sites were related to free thiol 
groups produced by the reduction of the disulphide bridges linking the 
two heavy chains (section 1.2.2). They proposed the use of high affinity 
nn_ _ 
sites to bind "'"'u'Tc strongly to Mab's without the need for conjugating 
chelating agents such as DTPA. Although equal to conjugated DTPA 1n 
terms of effectiveness, with a much simpler protocol, this method of 
binding 99mTc cannot compete, in terms of in vivo kinetic inertness, 
with the use of a macrocyclic ligand e.g cyclam. 
3.1.6 Prevention of Non-Specific Binding 
Since the majority of non-specific technetium is bound by low affinity 
sites it can be removed using a chelate wash. In addition to EDTA and 
DTPA, other suitable chelates may include amino acids e.g histidine 
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responsible for non-specific binding or thiol-containing ligands e.g 2-
mercaptoethanol. Whatever the choice of chelate, there remains a limit 
to the amount of non-specifically bound 99IDrc which can be removed - 15% 
remains bound according to Paik et al. 4, but the quantity probably 
varies for different Mab's. 
The only effective way to reduce non-specific metal-binding to zero 
is to label the macrocycle before it is coupled to the antibody - this 
strategy is called pre-labelling. 
3.2 PRE-LABELLING 
3.2.1 Conventional versus Pre-Labelling 
The direct or "conventional" labelling of cyclam-antibody conjugates 
with 99IDrc produces a large excess of non-specifically bound radiolabel 
(Figure 3.3) which dissociates in vivo lowering the tumour:background 
activity ratio. Pre-labelling of the macrocycle with 99mTc in the 
absence of the Mab would seem to provide the ideal solution to this 
problem. Once radiolabelled, the macrocycle is conjugated to thiols on 
the antibody in the usual manner (Figure 3.4). 
The pH and temperature of the radiolabelling buffer is no longer 
restricted to close to physiological pH by the presence of the antibody. 
The macrocycle can therefore be labelled at a pH at which incorporation 
is known to be rapid. Another advantage of pre-labelling is that the 
Mab does not come into contact with the stannous chloride reducing 
agent, so the risk of damage to disulphide bridges is absent. 
Unfortunately pre-labelling is not a perfect solution to the 
problem of non-specific binding since it adds greater complexity to the 
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~/ 
s-s 
EDTA 
wash 
Figure 3.3 The Conventional Labelling Strategy 
CG 
tca.- ~( / SnCl2 s-s s-s ~ 
Figure 3.4 The Pre-labelling Strategy 
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preparation of the radiopharmaceutical. There are two reactions and 
purifications which must be performed by a hospital clinician, both 
involving potentially hazardous radioactive materials. Pre-labelling is 
also more time-consuming, especially if the conjugation step is slow; an 
important consideration in vieH of the short half-life of 99IDrc (6.02h): 
The advantages and disadvantages of conventional and pre-labelling 
protocols are summarised in Table 3.2. 
CONVENTIONAL LABELLING 
Advantages 
* Simple one-pot protocol 
Disadvantages 
* Reduced Tc binds 
non-specifically. 
* Some non-specifics 
cannot be removed by 
a chelate wash. 
* High liver uptake of 
non-specific Tc 
in vivo. 
PRE-LABELLING 
Advantages 
* No Non-Specific Binding 
* pH and temperature of 
labelling not restricted 
by antibody. 
* Tc insertion into 
macrocycle rapid and 
easily quantifiable. 
* Antibody does not "see" 
reducing agent. 
Disadvantages 
* More steps 
* Duration of conjugation 
step critical due to 
short half-life. 
Table 3.2 Conventional Labelling and Pre-Labelling Compared 
3.2.2 A Pre-Labelling Strategy for 99Mrc 
A radiolabelled macrocycle-linker conjugate was prepared by reacting 
reduced 99IDrc (SnC12; pH 6) with the cyclam-2-vinylpyridine conjugate 
(40) at pH 11 (80°C): 
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Tc04 pH11 
SnCl2 80° 
Ab-SH 
The incorporation was greater than 95% under these conditions and the 2-
vinylpyridine group was apparently unaffected by the high pH and 
temperature. The 99n~c complex was separated from excess free macrocycle 
and Tc04 using cation exchange HPLC. The recovery of activity from the 
column was poor(< 50%). The purified radiolabelled conjugate (46) was 
then reacted with the trauted antibody (B72.3) for 2 hours at 37°C. The 
yield of 99mTc-mac-ab was poor (< 0.5% of the activity was associated 
with the protein) due to the low reactivity of 2-vinylpyridines towards 
thiols. 
The 99IDrc-mac-ab conjugate was purified using a PD10 column and 
injected into mice. The biodistribution data at 19.5 hour!) is given in 
Table 3.3. The blood level is higher than that given by the conventional 
labelling strategy - 13.4% dose g- 1 at 19.5 hours for pre-labelling, 
compared to 7.8% dose g- 1 at 24 hours for conventional labelling. 
However the level of activity in the liver is extremely high, indicating 
accumulation of the radiolabel. On this occasion, the build up of 
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activity in the liver cannot be due to non-specifically bound 99~c, of 
which there is none, nor to cleavage of the macrocycle-antibody bond 
since 99mTc-cyclam is rapidly excreted by the kidneys. It is therefore 
likely that the high liver activity is due to aggregated protein, 
arising from intermolecular cross-linking of free thiol groups, but this 
cannot be a definitive statement on the basis of a single experiment. 
Tissue 
BLOOD 
KIDNEYS 
LIVER 
%D g·t 
13.4 ± 1.8 
4.3 ± 0.0 
14.1 ± 3.7 
%Dose 
32.4 ± 5.4 
2.5 ± 0.2 
22.6 ± 2.2 
Table 3.3 Biodistribution of a pre-labelled 99mTc-cyclam 
antibody conjugate at 19.5 hours; 
2 mice per time point. 
3.2.3 Xenograft Studies using Pre-labelled Antibody Conjugates 
A sample of the pre-labelled 99~c-mac-ab conjugate was injected 
intravenously into mice containing xenografts (human tumours implanted 
into immunosuppressed mice) displaying the antigen (TAG-72) recognised 
hv R7? ~ Ann+"hor 99111rr,.._m..,,., ..,l-, '"'~ ~ •• ~n4-~ •• n~ --n..:_ ___ .J -- - -- _, -, 
"" . -- w----- .... -........ .... ........ u-.-v II.NV VV.1.1.JU.6UIVV nu..Y }J.J.V_tJO..J.VU a..o a, \..UULl.U.l, 
containing the non-specific Mab MOPC21. The biodistribution data at 16 
hours and the tumour:blood and tumour:liver ratios are given in Tables 
3.4 ru1d 3.5 respectively. 
%D g·t 
TUMOUR 
BLOOD 
LIVER 
KIDNEY 
COLON 
SPLEEN 
MOPC21 
4.2 
13.6 
7.0 
4.9 
1.7 
4.2 
872.3 
7.3 
10.9 
6.5 
4.5 
1.3 
3.8 
Table 3.4 Biodistribution data for tumour-bearing animal 
at 16 hours. 
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TIME TUllfOUR/BLOOD TUMOUR/LIVER 
99
"Tc-MOPC21 (16h) 0.31 0.6 
99
"Tc-B72.3 (16h) 0.67 1.1 
125I-MOPC21 (24h) 0.44 1.7 
125I-B72.3 (24h) 0.90 3.9 
Table 3.5 Comparison of 072.9 Animal JJata for 99rnTc and 125 ! 
The tumour: blood and tumour:liver ratios for 99mTc-872.3 are roughly 
twice those of the control Mab (MOPC21), indicating selective 
accumulation of activity in the tumour. However this level of 
selectivity is lower than that obtained using 1251-872.3 - in particular 
tl 1. · · · f · f 99 Illm Th. tl t th 1e tumour: 1ver ratio 1s 1n er1or or 1c. 1s suggests 1a e 
method of attaching the 991~c-binding macrocycle may be more damaging 
than the method used for iodination of the antibody. Aggregated ~Iab' s 
produce higher liver levels, deactivated Mab's lower tumour levels. 
Aggregated Mab's are not removed using a PD10 column; size exclusion 
HPLC being required for their separation. However HPLC is not a 
practicable procedure for a hospital clinician to follow. Site-specific 
immunoreactivity if the macrocycle was suitably located outside the 
antigen-binding region. 
The specific activity of 99"Tc which could be attached to 872.3 
using the 2-vinylpyridine method was much too low for the tumour to be 
imaged externally. If the length of the conjugation procedure was 
extended, the yield of Tc-mab-ab could be improved but would be more 
than offset by the decay of 99mrc to 99rc (tt 6.02h). 
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3.3 M~RE REACTIVE THI~1-SPECIFIC CROSS-LINKERS 
3.3.1 Enhancing the Reactivity of Vinyl Pyridines 
The usefulness of a pre-labelling strategy for short-lived 99IDrc depends 
upon the kinetics of attachment of the labelled macrocycle being 
sufficiently rapid. Conjugation of a 2-vinylpyridine conjugate is 
simply too slow for sufficient specific activity to be attached to the 
Mab. For this reason a number of other vinyl-substituted nitrogen 
heterocycles are currently being tested by our collaborators at Celltech 
for enhanced reactivity towards antibody thiols e.g 4-vinylpyridine 
(47), vinyl-2,2-dipyridine (48) and 4-vinylpyrimidine (49): 
c; 
N 6 
(47) (48) (49) 
Unfortunately many macrocycle-linker conjugates containing faster-
reacting nitrogen heterocycles have proved much more difficult to 
synthesise than the 2-vinylpyridine derivative. Others have exhibited 
only modest improvements in reactivity. 
3.3.2 Maleimide Cross-Linking Agents 
Maleimides are much more reactive towards thiols than even the fastest-
reacting vinylpyridine5-7. Problematically, they are also more reactive 
towards other groups on the antibody (less thiol-specific). Maleimides 
are also more sensitive to pH; losing their reactivity through ring 
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opening at high pH (section 2.4.3). 
If these problems can be overcome, or at least minimised, 
maleimides are potentially useful as part of a pre-labelling strategy. 
Moreover since several maleimide cross-linkers are commercially 
available, no long synthetic procedures would be required for the 
preparation of macrocycle-linker conjugates. 
3.3.3 The pH Sensitivity of Maleimides 
One of the main shortcomings of maleimides for pre-labelling is their 
tendency to ring-open and/or react with amine groups at high pH. Since 
cyclam can only be labelled successfully above pH 10 and most maleimides 
ring-open below pH 7, the pre-labelling of a cyclam-maleimide conjugate 
is not a realistic option. However some maleimide cross-linkers are 
somewhat less pH sensitive than others8 ' 9 . One such derivative is 
commercially available: sulfosuccinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (50): 
-o3sl)-oJOcHr6 
0 0 
(50) 
It was found that the maleimide group of (50) was stable for at least 9 
hours in aqueous buffer at pH 6.5 in the presence of equimolar amounts 
of cyclam, as determined by 1u NMR. The integral of the maleimide 
singlet (o 6.83) remained unchanged throughout the experiment. The only 
hydrolysis reaction which occurred was that of the N-hydroxysuccinimide 
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ester group. 
This stability study suggests that the maleimide group of a 
macrocycle-(50) conjugate could be sufficiently stable towards r1ng 
opening and unreactive towards secondary ring nitrogens to allow 99IDrc 
labelling at neutral pH. 
3.4 LOWERING THE pH OF 99IDrc LABELLING 
3.4.1 Phenols versus Non-Phenols as Tc binders 
As discussed in section (2.2.1), it was hoped to enhance the kinetics of 
uptake of 99mTc by cyclam by providing an additional anionic donor site 
in the form of a phenol-pendent group. 
The influence of the phenol upon the kinetics of uptake was 
monitored radiochemically using acetylated forms of the functionalised 
phenolic and non-phenolic macrocycles (19) and (29). 
0 
II 
NHCCH3 
(52) 
0 
II 
NHCCH3 
The synthesis of the aminomethyl forms of these macrocycles has been 
described elsewhere (section 2.2.6 and 7.3.1). The exocyclic amino 
group can be acetylated selectively, with p-nitrophenyl acetate, using 
the strategy of pH control described in section 2.6.3. Acetylation 
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prevents any possible influence of the primary amino group upon the 
kinetics of association, thereby simulating the circumstances of the 
conjugated macrocycle. Cycles (51) and (52) were trrutsferred to our 
collaborators at Celltech for radiolabelling experiments. 
The rates of uptake of 99mTc by (51) and (52) were compared using 
cation exchange HPLC radiometry. At pH 10.8, the phenolic cycle was 
found to incorporate 99mTc at an essentially similar rate to the non-
phenol. However at lower pH (8.95), the difference between the two 
cycles \·laS much more marked (Figure 3.5). After 30 minutes, the non-
phenol had bound a mere 13% of the available activity, whereas the 
phenol had bound 72%. After 60 minutes the contrast between the 2 
cycles was slightly less pronounced. The incorporation by the non-
phenol had increased substantially (to 23%), the phenol only slightly 
(to 75%). The total amount of activity recovered from the HPLC column 
was less than 100% of the Tc04 activity for the non-phenol, indicating 
that uncomplexed Tc had been retained on the column. The activity 
ascribed to a single 99mTc-(51) complex actually comprised 2 peaks 
eluting very close together, suggesting two complexes with similar 
charge. 
The phenolic group of (51) must be implicated to explain its rapid 
association kinetics compared to (52). At pH 8.95 the phenol group of 
(2.) is substantially ionised (pKa 8.86); interacting strongly with the 
diprotonated ring and reducing the overall charge of the ligand from +2 
to +1 (Figure 3.6) 10 . 
The rate enhancement could be explained purely on the grounds of 
lower electrostatic repulsion towards the incoming technetium cation, 
without invoking bond formation between technetium and the phenol. 
Alternatively the phenol could serve to pre-orientate the "Tc0; 11 species 
for rapid incorporation into the ring (Figure 3.7). 
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Figure 3.5 The Incorporation of Reduced 99mTc by Phenolic and 
Non-Phenolic Cyclam Derivatives at pll 8.95 (1.0111 
NallCDa}; Reduction in O.SJI phosphate {pH 6.0); 2ooc. 
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Figure 3.6 Stabilisation of the phenolate anion of (g) 
0 /H 0 
II/ 2 
H o--Tc-o 
2 /II 
HO 0 
2 
Figure 3.7 Potential Intermediate Species in the 
Complexation of 99mTc by Phenolic Cyclam. 
The explanation for the apparent existence of two 99IDrc-(51) species may 
lie with the ability of the phenol to act as an extra axial donor 
(section 1.5.7). One species may involve axial phenolate coordination 
whilst the other may contain unbound phenol (Figure 3.8). 
Figure 3.8 A Possible Role for Axial Phenolate Binding 
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To the author's knowledge there is no precedent for Tc(V)-amine 
complexes containing mono-oxo rather than dioxo cores. However, if the 
oxidation state of Tc Here to be reduced from +5 to +4 by phenolate 
binding, the overall charge (+1) of the complex would not change, 
consistent with the observed HPLC profile. 
Whatever the exact role of the phenol group in the kinetics of 
association, the implication for radiolabelling is readily apparent. 
Antibody-bound phenolic cyclam may be labelled satisfactorily at a lo,~er 
pH than is possible for cyclam itself. However the pH must be reduced 
still further if maleimides are to provide a viable pre-labelling 
strategy. 
3.4.2 Nitrophenol-pendent Cyclams for Tc Binding 
If the increased rate of Tc binding observed for (51) at pH 8.95 is 
related to deprotonation of the phenol at that pH, it may be possible to 
achieve further rate-enhancing effects at even lower pH by reducing the 
pKa of the phenol still further. 
Generally electron-withdrawing substituents increase the acidity of 
phenols. The reduction of the pKa is dependent upon the number of 
substituents, their electron-withdrawing power and their position in the 
r1ng. Ortho and para-substituted nitro groups are particularly 
effective: 
OH 
0 
10.0 7.15 7.17 4.10 
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Kimura et az. 11 found that the pKa's of 4-nitrophenol and 2,4-dinitro-
phenol are even lower when attached to tetraamine macrocycles due to the 
stabilisation of the phenolate anion by the dipositive charge of the 
ring (Figure 3.6). 
H()H H()H H()H 
c J c J c J H~ H~ H~ 0 NOz 0 NOz HO HO HO 
NOz 
(~) (_~) (53) 
pKa 8.86 6.37 2.90 
The mononitrophenol of cycle (li) is substantially deprotonated at pH 7. 
The dinitrophenol of (53) is completely ionised. Both cycles may 
therefore be compatible with the use of maleimide linker molecules. The 
synthesis of a functionalised nitrophenol-pendent cyclam is described 
below. 
3.4.3 Synthesis of a F~ctionalised Nitrophenol-pendent cyclam 
A procedure reported by Kimura et az. 11 was adapted for the synthesis of 
a functionalised ortho-nitrophenol-pendent cycle (54) (see overleaf). 
The pentaamine (19) was protected with trifluoroacetic anhydride in an 
attempt to prevent N-nitration, ipso nitration and/or oxidative cleavage 
of the aryl group from the macrocycle. After nitration with HN03/H2So4 
(3:2), the protecting groups were removed with aqueous base in methanol. 
On acidification (acetic acid), a yellow solid precipitated which was 
identified by 1H NMR and Negative FAB mass spectroscopy to be a pure 
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sample of the dinitrophenolic cycle (53). The absence of benzylic 
methylene protons (o N 4 ppm) in the 1H mfR spectrum was diagnostic. 
1 HCF3COlzO 
2) HN03/H2S04 
3)NaOH/MeOH 
(19) (54) 
It was apparent that ipso-nitration had occurred at the para position 
bearing the protected aminomethyl substituent (follmved by loss of the 
amido substituent). It is possible that primary trifluoroacetamides are 
less robust than secondary trifluoroacetamides in the nitrating mixture 
of concentrated acids, HN03 and H2so4. Certainly the alkyl substituted 
ortho position will be more hindered (by the macrocycle) than the para 
position towards attack by nitronium ions. Perhaps this explains why 
predominantly dinitro compound is obtained. A small amount of the 
desired product (54) was isolated as a yellow solid by cation exchange 
HPLC from the crude materia1 which remained in solution in aqueous 
acetic acid. Since the overall yield of (54) was a meagre 2.3%, this 
would not appear to be a viable route. 
3.4.4 Sulphonic Acid-Phenol-pendent Cyclams for Tc Binding 
There are few electron-withdrawing groups which can be introduced in a 
one-pot reaction of the functionalised pentaamine (19). One such group, 
a sulphonic acid, is easily introduced by dissolving the macrocycle in 
98% H2so4. Low temperature sulphonation generally produces a mixture of 
ortho and para isomers. At higher temperatures, the more 
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thermodynamically stable meta isomer is formed12 . In terms of reducing 
the pKa of the phenol, sulphonic acid substituents are much less 
effective than nitro groups. Hmvever sulphonic acid groups themselves 
are ionised at neutral pH and it would be instructive to investigate the 
effect of another charged species other than phenol upon the rate of 
uptake of 99IDrc at this pH. 
One ortho and two meta positions in the phenol group of cycle (19) 
are available for sulphonation. The cycle was dissolved in 98% H2so4 
and heated to 100°C for 1 hour. Somewhat surprisingly in vieH of the 
elevated temperature used, the major isomer in the product mixture Has 
the ortho derivative (55); the meta coupling (2.2 Hz) of the two protons 
of the aromatic ring being diagnostic. A small sample of (55) was 
isolated by cation-exchange HPLC as the triacetate salt, for analytical 
purposes and 99IDrc labelling studies (section 3.5.1). 
(19) 
98"/o H2S04 
lh, 100° 
3.5 TECllNETIUM LAllELLING STUDIES AT NEUTRAL pll 
(55) 
3.5.1 The Potential o£ a Series of Tetraamine Ligands for pll7 Labelling 
In experiments conducted at the MRC Radiobiology Unit, Harwell for 
safety reasons, the author tested the binding efficacy of a series of 
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tetraamine ligands towards 99IDrc at neutral pH (section 3.7). The aim 
was to identify cycles which might be used in conjunction Hith 
maleimides in a pre-labelling protocol. 
Eight ligands were investigated: 6 macrocyclic and 2 open-chain 
tetraamines (Figure 3.9). 
n H,()H HnH HnH HN NH 
eN NJ eN NJ c J c J H2 H2 H2 Hz Ht.,JNH H~ 
HO 0 (14) (15) CYCLAM (2) 
n HNf)H H,()H H,()H HN NH 
eN NJ c J e J eN NJ H~ H~ H~ H~ 
HO 0 0 
NOz 0 N02 0 NHz 
HO HO HO 
(56) ( 5) (53) NOz (55) SOJH 
Figure 3.9 Candidate tetraamine ligands for neutral pH 
99mTc labellin_q. 
By analogy with the association kinetics of copper(II) and tetraamine 
ligands (section 5.1.2), the rate of incorporation of 99mTc by open-
chain ligands is expected to be substantially faster than for 
macrocycles, under a pH regime (e.g pH 7) where both ligands are 
protonated. The application of open-chain ligands for binding transition 
metals e.g Tc is usually limited by the instability of their chelate 
complexes in vivo (section 1.4). However the work of Volkert et al. 2 
could not distinguish between the stability of 99~c-cyclam and the 
99mTc complex of the open-chain tetraamine, 1,5,8,12-tetraazadodecane 
with respect to acid-induced decomplexation. 
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The basic cyclam system is included as a reference, even though its 
rate of uptake is likely to be very slow at this pH. The phenolic 
ligands (2), (Q), (53) and (55) have been discussed vide ante. The 
inclusion of the 13N4 cycle (56) should provide an indication of the 
role of the phenol in a smaller macrocycle. Volkert et az. 13 hinted 
that the Te-N bonds in 99mTc-cyclam might be slightly longer than their 
optimum value (section 1.6.4). The slightly smaller cavity of 13N4 
might enhance in vivo stability still further. 
3.5.2 Results of the Labelling Studies 
The labelling yields for all 8 ligands, as determined by HPLC 
radiometry, were relatively low at pH 7 (Table 3.6). However these 
figures are misleading because the recovery of activity from the cation 
exchange column was very poor. An injection of Tc04 gave a recovery of 
activity of only 34% (Tc04 should pass straight through the column). 
This suggests that the generator eluent was impure (a previous generator 
had produced 2 separate peaks for an injection of supposedly pure 
Tc04!). It was therefore decided to relate the labelling yields to the 
amount of recovered rather than injected Tc04 (Table 3.6). 
3.5.3 Discussion of Labelling Yields 
As expected, cyclam did not incorporate measurable amounts of 99mTc at 
pH 7 due to electrostatic repulsion between the diprotonated ring and 
· · T o3+ d T o+ · 1ncom1ng c an c 2 spec1es. 
The phenolic groups of (2) and (56), with pKa's 8.86 and 8.71 
respectively, will also be substantially protonated at pH 7. However 
since both ligands show significant uptake of 99IDrc, it is conceivable 
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that sufficient is ionised to reduce the charge on the ring and its 
electrostatic repulsion towards the oxo-technetium cation. 
LIGAND Reaction % Labelling Yield % Labelling Yield 
Time(mins) vs Tc04 standard vs Tc04 injection 
(14) 48 7.8 23 
(15) 46 20.8 60 
CYCLAM 25 0.0 0 
(l) 33 c~ 5.6 (i~ 16 (i~ 12.7 (ii 38 
(56) 34 12.2 36 
(.Q.) 38 15.5 46 
(53) 32 2.5 7 
(55) 32 4.0 11 
Table 3.6 Labelling Yields for a series of Tetraamine 
Ligands with 99mTc. 
There does not seem to be a direct correlation between the pKa of the 
phenol and the rate of uptake. The dinitrophenolic cycle (53) shows 
very low incorporation at pH 7 even though it.:;; !lh P.no 1 1 R rom!' 1 P-f:: t:> l~' 
ionised (pKa 2.90). The mononitrophenol (.Q.) shows much better 
incorporation even though its phenol is not completely deprotonated at 
pH 7 (pKa 6.37). However the sulphonic acid-phenol cycle (55) shows 
much lower incorporation than (l) which is consistent with the lm,rer 
acidity of the phenol (pKa N 12). There would not appear to be a rate-
enhancing effect arising from the negative charge on the sulphonic acid 
group at this pH. 
A most curious feature of 99mTc binding by (2) is the appearance of 
two peaks (Figure 3.10). These peaks are more widely separated on HPLC 
than those observed previously for the acetamidomethyl derivative (51). 
The second peak (at 9 minutes) may be due to a dicationic species 1n 
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activity 
0 2 4 6 8 10 ret. time (mins) 
Figure 3.10 HPLC Radiometry Profile for the Reaction between 
Reduced 99mTc and (g) at pH7 {33 min; 200 C). 
activity 
0 2 4 6 8 10 rel.lime jminsl 
Figure 3.11 HPLC Radiometry Profile for the Reaction between 
Reduced 99mTc and (15} at p!l7 {46 min; 20°C). 
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Hhich an axial phenolate group (one e- donor) has replaced one of the 
oxo groups (two e- donor) (Figure 3.8). If both species were mono-
cationic, technetium would be present in the +4 rather than +5 oxidation 
state in the complex where the phenolate was bound. It is a mystery why 
no secondary peaks are observed for (56), (~), (53) and (55). If the 
two peaks are taken together, the uptake of 99mrc by (~) is better than 
for any of the other macrocycles (54%). 
The best incorporation of all (60%) was provided by the acyclic 
tetraamine, 1,4,8,11-tetraazaundecane (15), essentially a single peak 
eluting at 5.1 minutes (Figure 3.11). In contrast, 1,4,7,10-tetraaza-
undecane (14) gave a disappointing incorporation (23%) and the reaction 
mixture contained large quantities of Tc04,. In fact several of the 
samples contained Tc04,, whether from re-oxidation or incomplete 
reduction is not clear on the basis of one result. Many of the peaks 
were broad - this may be improved using a gradient eluent system. 
The reason for the generally low recovery of injected 99mTc from 
the column, even in the case of Tc04,, is unclear. The recovery of 
activity was particularly poor for those ligands which gave little or no 
peaks with retention times 4-5 minutes. This sugg.ests that reduced 
. 99 
uncomplexed IDrc sticks to the column. 
Since these results are based on a single experiment, it would be 
unwise to draw too many conclusions from the data. In view of the 
necessity to conduct all radiolabelling experiments at Harwell, it was 
not possible to substantiate these observations in repeat experiments. 
However it is likely that this work will be continued by other workers. 
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3.6 CONCLUSI~NS 
It has been established by a number of workers, including our 
collaborators at Celltech, that 99IDrc binds non-specifically to the 
protein when Mab's are labelled directly with reduced technetium. Non-
specifically bound Tc dissociates in vivo and is removed from the blood-
pool. Pre-labelling solves the problem of non-specific binding but 
introduces other constraints. The only cross-linker which could 
withstand the pH required for 99mTc labelling of cyclam (pH 11), a 2-
vinylpyridine derivative, reacted too slowly for sufficient specific 
activity to be attached to the Mab B72.3 for imaging a xenograft bearing 
the antigen TAG-72. The tumour uptake was also relatively lm~ 
presumably due to damage to the antigen-binding site caused by the 
"trauting" and conjugation procedure - site-specific labelling would be 
better. 
Commercially available cross-linkers containing maleimide groups 
should be more effective in a pre-labelling strategy by virtue of their 
greater reactivity towards thiols. However, since maleimides are 
unstable at the high pH required for 99IDrc labelling of cyclam, 
alternative macrocycles which could be labelled at neutral pH were 
required. A phenol-pendent cyclam derivative was found to incorporate 
reduced Tc more rapidly at pH 9 than cyclam itself. With this result 1n 
mind, the rate of uptake of 99mTc by a series of derivatised phenolic 
macrocycles and acyclic ligands was investigated by the author. At this 
pH, cyclam did not incorporate 99mTc at all. The phenolic derivatives 
were much better although yields were lower than at pH 9. An acyclic 
ligand, 1,4,8,11-tetraazaundecane gave the best uptake of all at neutral 
pH. It may prove to be useful for pre-labelling if the in vivo stability 
of its 99IDrc complex is sufficiently high. 
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The phenolic cyclam (2) was the only ligand to produce two distinct 
99mTc complexes. It is possible to speculate that the phenol is bound 
(as phenolate) to technetium in one of these complexes (Figure 3.8) but 
this postulation cannot be substantiated from experiments at the tracer 
level. A crystal structure of the 99Tc complex of (2) would be required 
to ascertain whether or not the phenol coordinates to Tc. Similarly 
association kinetics experiments at the macroscopic level (using 99Tc) 
would be required to rationalise the role of the phenol in enhancing the 
rate of uptake at low pH. 
There did not appear to be a direct relationship between the rate 
of uptake at lower pH and the pKa of the phenol, although these results 
are based upon a single experiment and should not be over-interpreted at 
this stage. 
In conclusion it appears that pre-labelling is the only effective 
strategy for avoiding non-specific Tc binding. Several phenol-pendent 
macrocycles and acyclic ligands show promising rates of uptake of 
reduced Tc at neutral pH. Their use in conjunction with maleimide 
cross-linkers as part of a pre-labelling strategy is worthy of further 
investigation. 
3.7 EXPERIMENTAL 
3.7.1 Reagents 
The ligands, 1,4,8,11-tetraazacyclotetradecane (cyclam), 1,4,7,10-
tetraazadecane (2,2,2-tet) and 1,4,8,11-tetraazaundecane (2,3,2-tet) 
were purchased from Aldrich, Fluka and Strem respectively and were used 
without further purification. 
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The phenolic macrocycles, 11-(2-hydroxyphenyl)-1,4,7,10-tetraaza-
cyclotridecane (56), 5-(2-hydroxyphenyl)-1,4,8,11-tetraazacyclotetra-
decane (.f.) and 5-(2-hydroxy-5-nitrophenyl)-1,4,8,11-tetraazacyclotetra-
decane (Q) were synthesised according to the method of Kimura et az~0 , 11 
(see sections 7.3.1 and 7.3.5 for synthetic procedures). 
The dinitrophenolic cycle, 5-(2-hydroxy-3,5-dinitrophenyl)-
1,4,8,11-tetraazacyclotetradecane (53) was synthesised accidentally 
during the nitration of (19) (see sections 3.4.4 and 7.3.6). The 
synthesis of 5-(2-hydroxy-3-sulphonic acid-5-aminomethylphenyl)-
1,4,8,11-tetraazacyclotetradecane (55) is described in section 3.4.5 and 
outlined in section 7.3.6. 
Stannous(II) chloride was purchased from Aldrich and all buffer 
materials were obtained from BDH. The 99mTc04 was eluted from a sterile 
99Mo-99mTc shielded "Amertec 11" generator (Amersham) with 0.9% saline. 
Doubly distilled deionised water was used throughout. 
3.7.2 Stock Solutions 
Ligands 
Most of the stock solutions were 20mM in ligand. However the nitro-
phenol-pendent cycles (Q) and (53) could only provide a 14.3 ~I stock 
solution due to their poor solubility in water. 
Stannous chloride 
Stock solutions of SnC12 (2.18 ~I) were prepared daily by dissolving e.g 
17.5 mg SnC12 in 4.23g of 10mM HCl (21.8 mM), followed by a ten-fold 
dilution in distilled water. 
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Buffers 
0.5M phosphate (pH 7.0) and 0.2M citrate (pH 6.0) buffers were prepared. 
Technetium 
The eluent volume was adjusted each day (to allow for decay of the 
generator) to provide a stock solution which contained an activity of 
5.6 pCifpL at 10:00h on the morning of the labelling experiment. 
3.7.3 Labelling 
Pertechnetate (11.2 pCi; 21.3 x 10-15 mol) was reduced using stannous 
chloride (54. 7 pM) in the presence of the tetraamine ligand (1 rrilll) at pH 
7.0 (0.5M phosphate) at room temperature. 
The reaction mixture (total volume 100 pL) was prepared from the 
following ingredients: 
1) 99IDrc04 (11.2 pCit in 2 pL saline) 
2) SnC12 (2.5 pL of 2.188 mM solution in 1 mM HCl) 
3) Phosphate buffer (90.5 pL of 0.5M solution) 
4) Ligand (5pL of 20 mM solution) 
The reaction mixtures containing the less soluble nitrophenolic ligands 
were prepared using 7 pL of 14.3 ~~ ligand stock solution with 
correspondingly less phosphate buffer (88.5 pL). 
3.7.4 Monitoring the Rate of Incorporation 
The rate of uptake of 99IDrc was monitored by IIPLC radiometry. After a 
reaction period of between 25 and 48 minutes, 20 pL of the reaction 
tat 10:00h on the morning of the experiment 
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mixture was mixed with 10 p,L of 0.2M citrate buffer (pH 6.0). 20 p,L of 
the resulting solution was injected onto the HPLC column (cation 
exchange resin CM300 "Synchropak") and eluted isocratically with pH 6.5 
buffer (6% l.OM NH40Ac; 30% CH3CN; 64% H20) at a flow-rate of 1.4 cm
3 
. -1 
mln 
3.7.5 Recovery of Activity 
The total eluent from each injection (flow time N 15 mins) was collected 
and counted separately to establish the activity recovered relative to 
that retained on the column. The recovered activity was compared to the 
amount of injected activity. A Tc04 standard was used for this purpose: 
20 p,L of a solution containing 2 p,L of Tc04 stock solution in 98 p,L 
phosphate buffer was diluted with 10 p,L citrate buffer and 20 p,L was 
counted. The time at which the Tc04 standard was counted was recorded 
such that all further counts could be time-corrected for decay using the 
equation: 
A = A e-At 
t 0 . 
where At = activity at time, t, 
A0 = activity at time, t 0 and 
A =transformation constant = 0.693/tt = 0.63/6 = 0.105 h- 1 for 
99~c 
For example, a sample giving 2100 cpm at 12:00h will give at 14:30h on 
the same day: 
2100 x e-(2·5x0·693)/6 = 1573 cpm. 
It became clear at an early stage that a large amount of activity was 
sticking to the column despite the use of citrate buffer in an attempt 
to chelate unreacted reduced technetium. In fact an injection of Tc04 
as a control gave a recovery of activity of only 34%. All the reaction 
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mixtures produced lm-1er recoveries, although several were above 30%. 
The percentage recovery values relative to the Tc04 standard, time 
corrected for decay, are given in Table 3.7. 
3.7.6 Calculation of Incorporation of 99IDrc into macrocycles 
All samples, except that containing cyclam, produced HPLC peaks between 
4.27 and 5.20 minutes which were consistent with a monocationic complex 
containing a trans-TeO~ core (e.g 2,3,2-tet, Figure 3.11). Variable 
amounts of activity were also eluted between 1 and 3.2 minutes which 
might be attributed to neutral e.g Tc02 or anionic species e.g Tc04. 
The phenolic cyclam (2.) was the only ligand which gave a peak l-li th 
a much longer retention time (8.94 mins), in addition to one at 4.27 
minutes. When repeated with freshly prepared ligand stock solution the 
same result was obtained: peaks at 4.39 and 8.68 minutes (Figure 3.10). 
All ligands were later found to be stable in aqueous stock solution (20 
~I) for a period of more than 10 days, as determined by 1H miR 
spectroscopy. 
The percentage of recovered activity contained within the major 
peak (some ligands produced multiple peaks) with a retention time 
between 4.27 and 5.20 minutes was determined by cutting out and weighing 
the shaded areas (Figures 3.10 and 3.11) and comparing this with the 
weight of the total area above the dotted baseline. The baseline 
represents the background level of activity at the start of each run. 
For the phenolic cyclam (2.), each of the two peaks was weighed 
separately. 
Approximate percentage values (C), for the degree of incorporation 
of 99111Tc by the series of ligands, have been calculated by multiplying 
the percentage activity recovered from the column relative to injected 
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Tc04 (A) by the percentage activity contained within the shaded areas 
(B). The values of A, B and C for each of the 9 systems are given in 
Table 3.7. 
LIGAND COUNTS % COUNTS RECOVERED % SHADED % 
RECOVERED vs STAND vs INJECT PEAK INCORPORATION 
Teo-4 - Tc04 (A) (B) (C) 
(14) 25761 23 68 34 23 
(15) 35327 32 93 65 60 
CYCLAM 17985 16 47 0 0 
(.f) 34920 31 92 ~.) 18 c) 16 L) 41 ti) 38 
(56) 36734 33 97 37 36 
(.5.) 36739 . 33 97 . 47 46 
(53) 27740 25 73 10 7 
(55) 19947 18 52 22 11 
STAND 38001 34 
TeO-4 
INJECT 111147 
TeO-4 
. - -
Table 3.7 Recovery of Activity and Calculated Incorporation 
of 99 mTc for a series of Tetraamine Ligands. 
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CHAPTER FOUR 
RADIOLABELLING STUDIES USING COPPER-64 
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4.1 INTR~DUCTION 
4.1.1 64cu for Positron Emission Tomography 
The advantages of positron emission tomography (PET) for imaging tumours 
and the choice of 64cu as a suitable positron emitter have been 
discussed in the introduction (sections 1.3.5 and 1.3.7). Copper 
isotopes form kinetically inert complexes with a number of macrocyclic 
tetraamine ligands, in particular the [14]-membered system cyclam and 
its phenol-pendent derivative(~) (section 1.5). 
H()H H()H c J c J H~ Ht~}H 
HO 
cyclam (~) 
Copper(II) cyclam complexes are much easier to prepare than those 
·containing Tc(V) since there is no need to use a reducing agent e.g 
SnC12 or a high pH regime. Any copper(II) salt may be used in aqueous 
solution at pH 7. 
Unfortunately 64cu is much more expensive and less readily 
available than 99mTc. It is made from 64zn by a (n,p) reaction: 
64
zn + n 64cu + p 
6 mCi of 64cu was made at Harwell by bombarding spectral grade Zn02 with 
neutrons, the first time 64cu had been produced in a "carrier-free" form 
in the U.K. The "carrier-free" material was extracted electrochemically; 
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the electrode being washed with 0.04N HCl to give a solution of 64CuC12. 
4.1.2 Conventional Labelling of Macrocycle-Antibody Conjugates 
with 64cu 
The opportunity to label antibody-bound cyclam with 64cu at neutral pH 
removes the risk of damaging the sensitive macrostructure of the protein 
during labelling (for 99~c, pH 11 is required). 
The macrocycles, cyclam and its phenolic derivative (£),as their 
2-vinylpyridine conjugates, were conjugated to "trauted" Mab (B72.3) 1n 
the manner described in section 2.7.3, then labelled with 64CuC12 at 
pH 7. The in vivo stability of the radiolabelled mac-ab conjugate was 
compared with that of a radiolabelled native antibody in biodistribution 
studies. The radiolabelled Mab was separated from unbound 64cu using a 
PD10 column, then injected into mice. The animal data is presented in 
Table 4.1 (the interpretation of biodistribution data is discussed in 
section 3.1.3). 
TISSUE 
BLOOD 
KIDNEYS 
LIVER 
64 
- Cn-mar.1 -::th -
%Dg- 1 - %Dose 
64 
- r.n-m!H'n-~h-
-- -----&.,. --~ 
%Dg-1 %Dose 
8.1 ±0.8 21.7 ±1.2 9.6 ±1.5 26.4 ±4.1 2.1 
6.1 ±0.4. 3.3 ±0.3 5.4 ±0.8 3.1 ±0.6 9.1 
19.5 ±2.1 33.5 ±2.0 15.4 ±2.9 27.7 ±6.5 12.4 
Table 4.1 Biodistribution data for pH 7 conventional 
labelling; 24 hours, mac1=cyclam; mac2=(g); 
ab=B72.3; no.of mice per dataset=2. 
5.6 
4.1 
21.7 
The level of cardiovascular activity after 24 hours is higher for the 
macrocycle-containing antibody conjugates than for the native Mab 
indicating a greater in vivo stability for the radiolabel. However the 
accumulation of activity in the liver is much higher than would be 
expected from its blood content. The liver is roughly 30% blood by 
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weight so the expected % dose g- 1 for the liver should not be 
significantly greater than one third of the % dose g- 1 for the blood-
pool. The fact that the liver % dose g- 1 is roughly twice that of the 
blood may be attributed to either the removal, by the liver, of 
"aggregates" of labelled antibody or the dissociation of copper from the 
Mab (non-specifics)t. Free copper is rapidly removed from the blood by 
the liver and kidneys where it accumulates readily. It is not possible 
on the basis of the present data to differentiate the contributions of 
these two effects to the loss of cardiovascular activity, but it seems 
likely that both are implicated. 
4.2 A PRE-LABELLING STRATEGY FOR 64cu 
If the high liver activity is due to non-specifically bound copper 
dissociating from the antibody, a pre-labelled 64cu-mac-ab conjugate 
should reduce the activity in the liver and give a correspondingly 
higher cardiovascular activity. (The pre-labelling protocol is reviewed 
in section 3.2). Any excess liver accumulation could then be attributed 
to the removal, by the liver, of aggregates of IgG from the blood. 
4.2.1 Pre-labelled 64cu-Cyclam Conjugates 
Since cyclam macrocycles can be labelled with copper(II) at neutral pH, 
there is no restriction upon the use of maleimide cross-linkers for pre-
labelling (unlike 99IDrc: see section 3.3). 
A macrocycle-maleimide conjugate (57) was prepared by reacting the 
tSee sections 3.1.4 and 3.1.5 for definitions of the terms "aggregates" 
and "non-specifics". 
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functionalised non-phenolic cyclam macrocycle (29) with the commercially 
available cross-linker (50), sulfosuccinimidyl-4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate, in "Pipes" buffer at pH 6.8 (Figure 4.1). 
The conjugate (57) was then labelled with 64CuC12 at pH 6.5 and 
conjugated to the "trauted'' Mab (B72. 3) in the usual manner. 
NHz 
( 29) 
-o3s-0. R-Q h 
YN-0-C CHz-N~ 
0 0 
(50) 
!"Pipes" pH6.8 
(57) 
1) 6I.CuCt2 
2)Ab-SH 
0 0 
11-o fy-S-Ab 
NH-C CHz-NV 
0 
(58) 
Figure 4.1 Synthesis of 64 Cu-mac-ab con fuga t e.s u.szng 
maleimide-ba.sed pre-labelling. 
- 145 -
After 2 hours reaction more than 60% of the total activity was 
associated with the protein. This compares with a paltry 0.5% for 
99IDrc-cycla.m, conjugated to 11 trauted 11 B72.3 using a 2-vinylpyridine 
linker molecule (section 3.2.2), and well-illustrates the merit of a 
more reactive maleimide cross-linker for pre-labelling. 
4.2.2 Biodistribution of the Pre-labelled Conjugate 
The radiolabelled conjugate (58) was purified from small molecules e.g 
(57) and 64cu-(57) using a POlO column (Sephadex G-25) and was injected 
into mice. The biodistribution data at 18 hours is given in Table 4.2 
TISSUE 
BLOOD 
KIDNEYS 
LIVER 
LUNGS 
SPLEEN 
POlO (Seph.G-25) 
%Dg-1 %Dose 
17.5 ±0.7 
5.7 ±0.8 
8.9 ±0 .4 
7.8 ±1.0 
5.2 ±0.3 
47.8 ±1.2 
2.9 ±0.2 
16.0 ±0.9 
1.4 ±0.1 
0.4 ±0 .0 
HPLC (GF-250) 
%Dg-1 %Dose 
18.4 ±1.2 
6.3 ±1.2 
6.0 ±0.5 
8.1 ±0.6 
5.1 ±0.5 
55.8 ±0.7 
3.3 ±0.4 
12.3 ±1.1 
1. 5 ±0. 2 
0.4 ±0 .1 
Table 4.2 Biodistribution data for pre-labelling; 18 hours; 
non-phenolic cyclam; no.of mice per dataset=3. 
The level of cardiovascular activity is much higher than was observed 
previously (Table 4.1) for the 64cu-mac-ab conjugate prepared by 
conventional labelling. In addition, the liver activity is 
substantially reduced. This suggests that non-specifically bound copper 
(which is absent from pre-labelled conjugates) may have been responsible 
for the low cardiovascular and high liver activities produced by 
conventionally-labelled conjugates in vivo. 
If the PDlO-purified conjugate is further purified using size-
exclusion HPLC (Dupont GF-250), the blood:liver activity ratio can be 
improved still further (Table 4.2). The blood level (55.8 %Dose) is 
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close to the theoretical maximum value after 18 hours, predicted by the 
equilibration of IgG with the extracellular tissues (section 3.1.3). 
The liver activity is little more than one third of the cardiovascular 
level, consistent with its blood content and with equilibration. The 
fact that HPLC purification improves the blood:liver ratio suggests that 
aggregated protein still presents a problem. HPLC can remove aggregates 
and fragments (PD10 does not) but unfortunately cannot be used routinely 
in hospitals for this purpose - steps must be taken to prevent protein 
damage e.g site-specific labelling. 
4.2.3 Conclusions 
The observation that a pre-labelled 64cu-cyclam-antibody conjugate 
remains in the blood, unless the protein itself is damaged, confirms the 
v1ew that the 64cu-cyclam complex is kinetically stable in vivo. 
Additionally the bonds linking macrocycle and antibody (amide, 
thioether, amidine) would also appear to possess high in vivo stability. 
Thus by preventing non-specific metal binding, pre-labelling allows 
,. ' 
stable u~Cu-mac-ab conjugates to be prepared. However it is not 
considered to be an ideal procedure for preparing radiopharmaceuticals 
routinely (section 3.2.1). Conventional labelling involves a much 
simpler one-pot protocol and would be preferred if the problem of non-
specific binding could be overcome. 
There is little doubt that much of the non-specifically bound 
copper could be removed using a chelate wash e.g EDTA, DTPA, cyclam but 
as for 99IDrc, it seems unlikely that all would be readily removed in a 
single and rapid treatment. A more effective approach is to prevent 
non-specific binding from occurring in the first place by using a low pi! 
labelling regime. To understand this approach, it is necessary to 
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consider the origin of non-specific binding of copper by proteins. 
4.3 1ABE1LING MACROCYCLE-ANTIBODY C~NJUGATES ~ITH 64cu AT LOW pH 
4.3.1 The pH Dependence of Non-Specific Copper Binding 
According to Pettit et al. 1 '~, copper(II) binds to most peptides (HL) 
below pH 5 through the terminal-NH2 group and the carbonyl oxygen of the 
neighbouring peptide linkage. This Cu-0 bond is weak such that the 
complex formed [CuL]+ has only a small range of existence. Above pH 5, 
Cu(II) promotes deprotonation of the adjacent peptide nitrogen to form a 
more stable Cu-N bond with a 5-membered chelate ring. As the pH is 
raised, further chelate rings are formed by bonding to successive 
peptide nitrogens. Hence the final complex with tetraglycine will 
involve displacement of 3 peptide hydrogens to give the NNNN-bonded 
complex [CuH_3L]
2
-. With a tripeptide (e.g triglycine) the final 
species will be a NNN-bonded complex, the fourth centre to coordinate 
being the carboxylate group. Stepwise coordination of copper(II) by 
triglycine is shown in Figure 4.2. The species distribution plot for 
the copper(II) complex of tetraglycine is given in Figure 4.3. 
At high pH, copper(II) coordinates readily to any sequence of amino 
acids except those containing large amounts of proline (proline does not 
possess an ionisable hydrogen and cannot form a typical Cu-N peptide 
bond). Hence coordination of copper(II) by deprotonation of the peptide 
nitrogens of the backbone of proteins is the primary origin of the non-
specific binding of this metal at neutral pH. From the species 
distribution curves of Figure 4.3, it is clear that Cu2+ is not bound by 
tetraglycine at pH 4. By analogy, 64cu should not bind non-specifically 
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/Giy-Giy 
c 
/"0 ~~2 I 
H2N~~u-
Q 
c 
/CO /CH2-CO-Giy / ""-.N 
\H2 I 
H2N-cu-
l b 
Figure 4.2 Coppe·r{II) Complexes of TTiglycine (HL); a: {C'UL} 
b:[C'UH- 1 L}; c:{C'Ull-2L] species. 
Figure 4.3 Spedes distribution curve.s (%)for the C'U2+ complex 
of tetraglucine in a 1:1 solution of 0.001 mol dm- 3 . 
1: Cu2 + ; 2: l CuL] ; 3: [CulL 1 L] ; 4: [CulL 2 L] ; 5: [Cuff_ 3 L] . 
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to macrocycle-antibody conjugates if the pH of the labelling buffer is 
reduced from 7 to 4. 
4.3.2 Enhancing the Kinetics of Uptake at Low pH 
The success of the low pH strategy for avoiding non-specific binding 
depends upon the rate of uptake of 64cu by the macrocycle being 
sufficiently rapid. At pH 4, the macrocycles, cyclam and phenolic 
cyclam (~),are almost exclusively diprotonated. The rate of reaction 
between Cu2+ and diprotonated macrocycles is generally slow due to 
electrostatic repulsion in the outer-sphere complex (section 5.1.2). 
Kimura et a l. 3 found that the rate of reaction bet\,~een Cu2+ and 
diprotonated cyclam was faster in acetate buffer by virtue of reduced 
electrostatic effects. In kinetics experiments at Durham, it was found 
that a succinate buffer enhanced the rate of incorporation still further 
(section 5.2.1). 
4.3.3 Radiolabelling Studies with 64cu at pH 4 
The effects of low pH (i.e 4) and of stripping agents (chelate wash) 
upon the incorporation of 64cu by a control antibody and a macrocycle-
antibody conjugate were investigated by our collaborators at Celltech 
and Harwell. 
A mac-ab conjugate (mac= phenolic cyclam (~); ab = 872.3), 
containing 0.24 macrocycles per antibody, was incubated for 30 minutes 
with 64CuC12 in 0.3M phosphate buffer (pH 7). The radiolabelled 
conjugate was purified using a PDlO column: 38.67. of the added 64cu 
activity was associated with the protein fraction. The labelling was 
repeated for the control antibody (872.3); 4.7% of the activity being 
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bound by the protein. 
The effect of lowering the pH was then investigated using a 0.2M 
succinate buffer at pH 4.0. The effect of a stripping agent was also 
investigated by incubating the labelled conjugate with a 150 fold excess 
(over Mab) of cyclam for 30 minutes. The activities associated with 
conjugated and control Mab's (after PD10 purification) and the 
conjugated:control activity ratios are summarised in Table 4.3. 
BUFFER pH STRIPPING mac-ab control-ab RATIO 
AGENT (X) (Y) (X/Y) 
0.3M 
PHOSPHATE 7 38.6 4.7 8.2 
0.2M 
SUCCINATE 4 33.2 0.64 52.0 
0.2M 
SUCCINATE 4 CYCLAM 35.3 0.20 176.0 
Table 4.3 Percentages of 6 4 Cu activity bound; mac= (g); 
ab=B72.3; 30 minutes; 20°0. 
The use of a pH 4 succinate buffer seems to be a very effective method 
for reducing the non-specific binding of copper(II) to the control 
an~1ooay. Ihe reauct1on in the activity associated with the mac-ab 
conjugate is of a similar magnitude, presumably due to a decrease in 
non-specific binding rather than a reduction in specific binding by the 
macrocycle. If true, the use of a succinate buffer to provide rapid 
association kinetics at pH 4 is vindicated. The mac-ab:control-ab ratio 
is much superior at pH 4 than at neutral pH, 
The incubation of the control antibody (radiolabelled at pH 4) with 
excess cyclam reduced the activity associated with the protein still 
further. This suggests that a small amount of no~-specific 64cu may be 
bound even at pH 4. Washing the 64cu-mac-ab conjugate with cyclam does 
not make a significant difference to the amount of associated activity. 
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4.3.4 Biodistribution Studies Using Conjugates Labelled at Low piT 
A sample of 64cu-mac-ab conjugate (mac= (2); ab = B72.3), prepared 1n 
succinate buffer at pH 4.0 and purified using PD10, was injected 
intravenously into mice. The biodistribution data at 21 hours is given 
in Table 4.4. Another sample of 64cu-mac-ab, prepared similarly, was 
further purified using size-exclusion HPLC to separate the IgG peak from 
other radiolabelled components. The biodistribution data for this 
second sample at 21 hours is also given in Table· 4.4. 
TISSUE 
PD10 (Seph.G-25) 
%Dg-1 %Dose 
HPLC (GF-250) 
%Dg-1 %Dose 
BLOOD 18.5 ±0 .4 47.9 ±2.3 20.0 ±0.0 55.6 ±0.7 
KIDNEYS 5.7 ±0.8 2.5 ±0.3 5.8 ±0.1 2.6 ±0.0 
LIVER 8.3 ±1.2 13.3 ±2.0 8.0 ±0.2 13.8 ±0.2 
LUNGS 7.5 ±0.4 1. 3 ±0.0 7.8 ±0.5 1.4 ±0. 2 
SPLEEN 5.8 ±0.1 0.4 ±0.0 5.0 ±0.4 0.4 ±0 .0 
Table 4.4 Biodistribution data for pH 4 conventional labelling 
21 hours; phenolic cyclam; no.of mice per dataset=2. 
The PD10 purified sample gave a biodistribution profile which was 
conjugate (Table 4.2). This illustrates the success of the low pH 
strategy for reducing non-specific 64cu binding. The fact that the 
HPLC-purified material gave a marginally higher blood and lower liver 
activity may reflect the removal of aggregated protein from the PD10-
purified material. The level of activity in the liver is slightly 
higher than expected even for the HPLC sample. It is conceivable that 
HPLC failed to separate the IgG and aggregate peaks cleanly - they elute 
in close proximity on a size-exclusion system. This illustrates the 
importance of using freshly "trauted'' IgG and of capping excess thiols 
to prevent intermolecular cross-linking. It is possible that a low pU 
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regime damages the Mab in some way which is recognised by the liver, 
although this seems less likely if exposure to the pH 4 labelling buffer 
is limited to 30 minutes. 
4.4 CONCLUSIONS 
The conventional labelling of cyclam-antibody conjugates with 64cu at 
neutral pH produces an excessive amount of non-specifically bound 
radiolabel which dissociates in vivo and accumulates in the liver and 
kidneys. 
Although pre-labelling eliminates the problem of non-specific 
binding, a better solution is to label conventionally at l01.r pH where 
the binding of copper(II) to the protein backbone is minimised. This 
approach may be improved still further using a single, rapid chelate 
wash with excess free cyclam, EDTA or DTPA. 
The biodistribution profile obtained for the 64cu-mac-ab conjugate, 
labelled at pH 4, is close to being acceptable for clinical use. The 
cardiovascular activity at 24 hours is close to the expected value, 
indicating that 64cu forms kinetically inert complexes with 
unsubstituted (at N) cyclam macrocycles which are stable in vivo. Hence 
the four carboxylic side-arms of Meares' Cu-binding cycle TETA4 are at 
best superfluous and at worst potentially destabilising (section 1. 5. 5). 
This is substantiated by the work of Volkert et al. 5 who found that the 
64
cu complex of a di-N-alkylated cyclam, which also lacks carboxylic 
acid groups, is stable in serum (although no animal data has been 
reported). 
The level of activity in the liver remains slightly elevated; 
probably due to the presence of damaged protein rather than to the 
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instability of the radiolabel. Further steps must be taken to minimise 
protein damage since HPLC will not be available in a hospital to remove 
aggregates. 
The chemistry of 64cu is certainly more amenable to its successful 
attachment to Mab's than that of 99IDrc. The results reported in this 
chapter are certainly very encouraging and will be pursued further ln 
experiments with 67cu in Chapter 6. The prospects for the further 
development of 64cu radiopharmaceuticals for in vivo imaging depend more 
upon financial considerations than upon its chemistry and in vivo 
f 64c · h · t d h · h 99mT per ormance. u IS muc more expensive o pro uce t an e1t er c or 
111rn. Moreover PET cameras are currently up to 10 times more expensive 
than conventional Anger cameras. Recently hm~ever, a new and much 
cheaper type of positron camera has been developed at the Royal Marsden 
Hospital. If further cost-reductions are realised, the superior 
definition of PET could make 64cu an important radioisotope for 
radioimmunoimaging. 
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CHAPTER FIVE 
KINETIC STUDIES ON COPPER(II) COMPLEXES OF [13]-
AND [14]-MEMBERED TETRAAMINE MACROCYCLES 
- 155 -
5.1 INTRODUCTION 
5.1.1 Vhy study Kinetics? 
Copper-64 and copper-67 are potentially useful radioisotopes for 
positron imaging and radiotherapy respectively. Work by Pettit et al. 1 
established that copper(II) ions do not bind to oligopeptides at a pH 
below 5 (see section 4.3.1). Moreover we have found that copper does 
not bind "non-specifically" to the protein backbone of derivatised 
antibodies at pH 4 (section 4.3.2). This is an important advance over 
the prior art since at lower pH, antibody-bound macrocycles may be 
labelled to produce a radiopharmaceutical which does not lose copper ~n 
V'tVO. 
The proverbial "fly-in-the-ointment" concerns the extremely slow 
rate of incorporation of copper by antibody-bound tetraamine macrocycles 
at lm.; pH. The poor kinetics can be explained in part by the very lm.; 
concentration of "carrier-free" isotope which must be used in the 
labelling procedure, typically 10- 15 mol dm- 3. More importantly, the 
protonated forms of the macrocycle, predominant at lm,r pH, are much less 
reactive than the free ligand or indeed than their analogous open-chain 
equivalents. 
It is of paramount importance to optimise the kinetics of 
complexation in view of the short half-life of these isotopes, 
especially 64cu (12.8 hours), and the need to avoid exposing potentially 
pH sensitive antibodies to excessively long periods of acidity. 
5.1.2 Mechanistic Considerations Determining Rate 
It has been known for some time that the protonated forms of tetraamine 
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macrocycles form metal complexes at a much slower rate than their open-
h . . 1 2 c a1n equ1va ents . In contrast, unprotonated forms of cyclic and 
acyclic ligands react at a similar rate. To understand these kinetic 
effects, it is necessary to distinguish between mono- and di-protonated 
forms of the macrocycle, which exhibit different reactivities and react 
vza different mechanisms. 
Both cyclam and 13N4 exist predominantly as the diprotonated form 
(LH~+) at pH 4 (see Table 5.1 for pKa values). Although the mono-
protonated form (LH+) is rare, it is still kinetically significant by 
virtue of its much higher reactivity. 
pK1 pK2 pK3 pK4 
13N4 11.1 10.1 rvl. 7 rv1.0 
CYCLAM 11.5 10.2 rv1.7 rvl.O 
Table 5.13 1=0.20 mol dm -:J; 25°C 
In a study of a series of macrocycles, 12N4 - 16N4, Kaden et al.
4 found 
that the reactivity of LH~+ towards Cu2+ was dependent on the ring size 
of the macrocycle, there being a correlation between rate and pK~. In 
fact pK3 decreases with decreasing cavity size due to larger 
electrostatic repulsion of 3 protons in a smaller ring. Similarly 
electrostatic repulsion between LH~+ and Cu2+ in the "outer-sphere 
complex" was cited as an important factor in determining rate. 
Generally the reactivity of LH+ was found to be relatively 
independent of ring size implying that electrostatic repulsion alone 
could not be responsible. The lower reactivity of LH+ relative to the 
unprotonated ligand and open chain systems was explained in terms of a 
rate-determining pre-equilibrium involving two conformations, only one 
of which is able to bind the metal. 
As a general rule, Kaden found the rate of complexation of Cu2+ to 
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increase with increasing ring size. However the reactivities of the 
[13]- and [14]-membered systems were exceptional in that 13N4 was faster 
than cyclam. Moreover, there was a decrease in the reactivity of both 
LH+ and LH~+ forms of cyclam relative to 13N4 and this decrease was of a 
similar magnitude for both forms (Table 5.2). 
13N4 
CYCLAM 
kLH2 
1.9 ± 0.9 
0.39 ± 0.03 
-6 10 kLH 
9.2 ± 0.9 
1.8 ± 0.2 
-3 0 Table 5.2 I=0.5 mol dm ; 25 C 
The explanation for such a trend reversal is not clear but suggests that 
the expected increase in the electrostatic repulsion bet,~een LH~+ and 
Cu2+ in. the outer-sphere complex for 13N4 is offset by some other 
effect, perhaps a more favourable conformational pre-equilibrium similar 
to that proposed earlier for LH+. Since the reactivity of LH+ itself is 
equally dependent upon the change of ring size, the conformational pre-
equilibrium for 13N4 must also be more favourable than for cyclam. It 
13N4 and cyclam is less pronounced for a monocationic copper species, 
Cu(CH3C02)+, than for Cu
2+ implying that electrostatic effects are still 
. 3 5 Important ' . 
Although by no means the only factor explaining the slow rate of 
complexation at low pH, electrostatic repulsion is an important 
consideration and steps must be taken to minimise it. Kimura and 
Kodama3' 5' 6 found that the incorporation of copper by a series of 
polyamine macrocycles at low pH was significantly faster in acetate 
buffer, by virtue of the reduced repulsion between monocationic CuAc+ 
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(Ac = CH3COO-) and LH~+ relative to Cu2+ and LH~+. The LH+ species is 
less reactive in acetate buffer. The rate constants for cyclam and 13N4 
are given in Table 5.3. 
(1 mol- 1s- 1) Cu2+ Cu2+ kCuAc+ kCuAc+ kLH+ kLH2+ LH+ LH2+ 
2 2 
CYCLAM 1.7x10 7 0.14 5.6xl0 6 10.1 
13N4 7.9x10
6 7.9x10 -2 5.0x10 6 7.9 
Table 5.3 -3 I =0. 20 mol dm ). 25°C 
Later Kaden and Wu7 studied the reactivity towards cyclam of a series of 
copper complexes incorporating anionic carboxylate donors and found that 
succinate produced the most significant rate-enhancing effect. In 
contrast to the acetate system, the reactivities of both ligand species, 
+ 2+ ( - -) LH and LH2 , are greater towards CuSucc Succ = 02CCH2CH2co2 than 
Cu2+, although the reduction in electrostatic repulsion has a more 
pronounced effect upon the rate constant for the diprotonated form 
(kCuSucc 1 t) LH2+ , see Tab e 5.4 . 
2 
CYCLAM 2 .4x106 
Cu2 + k- --~ 
Ltl"'T 
2 
0.39 
5.1.3 Potential Rate-Enhancing Effects 
Buffer 
lrCuSucc 
-Ltf• 
5.6x107 
1,CuSucc 
.. LHZ+ 
2 
48.0 
The reactivity of copper species towards LH~+ (cyclam) increases in the 
order: Cu2+< CuAc+< CuSucc. This suggested a direct correlation between 
tThe precise values for the rate constants involving CuSucc will later 
be shown to be incorrect (section 5.3) but the trends which they portray 
are nonetheless valid. 
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the number of carboxylate groups bound, which determines overall charge, 
and the reactivity of the species. On this basis, it was decided to 
study whether this trend would be continued when three carboxylate 
groups were available, by using a citrate buffer. In fact, it 1wuld be 
wise to study each of the combinations of ligands (cyclam, 13N4) and 
buffer (acetate, succinate, citrate) to establish which would give the 
most rapid overall incorporation. 
Phenols 
l{e have found that phenolic cyclam (2.) incorporates technetium faster at 
pH 9 than cyclam itself (section 3 .4.1). A similar effect for copper at 
pH 4 is unlikely on electrostatic grounds since the phenol in the copper 
complex of ·(2.) is extensively protonated at this pH (viz. Kimura8, pKa 
9.2). Hmvever the observed effect for technetium may not be purely 
electrostatic in nature but may involve a pre-orientation of technetium 
by the phenol for rapid uptake by the nitrogens of the ring. If true a 
catalytic effect by the phenols (56) and (2.) may still be possible at 
lm.,r pH. 
Tempe1·ature 
A t1vofold rate increase for each 10°C nse 1n temperature is commonly 
found for reactions which obey the Arrhenius law: k2 =A exp (-Ea/RT). 
The antibody should withstand a temperature of 40°C, perhaps 45°C in 
some cases, so a useful rate enhancement over room temperature is 
possible. 
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Ionic Strength 
According to Debye-Huckel Theory, the rate of reaction, (k) at a given 
ionic strength (I) is relaterl to the rate at zero ionic strength (k0 ) by 
the equation: 
log (k/k0 ) = 1.018 zAz8J'I (H20; 298 K) 
2 where I= 1/2 E-c.z. 1 1 1 
Rate increases 1~ith I for reactant ions of like charge and decreases for 
ions of opposite charge, since the surrounding ionic atmosphere (of 
equal but opposite charge) stabilises an encounter pair of like charges 
but destabilises one of opposite charges. 
Evidence from the literature suggests that copper complexes of 
tetraamines are formed by reaction of positive ligand species 1•ith 
positive or neutral copper species, in which case a positive or zero 
ionic strength dependence should be observed. If the rate increases 
with increasing ionic strength, steps should be taken to raise the salt 
concentration in the radiolabelling buffer. 
5.1.4 Measurement of Rate 
The effect of each of the above factors, nng size, buffer, phenol-
pendency, temperature and 10n1c strength, on rate was studied at first 
in a qualitative manner by varying one factor whilst keeping the others 
constant. However no attempt was made to control ionic strength for the 
different buffer systems, since the experiments were intended to 
investigate order-of-magnitude rate-enhancing effects rather than to 
measure precise values for rate constants. By comparing the rate of a 
given reaction for a series of different buffers of constant molarity, 
but varying ionic strength, we obtain information which is of direct 
relevance to the choice of radiolabelling buffer, for which ionic 
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strength is not really an important consideration. However the observed 
relative rates are not necessarily truly representative of the intrinsic 
relative rates which would have been obtained had the ionic strength 
been held constant. 
In reality, the kinetics for the reaction of copper and ligand are 
second-order but the mathematical calculation of the rate constant can 
be simplified by us1ng a ten-fold excess of one component. \¥e can make 
the approximation that the concentration of this component at any time 
during the reaction does not differ significantly from its initial 
concentration. Since this concentration is constant, it can be 
incorporated into a new rate constant, kobs' the pseudo-first order rate 
constant. In most experiments described here, the ligand Hill be used 
in excess, 1n Hhich case the rate expression will simplify as follo1~s: 
Rate= k2[Cu]tot[L]tot = kobs[Cu]tot 
kobs can be calculated directly from the increasing intensity of the 
"d-d" band (500-600 nm) as the copper-ligand complex is formed. The 
absorbance (At) increases exponentially with time and kobs can be found 
from the slope of a plot of ln {(A -At)/(A -A0 } against time, 00 00 
according to the first-order integrated rate equation: 
ln [ Aoo -At l = -kobs't 
A -·A 
00 0 
time 
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For relatively fast reactions such as these, the absorbance must be 
monitored using the "stopped-flow" method. The solutions of copper and 
ligand are injected by syringe into a mixing cell where they react. When 
the flow is stopped by a third syringe, the absorbance is monitored at a 
fixed observation point using a photomultiplying light guide. The 
pseudo-first order rate constants can be calculated routinely from the 
absorbance profile using a least-squares linear regression program 
(Hitech ADS-1 package). 
5.2 RELATIVE RATE EXPERIMENTS 
Experimental details are given 1n Section 5.4. 
5.2.1 Kinetic Effect of Ring Size and Complexing Buffer Type 
The effects of varying ring size (13 vs 14) and buffer type (acetate vs 
succinate vs citrate) were studied under the same experimental 
conditions (Experiment 1.1). Solutions of copper perchlorate (10- 3 M) 
and of ligands, cyclam and 13N4 (10-
2 M), were prepared in each of the 
carboxylate buffers (0.2M) at pH 4.0. The ligand was used in ten fold 
excess (pseudo-first order in copper) since copper ions were found to be 
insufficiently soluble in succinate buffer to provide a 10-2 M solution. 
The total concentrations of copper ions and ligand after mixing would 
therefore be 5 x 10- 4 M and 5 x 10-3 M respectively. The pseudo-first 
order rate constants are given in Table 5.5. As expected the 13N4 cycle 
is faster than cyclam in every case - 7 times faster for acetate; 6 
times for succinate and 2.7 times for citrate. For 13N4, succinate 
buffer provides the fastest incorporation, followed by citrate then 
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acetate. For cyclam, citrate buffer is slightly better than succinate 
and much better than acetate. 
-1 
kobs(s ) 
13N4 
CYCLAM 
ACETATE 
0.530 
0.077 
SUCCINATE CITRATE 
2.550 1.670 
0.422 0.627 
Table 5.5 plf4; {b·uffer}=0.20Jf; {Cu}=5x10-4JI; {L}=5x10- 3JJ; 25°C 
In a separate experiment (1.2), the effect of varying the buffer 
was investigated under 2 different pH regimes. The same concentrations 
of copper and ligand were used. Acetate (0.2M), succinate (0.05M) and 
citrate (0.1M) buffers were used at pH 4.50 and pH 5.40. The results 
are tabulated in Table 5.6. 
For cyclam in acetate and succinate buffers, the rate shows the 
expected increase as the concentration of free copper decreases and the 
concentration of monoprotonated ligand increases. Hm"ever in citrate 
buffer, the rate decreases with increasing pH for both cyclam and 13N4 
ligands. 
13N4 
CYCLAM 
ACETATE 
4. 50 5.40 
0.144 0.428 
SUCCINATE 
4.50 5.40 
0.526 1.38 
CITRATE 
4. 50 5.40 
2. 83 1. 94 
0.752 0.403 
Table 5.6 [Cu}=5x10-4Jt; [L}=5x10-3H; 25 °C 
It is interesting to note that the difference in rate between cyclam and 
13N4 is at a minimum at 101~ pll in citrate buffer (2.8 times at pH 4.0), 
then increases with increasing pll. 
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There seems to be uncertainty in the literature about the range of 
citrate complexes formed by copper(II). Warner and Weber9 reported that 
1:1 complexes were formed exclusively under their set of conditions 
(0.012M Cu2+; 0.012M citrate) and that at pH 7, all four ionisable 
protons were displaced from the ligand (3 carboxylate and 1 alkoxide 
donors). At pH values below these, other 1:1 complexes were formed, 1n 
which fewer than 4 protons were displaced. The species distribution 
plot (Figure 5.1) suggests that the observed decrease in rate at higher 
pH may be due to conversion of more reactive protonated forms e.g HCiCu-
to less reactive fully deprotonated forms e.g CiCu2-. The neglect of 
the species H2CiCu is a mistake. 
c 
0 
-;:: 
1.0 
0.8 
b 0.6 
c:: 
.. 
u 
= 0 
u 
~ 
';l 0.4 
~ 
lli 
0.2 
pH. 
Figure 5.1 Relative concentration of copper(II) citrate species as 
a function of p!l. A=lf3CiCu+; D=lfCiCu-; C=CiCu 2 -; IJ=C~t2 + 
Campi et az. 10 insist that dinuclear species must be considered 
under the same set of conditions (pll range 3-8; equimolar amounts of 
Cu2+ and citrate), namely HCiCu; (log K = 13.2) and CiCu2 (log K = 
-0.87). Rajan and Martell 11 also report the formation of dimeric species 
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of the type (HCi) 2Cu~- (log K = 13.2) and Ci 2Cu~- (log K = -8.03). 
However under our conditions of excess citrate, it is unlikely that 
species containing more than one copper need be invoked. Indeed it is 
more likely that copper will form complexes in which more than one 
citrate ligand is bound, as reported by Parry and Dubois12 . 
It is interesting that the copper(II) complexes of di- and 
tricarboxylic acids are reported10 to be unusually stable if an 
additional alcoholic donor group is available. This could explain the 
qualitative difference in trends observed here for the citrate and 
succinate systems. 
In conclusion, it appears that the best kinetics for cyclam at pH 4.0 
are observed in citrate buffer whereas at higher pH, succinate buffer is 
preferred. However the best overall rate of uptake was observed using 
the 13N4 ligand in succinate buffer. 
5.2.2 Kinetic Effect of Phenol-Pendency 
Solutions of copper perchlorate (10-~ M) and phenolic ligands (Z) and 
(56) (10- 2 M) were prepared in 0.2M succinate buffer, since this system 
provided the most favourable kinetics at pH 4.0 in experiments (1.1) and 
(1.2). The rate constants for these ligands, obtained in experiment 
(2.1), are given below: 
LIGAND: 
kobs(s-1) 
CYCLAM 
0.422 
(Z) 
0.387 
13N4 
2. 5.5 
(56) 
complex 
The phenolic derivative of cyclam (Z) incorporates copper marginally 
sl01ver than cyclam itself. The [13] -membered phenol (56) appears to 
react by a more complex mechanism than the other ligands since no single 
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exponential curve could be resolved from the absorbance profile. Instead 
the profile was fitted to three separate exponentials, comprising a very 
fast reaction complete within 50 milliseconds (kobsN110), a slower reac-
tion (kobs=0.5323) and a very slow reaction (kobs=0.0472) (Figure 5.2). 
Abs. 
2 3 time 
Figure 5.2 Absorbance profile for the reaction between Cu(II) 
succinate and (56). Not drawn to scale. Reactions 
numbered: 1) kobsNllO; 2) kobs=0.532; 3) k0 b3 =0.047 
Since this behaviour was not observed for the non-phenolic system, a 
stepwise mechanism is suggested, possibly involving participation by the 
phenol group. The initial very rapid step might involve dissociation of 
the succinate ligand to form a snecies with :1.n N~n flnnnr ~t:>t, £0ll0~-:'2d 
- 0 
by a slower step in which the fourth nitrogen is deprotonated to form an 
N40 species. The final very slow step might be a rearrangement of the 
macrocycle from a folded conformation in the N40 species to planar N4 
coordination. 
Whilst the difference in rate between cyclam and (2.) is not 
particularly significant at pH 4.0 in 0.2M succinate buffer, it is much 
more obvious in 0.1M citrate buffer at pH 4.25 (Experiment 2.2); cyclam 
reacts almost twice as rapidly (Table 5.7). 
Interestingly in citrate buffer at higher pll (5.17), the "phenol" 
effect again becomes less apparent. It is improbable that the phenol 
will have any electrostatic effects in this pH range. However it is 
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conceivable that an intermediate copper species is formed involving the 
pendent phenol and one or more nitrogen donors. 
kobs(s -1) CYCLAM (2.) 
pH 4.25 0.4625 0.2437 
pH 5.17 0.2001 0.1850 
Table 5.7 [citrate}=O.NI; {Cu}=5x10-3JJ; [L}=5x10-4JI; 25°C 
At lmv pH, the kinetic inertness of the diprotonated ligand might 
encourage reaction through this intermediate which is itself kinetically 
quite inert. At higher pH, the disappearance of the "phenol effect" 
might be attributed to the greater abundance of the monoprotonated form 
of the ligand providing an alternative pathway with a much lmver kinetic 
barrier, not involving a stable intermediate. Therefore it seems 
possible that (2.) is also reacting through a stepHise mechanism similar 
to that observed for (56), but the first two steps are too rapid to be 
observed separately in the absorbance profile. 
In conclusion, the behaviour of phenol-pendent macrocycles is 
complex and does not seem to offer any ohvio11R H.nv:l.nt-A~P!=: nuPr nnn-~ -----
phenols in terms of the association kinetics at pH 4.0. 
5.2.3 Kinetic Effect of Temperature 
It seemed sensible to pursue the 13N4 ligand in succinate buffer in all 
further experiments since this system gave the best overall rate of 
incorporation of copper at pH 4. Solutions of copper (10- 3M) and 13N4 
( -2 10 M) were prepared in the usual manner in 0.2M succinate buffer at 
pll 4 (Experiment 3). The temperature was raised in 5°C steps from 25°C 
to 45°C and the following rate constants were obtained: 
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25 30 35 40 45 
2.30 3.21 5.32 8.31 12.55 
The rate of uptake was found to increase quite sharply with temperature, 
by a factor of 2.3-2.4 times for each 10°C rise. It is possible to 
obtain an indication of the activation energy (Ea) for the reaction 
using the Arrhenius equation: 
k2 =A exp (-Ea/RT) 
Ea may be determined from a plot of log kobs (or k2) against 1/T (Figure 
5.3, see section 5.5.2). The plot gives a straight line indicating 
( -1 f Arrhenius-type behaviour and gives a value of 63 ±5) k.J mol or the 
activation energy. This value is only valid for these precise 
conditions and gives only a qualitative indication of the effect of 
temperature at different pH and for other concentrations of reactants, 
where the distribution of reactive species will differ. This study 
gives a rough guide to the effect of increasing temperature on the rate 
of uptake and suggests that as high a temperature as possible should be 
used within the constraints imposed by· the presence of the antibody. 
5.2.4 Kinetic Effect of Ionic Strength 
Solutions were prepared containing 10-3 M copper perchlorate and 10-2 M 
13N4 in 0.2M succinate buffer at pH 4. Sodium perchlorate was added to 
boost the ionic strength. The following rate constants were observed at 
25 °C: 
[NaC10 4 ] 
kobs(s-1) 
0. OM 0. 2~1 1. OM 
2.42 1.77 1.00 
The observed trend, decreasing rate with increasing ionic strength, is 
the reverse of that expected for reaction between cationic copper and 
ligand species. If the reaction proceeded vza cationic ligand and 
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neutral CuSucc, no ionic strength dependence would be expected. Since 
the ligand cannot be negatively Gharged, it would appear that anionic 
copper species must be involved. The formation of anionic copper-
succinate species and their role in the reaction mechanism will be 
studied in section (5.3). 
5.2.5 Conclusions 
The preceding experiments demonstrate that the optimum association 
kinetics at pH 4.0 are observed for the non-phenolic 13N4 macrocycle 1n 
succinate buffer, with the temperature as high as possible and the ionic 
strength at a minimum. These suggestions were passed on to our 
collaborators at Harwell and pursued in radiochemical experiments using 
64cu and 67cu, the results of which are given in section (4.3.2). 
There are a number of interesting experiments which I would have 
performed had time permitted it and which may yet be pursued by other 
workers. 
Although of no consequence to the choice of radiolabelling buffer, 
1~ would nonetheless be usetul to measure the rates of incorporation of 
copper(II) by 13N4 and cyclam for the series of 3 buffers at constant 
ionic strength. For example it is conceivable that the observed 
differences in rate between citrate and succinate (Table 5.5) are 
related to the differences in ionic strength, being considerably greater 
for 0.2M citrate (N0.31) than for 0.2M succinate (N0.12). If anionic 
copper-citrate complexes are formed, as seems likely from the literature 
evidence, the same ionic strength dependence as for copper-succinate 
would be expected. The slow-down for the 13N4 system in citrate (kobs= 
1.67 s- 1), relative to succinate (kobs= 2.55 s- 1), might then be 
explained partly or wholly in terms of the ionic strength difference. 
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Similarly, it is possible that some of the observed slm.,ring effect in 
citrate buffer at higher pH (Table 5.6) is due to its increasing ionic 
strength. 
Clearly an investigation of the mechanism by which tetraamines 
incorporate copper in citrate buffer is in order. By studying the ionic 
strength dependence, it would be possible to investigate a possible role 
for anionic copper-citrate species and gain an indication of their 
charge. It would also be interesting to study the variation of rate In 
citrate buffer over a wider pH range (pH< 4 and pH> 5.4) to ascertain 
whether the observed trends are continued. 
The mechanism of reaction of the phenolic ligands (2.) and, 
especially, (56), with copper-succinate seems to be complex and requires 
further investigation. The pH, succinate and wmc strength 
dependencies of the absorbance profiles and kobs values should provide 
important information about the distribution of reactive species under 
different sets of conditions and their possible role in the reaction 
mechanism. 
In the following section, the mechanism of the reaction bet,.,reen 
13N4 and copper-succinate will be explored in detail. 
5.3 KINETIC STUDIES ON COPPER(II) COMPLEXES OF 1,4,7,10-TETRAAZACYCLO-
TRIDECANE IN SUCCINATE BUFFER 
5.3.1 Ionic Strength Dependence 
The observed ionic strength dependence for the reaction between 
copper(II) succinate and 13N4, decreasing rate with increasing I 
(section 5.2.4), can only be explained in terms of a reaction between 
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oppositely-charged ions, essentially cationic ligand and anionic copper 
species. The NaCl04 background cannot explain the observed trend since 
Cl0,4 ions do not coordinate to copper(II) in aqueous solution. 
Similarly the coordination of hydroxyl groups to copper(II) succinate to 
give anionic species is highly improbable at pH 4. The only plausible 
explanation requires the simultaneous coordination of more than one 
succinic acid molecule per copper ion. 
5.3.2 Copper-Succinate Coordination Chemistry 
The work of liu and Kaden7 on the kinetics of copper(II) succinate \..rith 
cyclam made no mention of a possible role for anionic copper species. 
No ionic strength dependence was reported so it is difficult to judge 
l..rhether their omission was an oversight or whether there was a valid 
reason for not including anionic species. Certainly their system would 
contain feHer copper(II) succinate species in which more than one ligand 
was bound. In our system, succinate was used as a buffer and was 
present in large (400 fold) excess. Kaden et al. used a borate buffer 
containing succinate in much smaller (<5 fold) excess. The question is 
whether anionic copper species are only formed in kinetically 
significant amounts at pH ~4 when succinate is present 1n vast excess. 
An extensive, but probably not exhaustive, search of the literature 
revealed only one reference to copper-disuccinate species. Garg et al~ 2 
reported formation constants (/] values) for the neutral "CuSucc" species 
and the dianionic "CuSucc~-" species of 4.00 and 6.570 respectively, 
determined polarographically. Other papers report a formation constant 
for a protonated form of CuSucc, CuHSucc+, but contain no reference to 
copper-disuccinate species (Table 5.8). The reported values for the 
neutral complex CuSucc are reasonably consistent with the notable 
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exception of the value of Garget al., determined at I= 1.0, which is 
much larger (one would expect a lower value at higher ionic strength). 
This casts serious doubt on the validity of the P-value for CuSucc~­
determined by the same workers. 
I log KcuL log KcuHL log KcuL2 Ref 
1.0 4.000 2.570 13 
0.2 2.26 14 
0.1 2.6 15 
0.1al 2.93 1. 70 16 
0.1bl 2.58 17 
0.1 2.85 1.87 18 
0.1 2.608 1.86 19 
0.1 2.5 19 
0 3.33 20 
0 3.22 14 
Table 5.8 . 0 25 C except a) 20°C; b) 30°C; L= Succ2-
Given the absence of consistent P-values for copper-disuccinate species 
in the literature, it is not surprising that Wu and Kaden did not 
contemplate their involvement. Hm;ever the failure to consider a 
possible role for the protonated complex, CuHSucc+ is a curious 
oversight. It is therefore felt by the author that the quoted rate 
constants for the reactions between CuSucc and mono- and diprotonated 
forms of cyclam (5.6 x 107 and 48 respectively) are almost certainly too 
large. An additional inaccuracy concerns the use of a P-value for 
CuSucc, determined at I = 0.1, for analysing data acquired at I = 0.5. 
In view of the conspicuous absence from the literature of 
trustworthy P-values for copper-disuccinate species, it was decided to 
determine our own values by pH potentiometry. 
5.3.3 Equilibrium Studies on Copper(II) Complexes of Succinic Acid 
A solution containing copper(II) perchlorate (2mM), succinic acid (4mM), 
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perchloric acid (2rni\l) and sodium perchlorate (0. HI) was titrated against 
standardised sodium hydroxide (Experiment 5). The pH potentiometric 
data was then analysed using the non-linear least squares programs, 
"SCOGS" and "SUPERQUAD"21 . 
+ 2- d s -The P-values for CuSucc, CuSuccH , CuSucc2 an Cu ucc2H were 
refined, holding constant the P-values for succinic acid. The pKa 
values for succinic acid at I = 0.1 are known from the literature: pK1 = 
3.99; pK2 = 5.20. The set of P-values which provided the best "fit" to 
the experimental data are given in Table 5.9. 
SCOGS SUPERQUAD 
log p1 5.20 * 5.20 * 
log PnL 9.19 * 9.19 * 
log PcuL 2.59 2.58 
log PcuHL 7.03 7.03 
log PcuL2 4.30 4.35 
log PcuHL2 9.59 9.64 
Table 5.9 [Cu}=2x10- 3 J/; {H2 Succ 1=4x1 o- 3 JI; {I/Cl04 1=4x1 o- 3 Jf; 
JNaCl04}=0.1JI; 25°C; L= succ2 -; * = hetd constant. 
I!1e agreement between "SCOGS" and "SUPERQUAD" analyses was excellent, 
and the quality of the "fit" for usUPERQUAD" was indicated by a low 
value for the chi-squared parameter (3.33). The formation constants for 
CuSucc and CuHSucc+ were in good agreement with those reported in the 
literature (Table 5.8). 
2-It has been demonstrated that the copper-disuccinate species, CuSucc2 
and CuHSucc;, are formed during the pll titration of solutions containing 
copper(II) ions and a 2 fold excess of succinic acid, albeit in very 
small quantities (Figure 5.4). Their concentration in a 0.2M succinate 
buffer (Experiment 4) would obviously be much greater. However we 
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Figure 5.4 
80 
60 
40 
2 
ol:.~~ 
3 4 5 6 
pH 
Relative concentrations of copper(II) succinate 
species as a function of p!f. A=lhSucc; B=lfSucc; 
C=Succ2 -; IJ=CulfSucc+; E=CuSucc; F=CuHSucc2-; 
C=CuSucc2 2 -; {Cu }=2m,l/; {Il2 Succ ]=4mH; {lfCl04}=2m.ll; {NaCl04}=0.1J!. 
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cannot say with absolute certainty that the presence of these species 
can explain the observed inverse dependence of rate upon ionic strength, 
unless we explore the exact nature of the reaction mechanism in more 
detail. 
5.3.4 Kinetics of the Reaction of Copper(II) with 13N4 in Acetate 
Buffer3 
As mentioned 1n section (5.1.2), Kimura and Kodama investigated the 
mechanism of the reaction of Cu(II) ions \vi th 13N4 in acetate buffer at 
lmv pH and obtained the follmving rate expression: t 
d[Cu(13N4)] = kcuAc/H[CuAc+J [13N4H+] + kcuAc/2H[CuAc+J [13N4H~+J 
dt 
The kinetically important species in the pH range 3.2 - 3.7 ([Ac]=0.05-
0.15M) were therefore the (1:1) species, CuAc+, and the mono-(LH+) and 
diprotonated (LH~+) forms of 13N4. The role of CuAc+ was determined 
from the dependence of rate upon acetate concentration. the rolr. of T.H+ 
2+ 
and LH2 from the dependence of rate upon pH. 
The following equilibrium for copper(II) in acetate buffer was 
considered: 
KcuAc 
CuAc+ 
At constant pH, the apparent rate constant (kf) can be written: 
tThrou~hout this section, electrical charges will be omitted from the 
subscripts of rate and equilibrium constants for reasons of clarity 
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thus: 
[Cu] tot [Cu] tot 
kf = (kcu + kcuAcKCuAc[Ac-] + kCuAc2KCuAcKCuAc2 [Ac-]
2/ P 
where: P = 1 + KcuAc[Ac-] + KcuAcKCuAc2 [Ac-]2 
Since a plot of kf x P against [Ac-] gave a straight line with zero 
intercept, CuAc+ was judged to be the only kinetically significant 
copper species under these conditions. 
Kimura et al. also measured the variation of kf with pH keeping 
constant the total ligand concentration and the concentration of Ac-. 
Considering mono- and diprotonation of the ligand: 
13N n2+ 4 2 
= kHK1n[H+] + k2llK1HK2n[H+] 2 I a 
where a = 1 + K111 [H+] + K111K28 [H+] 
2 
Since all the reaction goes through a single Cu species, CuAc+: 
a.p a.p 
A plot of (kf x a)/[H+J against [11+] allows kcuAc/ll and kcuAc/ 211 to be 
determined from the intercept and slope respectively. 
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5.3.5 The Mechanism of the Reaction between Copper(II) Succinate 
and 13N4 
Mechanistically, the reaction betHeen Cu(II) ions and 13N4 in succinate 
buffer is much more complex than in acetate. There are many more copper 
species of possible relevance since, unlike acetate ligands, coordinated 
succinate may be mono-protonated and still remain bound to the metal. 
Diprotonated ligand is not expected to remain bound to the metal and is 
not considered in the reaction mechanism. A reaction scheme involving 5 
copper species and 2 ligand species Has envisaged (Figure 5.5). 
Cu2+ 
Ki 1L K4 
~ + 13N4H+ 
k2 [Cu(13N4)]
2+ CuSucc ~ CuSuccH + 
K2 1l 1L 
K5 
2- ~ CuSucc2H 
- 13N H2+ CuSucc2 ~ 4 2 
Figure 5.5 Copper-succinate and ligand equilibria of possible 
kinetic significance at low pH. 
The role of the free ligand (13N4), whose concentration is negligible 1n 
the pH range under study, and that of the copper species, CuH2Succ2, 
thermodynamically unstable with respect to CuSucc, are likely to be 
unimportant and may be neglected. All equilibria are sensitive to pH 
such that at higher pH, copper will be bound by an increasing number of 
less highly protonated succinate ligands. Since the direct dependence 
of rate on pH is a complex function of the redistribution of both copper 
and ligand species, we cannot separate the individual contributions of 
the 2 ligand species from a pH plot (viz. Kimura3). Thus \1e cannot 
determine exact values for the second order rate constants. Ho1.rever it 
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is possible, and indeed useful, to investigate the importance of 
different copper and ligand species at different pH and different buffer 
concentrations. 
The slope of the zonzc strength dependence of the rate at a 
particular pH will indicate the charge of the species involved in the 
rate-determining step. By varying the succinate buffer concentration at 
constant pH, we can also evaluate the relative contributions to the rate 
of free copper and its mono- and di-succinate complexes under a given p!I 
regime. 
5.3.6 Ionic Strength and Succinate Dependence - Experimental 
The concentration of [Cu(13N4)]
2
+ required for rate measurements by 
-4 
stopped-flow spectrophotometry is N2.5 x 10 M. Therefore solutions 
-4 -3 
were prepared containing 5 x 10 M copper and 5 x 10 M 13N4, which on 
mixing would give this concentration of complex. A 10 fold excess of 
ligand was used to provide pseudo-first order conditions since 
copper(!!) is too insoluble in succinate buffer to provide a 5 x 10-3 M 
t>OlUl;lOn. 
The reactant solutions were prepared by diluting stock solutions of 
copper (5 x 10-3 M), ligand (5 x 10-2 M), succinic acid (0.5M), sodium 
hydroxide (1. OM) and sodium perchlorate (1. OM). Succinic acid is 
insufficiently soluble in water to provide a solution of greater 
concentration than 0.5M. 
Both succinate and ionic strength dependencies were examined under 
different pH regimes: pH 5.7, 5.0, 4.0 and 3.6 for succinate; pll 5.6, 
4.2 and 3.7 for ionic strength. In the succinate dependence experiments 
(6.1- 6.4), the ionic strength was adjusted to a constant value of 0.3 
using the appropriate amount of NaCl04 . In the ionic strength 
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experiments (7.1- 7.3), the pH was adjusted to the given values using 
an appropriate amount of 1N NaOH or 1N HC104. 
5.3.7 Ionic Strength Dependence Analysis 
According to the "kinetic salt effect" and Debye-Hlickel theory, the 
dependence of the rate constant upon ionic strength for non-ideal 
solutions, approximates to the relationship: 
log k = log k0 + 2A
1
ZAz8[r 
1 + /r 
where k0 is the rate constant at zero ionic strength, ZA and z8 are the 
I 
charges of the reactant species A and B and A is a constant (0.509 
dm312 mol- 1/ 2 in water; 298 K). By plotting log k against [I/1+/I, we 
can determine the product of the charges of the reactive species (ZAZB) 
from the slope. 
The ionic strength was calculated us1ng: 
I = 1/2 Y:. 2 r..7. . 
• .1 
.1 l 
taking account of the distribution of succinate between neutral, mono-
and dianionic species. 
Under all three pH regimes studied (5.6, 4.2 and 3.7), the rate of 
complexation was found to decrease with increasing ionic strength, in 
accord with the result of Experiment 4; the slope being steepest at pU 
5.6. The calculated values for the abscissae and ordinates are given in 
Table 5.10 and the plots in Figure 5.6. 
A slope of -2.2 for pU 5.6 can only be explained in terms of 
reaction of species whose mean charge-product (ZAZB) is more negative 
than -2. There are many possible combinations of copper and ligand 
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species which collectively could explain this degree of slope; the most 
. . 2-/ 2+ -/ 2+ 2-/ + -/ N+ l1kely be1ng: Cu 13N4 ; Cu 13N4 ; Cu 13N4 ; Cu 13 4. 
The slopes for the pH 4.2 and 3.7 plots are very similar, both 
being considerably less steep than for 5.6. There is no need to invoke 
a contribution by Cu2 -/13N~+, but whether this reaction is still 
important at loHer pH cannot be ascertained from the ionic strength data 
alone. If the species pair, Cu2 -/13N~+, is no longer relevant, a 
significant contribution from Cu-/13N~+ and/or Cu2-/13N: must be 
considered. 
5.3.8 Succinate Concentration Dependence Analysis 
The rate of reaction accelerates with increasing succinate concentration 
under all four pH regimes studied (Table 5.11). By plotting log kobs 
against log [succ2-], it is apparent that the dependence is noticeably 
steeper at higher pH (Figure 5.7). At high pH, the observed dependence 
may be due to conversion of less reactive copper-monosuccinate species 
to more reactive copper-disuccinatett species with increasing [succ]. 
At low pH, significant amounts of free copper will be present so the 
more gentle slope of the dependence may arise from the conversion of 
free copper to more reactive copper-succinate. At intermediate pii, the 
steepness of the slope is possibly determined by a combination of the 
effects of these tHo interconversions. 
ttSince electrostatic factors are important in determining the rate of 
incorporation (section 5.1.2), anionic copper-disuccinate species should 
be more reactive towards cationic ligand species. 
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5.3.9 The Role of Copper-Disuccinate Species 
The kinetic significance of the 5 copper species envisaged in Figure 5.5 
can be investigated more thoroughly by expressing the theoretical rate 
constant in terms of their formation and protonation constants and the 
protonation constants of succinic acid. For simplicity's sake, it is 
sensible to omit the role of different ligand species until a later 
stage of the analysis. 
vel= k2[Cu]tot[13N4]tot = kobs[Cu]tot 
kobs= ~ = [ kcu[Cu2+] +kcuL[CuL] +kcuHL[CuHL] 
[Cu J tot 
•kcuL,[CuL,] •kcuHL,[CuHL,] ] I [Cu]tot ... (I) 
where L = succ2-
We need to express the concentration of each Cu species in terms of 
lmmm quantities, namely the equilibrium constants (K1, K2, K4 and K5) 
and the concentrations [succ2-] and [H+] : 
K1 = L IJUL J K2 = l CuL2J 
[Cu2+] [L] [CuL] [L] 
K4 = [CuHL] K5 = [CuHL2] 
[CuL] [n+ J [CuL2] [W] 
[Cu]tot = [Cu2+] +[CuL] +[CuHL] +[CuL2] +[CuiiL2 ] 
Writing in terms of [CuSucc]- gives: 
[Cu]tot= [CuL] +[CuL] +K4 [CuL] [WJ +K2[CuL] [LJ +K2K5[CuL] [LJ [WJ 
K1 [LJ 
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Writing [CuL] as a fraction of the total copper gives: 
[CuL] = K1[L] 
[Cu] tot 81 
where~ = 1 +K1[L] ( 1 +K4[H'] +K2[LJ(1+K5[H']) ] 
Since we know each concentration in terms of [CuL], we can write the 
other fractions: 
[Cu J tot [Cu] tot 
[Cu] tot [Cu J tot 
Substituting for each fraction in equation (I) gives: 
kobs = [ kcu +kcuLK1[L] +kcuHLK1K4[L] [H+] + kcuL2K1K2[L] 2 
+kcuHL2K1K2K5[1]2[H+J J I 8t 
= kcu +kcuLK1 +kcuHLK1K4[H+J 
[LJ 
+kcuHL2 Kl K2K5 [W J l [L J . . . (II) 
According to equation (II), a plot of kobs.81 j [L] against [L] will 
provide information about the role of copper-monosuccinate species from 
the intercept and copper di-succinate species from the slope. 
For the pH 5.7 and pH 5.0 experiments, the concentration of succ2-
(L) can be calculated directly from the amounts of NaOII and free ligand 
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added to the buffer solution. Since [succ2-] is so lm.; at pH 4.0 and pH 
3.6, it must be calculated from [HSucc-] using the following equation: 
pH = pKa + log [succ2-] 
[HSucc -] 
. . . (IIIa) 
The pKa values of succinic acid at ionic strength 0.3 are approximately 
4.0 and 5.2. Since the equilibrium constants K1, K2, K4 and K5 are 
knmm at I = 0.1 (Table 5. 9), their values at I = 0. 3 may be calculated 
using the Debye-Htickel equation: 
From (IIIb) : 
log K1 = log K0 + 2A.zAz8J'I 
1 + /1 
. . . (1IIb) 
e.g log K1 = 2.58 at 1=0.1 (ZAZB= -4) 
log K = log K0 - 0.96 0 ·1 
log K = log K - 1.42 
0 ·3 0 
log K1 = 2.58 - 0.46 
K1 N150 (at I=0.3) 
Ihe complete set of equilibrium constants is given in Table 5.12 
1=0.1 1=0.3 
K1 380 150 
K2 60 60 
K4 2.75x104 2.75x104 
K5 1. 95x105 1.17x105 
Table 5.12 
K2 and K4 are essentially independent of ionic strength since the net 
charge is equal on both sides of the equilibrium. According to Debye-
Hlickel theory, neither products nor reactants will be stabilised more 
than the other by the presence of a more intense ionic atmosphere, of 
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equal but opposite charge, at I = 0.3. 
The values of the cartesian coordinates, calculated using the 
equilibrium constants of Table 5.12, are given in Table 5.11 and arc 
plotted in Figures 5.8 and 5.9. 
The pH 3.6 and 4.0 data sets fit a reasonably straight line, with a 
positive slope and intercept, indicating that both copper mono- and 
disuccinate are kinetically significant species at this pH (Figure 5.8). 
At pH 5.7 and pH 5.0, there is also a positive slope suggesting that 
disuccinate species are again making an important contribution to the 
rate of reaction, but the lack of a positive intercept suggests that 
monosuccinate species are no longer of major importance. Moreover the 
intercept is negative, increasingly so with increasing pH, for a 
straight line drawn through these t'm sets of data points. This suggests 
that species with a greater than squared dependence upon the succinate 
concentration are contributing to the rate. The pH 5.7 data points 1n 
particular describe an upward curvature rather than the expected 
straight line if mono- and disuccinate species only were involved. 
5.3.10 The Possible Role of Copper-Trisuccinate Species 
The negative intercepts of Figure 5.9 signify terms with a cubed 
dependence upon the succinate concentration, suggesting that copper-
trisuccinate species may be involved in the reaction mechanism at high 
pH. This introduces much greater complexity into our treatment of the 
data since there are several protonated forms to consider in addition to 
the tetra-anion form of copper-trisuccinate, CuSuccj- e.g CuHSucc~- etc. 
Ideally equation (II) should be amended to include all possible forms of 
copper-trisuccinate, but unfortunately this is not possible since we 
have no knowledge of the formation and protonation constants for such 
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species. It would be difficult, if not impossible, to determine their 
,8-values using pH potentiometry since at low succinic acid 
concentrations, they are too rare to be detectable whereas at high 
concentrations, their endpoints would be swamped by the equivalence 
points of succinic acid itself. However a tentative value for the 
formation constant of CuSuccj- can be estimated, based on intuition and 
the knmm formation constants K1 (150) and K2 (60) - in the range 1 to 
10 would seem appropriate. It would seem unHise to estimate more than a 
single equilibrium constant if the analysis is to be in any Hay 
meaningful. Thus we cannot realistically cover contributions from 
protonated forms of copper-trisuccinate. If, for simplicity 1s sake, we 
consider a model system in Hhich contributions from non-protonated forms 
alone are important, Cu2+, CuSucc, CuSucc~- and CuSucc~-, we can 
envisage the reaction scheme given in Figure 5.10. 
Cu2+ 
K1 1l 
CuSucc 13N4H+ 
k2 
K2 1L + 1l 
2- 2+ CnSucc2 13N4H2 
K3 1l 
4-CuSucc3 
Figure 5.10 A model reaction scheme involving copper-
trisuccinate species 
The rate expression can then be written: 
K 1 = _[_Cu_L_J _ 
[Cu2 +] [LJ 
[CuL2] 
[CuL][LJ 
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... (IV) 
[CuL3] 
[CuL2] [L] 
[Cu]tot = [Cu2+] +[CuL] +[CuL2] +[CuL3] 
As before, each concentration (as a fraction of the total copper) may be 
expressed in terms of the equilibrium constants (K1-K3). We can there-
fore substitute 1n equation (IV) to give: 
kobs = kcu +kcuLK1[L] +kcuL2K1K2[L]
2 
+kcuL3K1K2K3[L]
3 
02 
where 82 = 1 +K1 [L J [ 1 +K2 [L ]( 1 +K3 [L]) l 
Neglecting free Cu2+ which has no kinetic significance at any pH, 've can 
Hrite: 
. . . (V) 
A plot of kobs.o2 / [1] 2 against [L] provides information about the role 
f 2- f 4-0 CuSucc2 rom the intercept and about CuSucc3 and CuSucc from the 
slope. Abscissae and ordinates, calculated using tHo estimated values 
of K3 (1 and 10) are given in Table 5.13, and are plotted in Figures 
The data points for pH 5.7 and 5.0 describe straight lines Hith positive 
slopes and intercepts. Bearing in mind the oversimplified nature of 
this system, it would appear from the positive slopes of these plots 
that trisuccinate-copper species may be participating in the reaction 
mechanism at high pH. The steepness of the slope, reflecting the 
f 4-importance o the contribution of CuSucc3 to the rate, is obviously 
greater if its stability constant is estimated to be higher (10 versus 
1). The positive intercepts confirm that copper-disuccinate species are 
also kinetically significant. 
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HoHever at pH 4.0 the slope is slightly negative and at pH 3.6 it 
is much more steeply negative. In this simple system, the only species 
. h . d d [ 2-] 2 . h . . w1t an 1nverse epen ence upon succ 1s t e monosncClnate spec1es, 
CuSucc. We can therefore conclude that at lower pH, the contribution 
from monosuccinate is more important than that from trisuccinate, 
particularly so at pH 3.6. For both pH regimes (4.0 and 3.6), a positive 
intercept indicates a contribution from copper-disuccinate species. 
The involvement of trisuccinate species is not necessarily 
inconsistent Hith the ionic strength dependence data (section 5.3.7). 
The slope of the ionic strength plot at pH 5.6 (Figure 5.6) is -2.2. 
This could be explained in the model system by a dominant reaction in 
Hhich CuSucc~- reacts l{ith monoprotonated 13N4 (expected slope: -2), 
with a smaller contribution from CuSucc~- reacting with 13N4H+ (-4). 
The reduced ionic strength slopes at pH 4.2 and 3.7 (-1.4 and -1.36) 
could then be explained in terms of a contribution of CuSucc (slope=O) 
and CuSucc~-, reacting with either mono- or diprotonated macrocycle 
(slope: -2 or -4). Of course in the real system, protonated forms would 
be present, allowing a greater contribution to the rate from 
trisuccinate species without contradicting the ionic strength slope. 
5.3.11 Conclusions 
Unfortunately it has not proved possible to explore the mechanism of the 
reaction between copper(II) succinate and 13N4 at low pH in the detail 
we had hoped for or to determine a set of 2nd order rate constants. 
Other workers have reported rate constants for the reaction of CuSucc 
Hith mono- and diprotonated forms of the analogous [14]-membered cycle, 
cyclam, but we believe their neglect of disuccinate species and the 
protonated form of CuSucc invalidates their treatment. We have 
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2-
established, by pH titration, that CuSucc2 and CuHSucc2 are indeed 
formed, albeit in small amounts, in the presence of a 2 fold excess of 
succinate (Figure 5.4). 
When protonated forms are taken into account, it is no longer 
possible to evaluate 2nd order rate constants for each individual 
species pair. The dependence of rate upon pH is a complex function of 
the degrees of protonation of both copper and ligand species. In our 
efforts to probe the reaction mechanism, we are therefore limited to 
exploring the ionic strength and succinate dependencies of the rate. 
The ionic strength dependence sh01o~s that anionic copper species play a 
dominant role in the reaction mechanism across the whole pH region 
2- -
studied (3.6-5.7). At high pH, both CuSucc2 and CuHSucc2 would seem to 
be involved. From the succinate dependence plots (Figure 5.9) the 
absence of a positive intercept implies no significant role for 
monosuccinate species. 
At lower pH, we conclude from the positive intercepts of the 
succinate dependence plots (Figure 5.8) that monosuccinate species are 
involved, but the ionic strength plot (Figure 5.6) indicates that 
n 
anionic species, CuSucc2-or more likely CuHSucc;, remain dominant. 
The negative intercepts shmm in Figure 5.9 cannot be explained by 
a rate expression involving mono- and disuccinate species alone. 
Retrospectively, it would have been useful to have obtained more than 
three data points for each pH regime, since it is often difficult to fit 
an accurate straight line to so few points. However the fact that both 
pH 5.7 and pH 5.0 data sets suggest negative intercepts lends credence 
to the view that this is a "real effect". If the effect is indeed more 
than an experimental artifact, we must invoke copper-trisuccinate 
species in the rate expression, in order to explain the greater than 
squared dependence of rate upon succinate concentration. Since we do 
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not know the ,B-values for such species, we have no option but to 
consider a simplified model system in which protonated species are 
neglected and the formation constant for CuSucc~- is estimated. 
Using this simple system, we can obtain plots against [succ2-] 
which give positive intercepts (Figure 5.12). 
are no further terms, with a higher dependence 
from the rate expression. Of course we cannot 
This implies that there 
[ 2-J . . upon succ , m1SS1ng 
4-be sure that CuSucc3 is 
the only copper-trisuccinate species involved or indeed that it is 
involved at all. In fact CuSucc~- is likely to be a rare species even 
in the upper reaches of this pH range, by virtue of its high charge 
density and the characteristic reluctance of Cu(II) to bind fifth and 
sixth donors (except water itself) in aqueous solution (section 1.5.1). 
Indeed CuSucc~- cannot play a major role since the observed ionic 
strength slope (-2.2) is considerably less than would be expected from 
reaction of a tetra-anion with mono- (4-) or diprotonated (-8) forms of 
the ligand. Protonated forms of copper-trisuccinate are therefore more 
likely to explain the observed succinate dependence in this pH range. 
In conclusion we have established that copper mono- and disuccinate 
spec1es are rate determining in the pH range 3.6-4.2. At higher pH (~ 
5), it seems necessary to consider both di- and trisuccinate species to 
explain the observed succinate dependence. It is not possible to 
distinguish between protonated and non-protonated forms from the 
succinate dependence plots. The ionic strength plots provide clues as 
to which species pairs are important at different pH. However the 
superimposed pH dependence of the copper and ligand equilibria prevents 
the quantification of these roles and the determination of rate 
constants, as was possible for the acetate system (viz. Kimura). 
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5.4 EXPERIMENTAL 
5.4.1 Reagents 
All purchased chemicals Here used Hithout further purification. Copper 
perchlorate, Cu(C104)2.6H20, was purchased from Aldrich for experiments 
(1) to (4), from Johnson-Matthey (99.9% purity) for experiments (5) and 
(6). Cyclam was obtained from Aldrich; 13N4, (2.) and (56) were 
synthesised according to the methods outlined in section 7.3.5. 
Acetate buffers Here prepared from glacial acetic acid (Durham 
Chemicals) and anhydrous sodium acetate (BDH). Citrate buffers 1vere 
prepared from citric acid monohydrate (Hopkin and Williams) and tri-
sodium citrate dihydrate (Fluka). Succinate buffers Here made using 
succinic acid (Fluka puriss p.a.) and analar sodium hydroxide (BDH). 
For experiments (5) and (6), sodium hydroxide was obtained as an analar 
volumetric 1.0M solution from BDH. 
Perchloric acid was purchased as a 69-72% solution from Aldrich; 
sodium perchlorate monohydrate was obtained from Fluka (purum p.a.). 
Distilled water was used throughout. 
5.4.2 Apparatus 
Rates of reactions were measured using a Hitech SF-3L/30C stopped-flow 
spectrophotometer, on-line with an Apple lie microcomputer with 80 
column card. Hitech ADS-1 software (SF 051.0#05) was used to analyse 
the raw data and compute the pseudo-first order rate constant. 
pll measurements were made using a Jemmy 3020 pll meter in 
conjunction with a Russell microelectrode. Equilibrium constants ~ere 
determined by pH potentiometry using a Mettler DL20 titrator and a 
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Mettler DG112 combination pH electrode in conjunction with a BBC micro-
computer. The titration data was stored on a disc and transferred to 
the mainframe (NUMAC) using the program KERMIT. It was then analysed by 
the two non-linear least squares programs, SCOGS and SUPERQUAD. 
5.4.3 Solution Preparation: Experiments (1) to (4) 
In the following experiments, a minimum of 50 cm3 of each of the copper 
and ligand solutions was found to be necessary. For experiments (1.1), 
(1. 2), (2 .1), (3) and ( 4), the concentrations of copper and ligand after 
mixing were 5 x 10-4 M and 5 x 10-3 M respectively (10 fold excess 
ligand). For experiment (2.2), the concentration of copper was 5 x 10-3 
M and that of the ligand 5 x 10-4 M (10 fold excess copper). 
Due to the hygroscopic nature of copper perchlorate, the percentage 
by mass of copper in our sample was found, by atomic absorption, to be 
lmver than expected for the hexahydrate. The molar mass was therefore 
corrected for absorbed water and found to be 426.2 i.e Cu(Cl04) 2.9.09 
H20. Similarly the percentage sodium in our sample of sodium 
pe1chluraLe was iounrl to he consistent with the formula, NaCl04 .1.88 
H20. 
Experiments 1.1, 2.1, 3 and 4 
3 -2 Separate solutions of 10- M copper perchlorate and 10 M ligand were 
prepared in 0.2M buffer, calculated to provide a pH of 4.0. For the 
copper solutions, the buffer components were dissolved in water, 5 cm3 
of 10-2 M copper perchlorate stock solution (0.426g in 100 cm3) was 
added and the volume was made up to 50 cm3. For the ligand solutions, 
the buffer components and the ligand [0.5 mmol: lOOmg cyclam; 93mg 13N4 ; 
146mg (2); 139mg (56)] were dissolved in 50 cm3 of water. 
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A solution of 0.2 M acetate buffer in water (50 cm3) at pH 4.0 
required 0.1477g sodium acetate and 0.4925g acetic acid. Similarly, 
succinate buffer required 1.1808g succinic acid and 0.160g sodium 
hydroxide, and citrate buffer required 1.2059g sodium citrate and 
1.2398g citric acid. 
In experiment 4, sufficient sodium perchlorate has added to provide 
0.2 M (1.5636g) and 1.0 M (7.818g) solutions. If found to be necessary, 
the pH of each of the copper solutions was adjusted to pH 4.0 with 1.0 Y 
NaOH and that of the ligand solutions with 1.0 M HC104. 
Experiment 1.2 
Solutions containing 10-3 M copper were prepared in acetate, succinate 
and citrate buffers, and solutions containing 10-2 M ligand were 
prepared in distilled water. 
In addition to 10-2 M copper stock solution (5 cm3 for acetate and 
succinate; 10 cm3 for citrate), each copper solution required the 
following buffer components to provide the given molarities after mixing 
(total volume: 50 cm3 for acetate and succinate; 100 cm3 for citrate): 
ACID/g SALT/g 
0.20 M acetate pH 4.5 0.7560 0.6071 
0.20 M II pH 5.4 0.1680 1.4110 
0.05 M succinate pH 4.5 0.5905 0.1336 
0.05 M II pH 5.4 0.5905 0.2736 
0.10 M citrate pH 4.5 2.0804 2.9706 
0.10 M II pH 5.4 1.0717 4.3824 
For the 10-2 M ligand solutions, 400mg cyclam was dissolved 1n 200 cm3 
water and 93mg 13N4 in 50 cm
3 water. 
Experiment 2.2 
Solutions containing 10-2 M copper 1n O.lM citrate buffer (pH 4.24 and 
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pH 5.17) and 10-3 M ligand in distilled water were prepared. The copper 
citrate solutions (100 cm3) required at pH 4.25: 0.426g Cu(Cl04) .9.09 
H20, 2.9706g sodium citrate and 2.0804g citric acid; at pH 5.17: 0.426g 
Cu(C104).9.09 H20, 4.3824g sodium citrate and 1.0717g citric acid. 
The solutions of cyclam and phenolic cyclam (2.) in distilled water 
(100 cm3) required 20mg and 29.2mg of ligand respectively. 
5.4.4 Calculation of kobs values: Experiments (1) to (4) 
The formation of the complexes of cyclam, 13N4, (2.) and (56) was 
follo1ved at 516, 561, 506 and 557 nm respectively, corresponding to A a 
me X 
in each case. For each separate reaction, a minimum of 5 injections 
were made and kobs was taken to be the average of these values. A 
typical data set is presented bel01•: 
1. 
2. 
3. 
4. 
5. 
6. 
2.633 
2.571 
2.403 
2.569 
2.583 
2.542 
[succ] tot 
[13N4] 
[Cu2+] 
= 2 X 10-1 M 
= 5 X 10-3 M 
= 5 X 10-4 M 
Average k(obs) = 2.550 
(Standard deviation = 0.071) 
5.4.5 Solution Preparation and Titration - Experiment 5 
A solution of approximate volume 490 cm3 was prepared, containing 2mM 
Cu(C104)2 .6H20 (0.3706g), 4rn~l succinic acid (0.2362g) and O.HI 
NaC104. H20 (7. 0230g). The pH was adjusted to "'2. 5 with 2 cm3 of 1. m1 
IIC104 and the volume was made up to 500 cm
3 with distilled 1vater. The 
titrant 1•as a standardised 0.05~1 NaOII solution, obtained from 0011. 
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The combination pH electrode was standardised using 0.05M KHP04 (pH = 
4.008 at 25°C) and 0.025M Na2HP04 and 0.025M KH2Po4 (pH = 6.865 at 
25°C). The temperature was maintained at 25°C throughout the titration. 
Sodium hydroxide was added, to a stirred solution of the above 
ingredients, until the pH reached 6, whereupon copper hydroxide 
precipitated. 
5.4.6 Solution Preparation: Experiments (6) and (7) 
Stock Solutions 
Copper Stock: 200 cm3 of 5mM solution (0.3706g Cu(Cl04)2.6H20). 
Ligand Stock: 200 cm3 of 50mM solution (1.863g 13N4). 
Succinic Acid Stock: 1000 cm3 of·0.5" solution (59.045g). 
NaOH Stock: 1.0M solution purchased from BDH. 
NaC104 Stock: 500 cm
3 of 1. OM solution (70. 23g NaC104. H20). 
Solutions were prepared by a 10 fold dilution of the copper and ligand 
stock solutions (5 cm3) in the appropriate buffer (50 cm3). The figures 
in parentheses indicate the volumes of stock solutions required in a 
total volume of 50 cm3 to give the indicated pH and ionic strength. The 
remaining volume is made up of distilled water. All volumes were 
measured using "Grade A" volumetric pipettes. 
Experiment 6.1 
pH=5.7; 1=0.3; [succ]= 1) 0.06M 2) 0.09M 3) 0.12M 
1) 0.06M H2Succ (6 cm
3); 0.1m1 NaOII (5 cm3); 0.16M NaCl04 (8 cm
3) 
2) 0.09M H2Succ (9 cm
3); 0.15M NaOII (7.5 cm3); 0.09M NaCI04 (4.5 cm
3) 
3) 0.12M H2Succ (12 cm3); 0.20M NaOII (10 cm3); 0.02M NaCI04 (1 cm3) 
- 195 -
Experiment 6.2 
pH=5.0; 1=0.3; [succ]= 1) 0.07M 2) 0.14M 3) 0.21M 
1) 0.07M H2Succ (7 cm
3); 0.09M NaOH (4.5 cm3); 0.19M NaC104 (8 cm
3) 
2) 0.14M H2Succ (14 cm3); 0.18M NaOH (9 cm3); 0.08M NaC104 (4.5 cm3) 
3) 0.21M H2Succ (21 cm
3); 0.27M NaOH (13.5 cm3); OM NaC104 (0 cm
3) 
Experiment 6.3 
pH=4.0; 1=0.3; [succ]= 1) 0.08M 2) 0.16~1 3) 0.24M 
1) 0.08M H2Succ (8 cm
3); 0.04M NaOH (2 cm3); 0.26M NaCl04 (13 cm
3) 
2) 0.16M H2Succ (16 cm
3); 0.08M NaOH (4 cm3); 0.22M NaCl04 (11 cm
3) 
3) 0.24M H2Succ (24 cm3); 0.12M NaOH (6 cm3); 0.18M NaCl04 (9 cm
3) 
Experiment 6.4 
pH=3.6; 1=0.3; [succ]= 1) 0.12M 2) 0.18M 3) 0.24M 
1) 0.12M H2Succ (12 cm3); 0.03M NaOH (1.5 c~3); 0.27M NaCl04 (13.5 cm3) 
2) 0.18M H2Succ (18cm3); 0.045M NaOH (2.25cm3); 0.255M NaCl04 (12.75cm3) 
3) 0.24M H2Succ (24 cm3); 0.06M NaOH (3 cm3); 0.24M NaCl04 (12 cm3) 
pH=5.6; [succ]= 0.04M; I= 1) 0.08 2) 0.18 3) 0.28 4) 0.48 
1) - 4) 0.04M H2Succ (4 cm3) + 0.06M NaOH (3 cm3) 
1) OM NaCl04; 2) 0.1M NaC104 (5 cm
3); 3) 0.2M NaCl04 (10 cm
3); 4) 0.4M 
NaC104 (20 cm3). 
Experiment 7. 2 
pH=4.2; [succ]= 0.04M; I= 1) 0.02 2) 0.12 3) 0.22 4) 0.42 
1) - 4) 0.04M H2Succ (4 cm3) + 0.02M NaOH (1 cm3) 
1) OM NaCl04; 2) 0.1M NaCl04 (5 cm3); 3) 0.2M NaCl04 (10 cm
3); 4) 0.4M 
NaCl04 (20 cm3). 
- 196 -
Experiment 7. 3 
pH=3.7; [succ]= 0.08M; l= 1) 0.02 2) 0.04 3) 0.08 4) 0.16 
1) - 4) 0.08M H2Succ (8 cm
3) + 0.02M NaOH (1 cm3) 
1) OM NaCl04; 2) 0.02M NaCl04 (1 cm
3); 3) 0.06M NaC104 (3 cm
3); 4) 0.14~[ 
NaCl04 (7 cm
3). 
kobs values were calculated in the same manner as for experiments (1) to 
(4) (section 5.4.4). 
5.5 RESULTS TADLES AND PLOTS 
5.5.1 Tables 
_b_ 
pH I 1+(1 log kobs SLOPEtt 
0.08 0.221 11.97 1.078 
5.6 0.18 0.298 8.22 0.915 -2.20 
0.28 0.346 6.27 0.797 
0.48 0.409 4.65 0.667 
0.02 0.124 1.32 0.121 
4.2 0.12 0.257 0.846 -0.073 -1.40 
0.22 0.319 0.700 -0.155 
0.42 0.393 0.555 -0.256 
0.02 0.124 0.464 -0.333 
3.7 0.04 0.167 0.407 -0.390 -1.36 
0.08 0.220 0.328 -0.484 
0.16 0.286 0.283 -0.548 
Table 5.10 Ionic strength dependence; 25°C; k b in s-1 
0 s 
tt slope determined by linear regression 
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kobs. 81 
pH [succ]tot [succ2-J kobs 81 [ succ2-] 
0.06 4.5x10- 2 9.40 32.28 6743 
5.7 0.09 6.5x10- 2 11.46 60.62 10688 
0.12 8.5x10- 2 14.18 97.84 16322 
0.07 2.5x10- 2 3.93 23.58 3707 
5.0 0. i4 4.5x10- 2 5.77 59.22 7593 
0.21 6.5x10- 2 6.71 110.49 11406 
0.08 2.8x10- 3 0.468 21.90 3660 
4.0 0.16 5.4x10- 3 0.664 42.91 5276 
0.24 7.9x10- 3 0.776 64.57 6343 
0.12 1. 2x1o- 3 0.240 44.27 8854 
3.6 0.18 1.8x10-3 0.286 66.20 10518 
0.24 2 .4x1o- 3 0.307 88.33 11299 
Table 5.11 Succinate dependence; 25°C; k(obs) in s-1; 
1=0.3 mol dnr3; [succ} in mol dm-3. 
K3=1 K3=lO 
kobs. 82 kobs. 82 
pH [succ2-J 02 2 82 [ succ2 -] [ succ2 - J 
t1 l:;v1 fl- 2 'l~ Of\ 1ClAf\f\A OA -til"'\ ... l'""rtl"\r\1"\ 
- .................... v tl..tVeVV .Li.J-..tVVV t.J"± • .lO .l<.I::JVVV 
5.7 6.5x10- 2 51.25 139000 73.49 199000 
8.5x10- 2 84.30 165000 134.05 263000 
2.5x10- 2 10.52 66000 11.78 74000 
5.0 4.5x10- 2 26.80 76000 34.18 97000 
6.5x10- 2 51.25 81000 78.49 117000 
2.8x10- 3 1.49 89000 1.49 89000 
4.0 5 .4x1o- 3 2.07 47000 2.09 48000 
7.9x10- 3 2.75 34000 2.79 35000 
1.2x10- 3 1.19 198000 1.19 198000 
3.6 1.8x10- 3 1.30 115000 1.30 115000 
2 .4x1o- 3 1.41 75000 1.41 75000 
Table 5.13 Succinate dependence; 25°C; k(obs) in s-1; 
1=0.3 mol dnr3; [succ} in mol dm-3. 
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5.5.2 Plots 
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Figure 5.3 AtT!tenius plot for the reaction between Copper(II) 
Succinate and l:JN4 
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Figure 5.6 Ionic Str-ength Dependence of the Rate of the 
Reaction between Copper-(!!) succinate and 13NJ. 
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Figure 5.7 Succinate Dependence of the Rate of the Reaction 
between Copper(II) Succinate and l:JNJ. 
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CHAPTER SIX 
RADIO IMMUNOTHERAPY 
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6.1 INTRODUCTION 
6.1.1 The Potential For Antibody-Based Tumour Therapy1 
Unlike normal cells, malignant cells will grow in any part of the body. 
Carried from primary tumours in the bloodstream they may set seed to 
form secondary deposits called metastases. Often relatively less 
hazardous forms of cancer e.g melanoma (skin cancer) become life-
threatening when the malignancy spreads to critical organs of the body. 
Surgical removal has proved to be the most effective \vay of 
treating easily accessible malignancies such as melanoma, and is likely 
to remain so. Howeve~, more deep-seated tumours, especially if close to 
vital organs, are generally more difficult to treat. Smaller growths, 
especially micrometastases, are difficult to detect let alone treat by 
conventional methods, yet all must be eliminated for the treatment to be 
effective. 
There has been much interest in the potential of monoclonal 
antibodies which bind specifically to tumour associated antigens for the 
treatment of some of the more troublesome types of tumour e.g breast, 
lung, stomach and colorectal. Monoclonal antibodies alone are rarely 
cytotoxic unless they bind to and inactivate cell surface molecules 
which are necessary for survival or proliferation. In some cases 
however antibodies may elicit a response from the immune system through 
their effector functions (Fe region) which ultimately destroys the 
tumour cell. Indeed this is the mechanism by which malignant cells are 
normally destroyed by the body, thereby preventing the development of 
cancer. However many antibodies are incapable of promoting a 
satisfactory response from the immune system and must instead be tagged 
with an anti-cancer drug. 
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Most anti-cancer drugs presently in clinical use act by preventing 
the replication of DNA, thus inhibiting cell division and tumour growth. 
HoHever the dose of drug which may be given is limited by its toxicity 
towards towards rapidly dividing normal tissues e.g bone marrow. The 
aim of antibody-based tumour therapy is to deliver a cytotoxic agent to 
the site of the tumour without exposing the rest of the body to toxic 
levels of the drug. Selective cytotoxic effects have been observed for 
a variety of monoclonal antibodies when coupled with biochemical toxins 
or radioactive isotopes. 
6.1.2 Biochemical versus Radioactive Cytotoxicity 
The coupling of chemotherapeutic drugs e.g methotrexate and of toxic 
proteins e.g ricin to Mab's has been much explored with the hope of 
combining the cytotoxic effect of the drug with the tumour specificity 
of the antibody. However this approach is often limited by the slow 
rate of internalisation of the toxin across the cell membrane. Since 
virtually all the cells of a tumour must be sterilised for long term 
remission, at least one cytotoxic agent must be incorporated per cell. 
Within some tumours there are clusters of cells which lack the 
target antigen. These so-called "cold-regions" will escape the effects 
of the cytotoxin. Generally tumours which take the form of a loose 
association of cells (sarcomas) or which are well supplied with blood 
vessels will respond better to biochemical cytotoxins. Tumours 
consisting of a poorly vascularised solid mass of tightly-packed cells 
(carcinomas), providing only limited access for Mab's, will tend to 
respond relatively poorly. 
Since radionuclides emit penetrating and ionising radiation 
throughout the localisation process, they are more indiscriminately 
- 209 -
toxic than biochemical toxins. Hm.,rever it is precisely because their 
radiation may span more than one cell diameter, so-called "cross-fire", 
that certain types of radionuclides are more useful for the treatment of 
larger and more solid tumour masses. The emissions can kill cells which 
surround the targeted cell, allowing the destruction of neighbouring 
cells which lack the target antigen and of cells in poorly vascularised 
tumours which the antibody itself cannot reach. 
6.2 RADIOIMMUNOTITERAPY 
6.2.1 Choice of Emission2-5 
Only particulate radiation interacts sufficiently strongly with bodily 
tissues, including cellular DNA, to cause large-scale sterilisation. 
Alpha particles are particularly effective cytotoxic agents since they 
dissipate a large amount of energy in a path length of only one or two 
cell diameters. Unfortunately most alpha-emitters are heavy elements 
(atomic number > 82) which decay to give hazardous daughter products. 
This is a major problem since the alpha recoil energy, typically several 
hundred keY, will rupture the radionuclide-antibody bond, leaving the 
daughter product to diffuse away from the tumour. 211At and 212Bi 
(212Pb) are examples of a-emitting radionuclides which are suitable for 
therapeutic use. Another approach is to generate an alpha-emitter in 
situ by bombarding a stable isotope e.g 10B with low energy thermal 
neutrons. Unfortunately thermal neutrons penetrate tissues so poorly 
that this method has only limited application. Radionuclides which 
decay by neutron capture or internal conversion have been proposed for 
the treatment of very small tumours since they emit X-rays and Auger 
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electrons of very short range (~ 1~m) which deliver a high radiation 
dose locally. Since sources of alpha particles and Auger electrons 
deliver their energy along a short path length they suffer from the same 
disadvantages as biochemical toxins. Thus they are of limited use for 
the treatment of larger and more poorly vascularised tumours which the 
antibody cannot penetrate effectively. In addition they rely upon 
almost every cell having a copy of the tumour-associated antigen (i.e no 
11 cold11 regions). 
The true benefits of 11 cross-fire" can only be realised if longer-
range particles are used, essentially P-rays. There is also a much wider 
choice of P-emitters which are potentially suitable for therapy, 
offering a range of particle energies and greater flexibility for the 
chemist who must attach them to the antibody. In fact the only 
radionuclides which satisfy all the general criteria outlined in section 
1.3.1, as well as those specifically required for therapy, are P-
emitters. 
6.2.2 Criteria for choice of P-emitter 
The following factors have been identified as being particularly 
important in the choice of a P-emitting radioisotope for therapy: 
1 Physical half-life 
2 Zero or low gamma emissions 
3 P particle energy 
4 Availability and cost 
5 Stable daughter product 
6 Appropriate chemistry for Mab attachment. 
Physical half-life 
The half-life must be sufficiently long to allow for the necessary 
tumour accumulation of the antibody, yet sufficiently short to ensure 
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that most of the possible "absorbed dose" is delivered before the 
antibody itself is completely catabolised and the radioisotope released. 
Wessels and Rogus3 developed a series of models to predict the half-life 
of an isotope which would give a maximum target:non-target ratio. Simple 
models suggested that the half-life should be at least 1.5 - 3.0 times 
longer than the time necessary for satisfactory accumulation in the 
tumour and clearance from non-target areas. Since the time required for 
a maximum target:non-target biodistribution ratio is typically 2 days, 
the ideal half-life is of the order of 72 to 144 hours. 
Gamma Emissions 
In theory, pure P-emitters, of which there are relatively few suitable 
ones, are preferred for radioimmunotherapy since they deposit all their 
energy in a relatively short path-length (maximum target:non-target dose 
ratio). However it is often advantageous to have a small gamma 
component, of appropriate energy, for imaging the tumour whilst the 
patient is receiving radioimmunotherapy. Moreover the use of the same 
isotope at low dosage for pre-therapy imaging allows accurate dosimetric 
information for an individual tumour to be acquired, permitting the 
precise therapeutic dose required for its sterilisation to be 
calculated. If a radioisotope of a different element e.g 99"1-c, 111In 
is used for pre-therapy imaging one can never be sure that its 
target:non-target biodistribution will exactly match that of the 
therapeutic isotope6. 
Beta Energy5 
A P-emitter may be selected on the basis of the energy of its P 
particle. This usually determines the size and morphology of tumour for 
which it is suitable. Generally the lower the P energy, the more 
- 212 -
localised will be the energy deposition. This is especially important 
for smaller tumours which must be sterilised without P particles 
penetrating and damaging the surrounding normal tissue. However the 
relationship between particle energy and tumour size is complicated by 
the extent of the capillary vasculature and the density of the antibody 
expression, which may differ for different tumours. If the vasculature 
is inadequate or there are "cold regions" devoid of antigens, the need 
for "cross-fire" will be greater and a longer range P particle must be 
employed to sterilise less accessible cells. 
Some radionuclides which appear eminently suitable for therapeutic 
applications on the basis of their decay characteristics must be 
discounted on other grounds e.g availability and cost, active daughters, 
inappropriate chemistry etc. 
6.2.3 Radioisotopes of Potential Therapeutic Value 
So far, only one radioisotope, 1311, has been used for radioimmuno-
therapy in man7. However it is by no means ideal for this purpose 
because of its high yield of penetrating gamma radiation \.rhich can 
escape from most tumours and damage healthy tissues. Iodine isotopes 
also tend to deiodinate from Mab's in vivo. Metals are much better in 
this respect, being attached to antibodies using chelating agents 
(section 1.4). A number of P emitting radiometals which have been 
considered for radioimmunotherapy are given in Table 6.1 (131r is also 
included for comparison). All of these radioisotopes produce abundant P 
emissions, which vary in range from 3.9 mm for 90v to 0.1 mm for 199Au, 
and all decay to give stable daughter products. However some of these 
radiometals are more favoured than others mainly on the grounds of cost, 
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availability and/or difficulty of chemistry. 
ISOTOPE 
1311 
90y 
64cu 
199Au 
186Re 
188Re 
111Ag 
161Tb 
tt(h) P (max MeV %) 8 Gamma (keV %) 8 
193 0.606 (90) 364 (79) 
64 2.25 (100) 
62 0.577 tol 93 ~lB 0.486 35 184 
0.395 45 
75 0.250 ~~~~ 158 (76) 0.296 
90 0.933 Hl~ 137 1.071 
17 1.96 g~~ 155 2.12 
179 1.04 (93) 342 (6) 
166 0.45 ~~~) 75 0.57 57 (21) 
Table 6.1 Candidate Radioisotopes for Therapy 
SOURCE 
Reactor 
Generator 
Accelerator 
Reactor 
Reactor 
Generator 
For example, 161Tb and 186Re are potentially useful but are unusually 
difficult to obtain in a "carrier-free" form. Its low P energy makes 
199Au an attractive choice for treating small tumours, micrometastases, 
lPnk::~.Pmi::~.~ pfr Hm.rPvPr t.hP m::~in ilr::~:wh::~.rk i~ t.hP. nnrnmnrnmiRin!T n::~.t.11rP. 
. ~ 
of gold coordination chemistry, making its attachment to the antibody a 
major challenge. Similarly, the aqueous chelation chemistry of isotopes 
of rhenium and silver is little known; few potentially suitable chelates 
or macrocyclic complexes have been reported to date. 
From this shortlist of radionuclide candidates, two are 
particularly promising - yttrium-90, by virtue of its cheapness, 
availability and high energy, long range P particle; and copper-67, by 
virtue of its ability to form "strong" complexes with macrocyclic 
ligands and its gamma ray, of suitable energy for imaging. These two 
isotopes are discussed further in sections 6.3 and 6.4 respectively. 
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6.3 YTTRIUM-90 FOR RADIOIMMUN~THERAPY 
6.3.1 The Nuclear Properties of 90y 
90Y is perhaps the most important radiometal which has been identified 
as a successor to 131r. Since it is a pure fi emitter, the majority of 
the absorbed dose will be to the tumour itself rather than to the 
surrounding tissues. The energy of the fi particle is sufficiently high 
(max E: 2.25 MeV; range 3.9 mm) to allow successful treatment of larger 
tumours with extensive "cold regions". 90Y has a physical half-life (64 
hours) which achieves the right balance between the rate of antibody 
localisation and the rate of antibody catabolism. With regard to the 
more general selection criteria of section 1.3.1, 90Y produces a stable 
daughter product (90zr) and is available cheaply and "carrier-free" from 
a 90sr generator. 
One disadvantage of 90Y arises from its lack of a suitable gamma 
ray. Being a pure fi emitter, the tumour localisation of 90Y-labelled 
antibodies cannot be visualised externally so the therapy dose 
distribution cannot easily be monitored. (The use of a gamma emitting 
isotope of yttrium e.g 86Y, 87Y may be necessary at the clinical trials 
stage to determine the precise dosimetry). 
6.3.2 The Chemical Properties of 90y 
Although yttrium belongs to group IIIa, its chemistry is often 
considered alongside that of the lanthanides9. The lanthanide 
contractiont is sufficiently large that the size of the y3+ ion IS 
tThe lanthanide contraction arises from the ~mperfect s~ielding of one 
4f electron by another. Thus across the series, effective nuclear 
charge increases causing a reduction in the size of the 4f shell. 
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reached in the Ho3+-Er3+ region. The heavier lanthanides (Gd-Lu) are 
often called "yttrium earths" since they share with yttrium many basic 
chemical properties which are determined by cation-charge/cation-size 
relationships e.g crystal structure, coordination number, stability of 
complex species. The relationship between effective ionic radius and 
coordination number is shown in Figure 6.110 . 
IONIC 
RADIUS 
0 
A 
Figure 6.1 
1·30 
1·20 
1·10 
·90 
I I 
7 8 9 10 11 12 
COORDINATION 
NUMBER ----+ 
The relationship between ionic radius and coordination 
number for yttrium and the lanthanides. 
In common with the heavier lanthanides, yttrium can form complexes with 
coordination numbers which vary between 6 and 9. However six-
coordination is rare; 7, 8 or 9 being much more common e.g Y(H20)~+ is 
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formed in aqueous solution. 
In contrast to the "d" block metals which prefer "softer" donor 
atoms e.g N or 85 lanthanides ("f" block) prefer "harder" oxygen donors; 
forming electrostatic non-directional bonds similar to those formed by 
the alkaline-earth or alkali metals. 
6.3.3 The Selection of Suitable 90Y Binders 
Bifunctional derivatives of EDTA and DTPA have been employed for 
attaching 90v to antibodies11 ,12 . The thermodynamic stability of these 
yttrium complexes is high (log K ~ 22.1 for DTPA; 18.1 for EDTA). 
Hm.Jever the stability constant is not the primary consideration for zn 
vivo applications; kinetic inertness being much more important (section 
1.4.3). Indeed, it is now known that 90v dissociates from EDTA and DTPA 
in vivo in much the same way as 67cu is lost (section 1.5.2). Once 
dissociated, 90Y accumulates readily in bone whereupon it delivers a 
toxic dose of {J radiation to the haematopoietic cells of the marrm-1. 
Hence there is an urgent need to replace 90Y-DTPA with a more 
kinetically stable 90Y-chelate which does not lose the radiolabel in 
vivo. 
In 1976, Stetter and Frank13 reported that the macrocycle, 
1,4,7,10-tetraazacyclododecane-N,Nl ,N2,N3-tetraacetic acid ("DOTA"), 
formed an extremely stable Ca2+ complex (log K = 17.2) (Figure 6.2). It 
was predicted that DOTA would also formed complexes with the lanthanides 
by virtue of the similarity in ionic radius between Ca2+ and Ln3+. The 
following year, Desreux et al. 14 found that DOTA complexes of the 
heavier lanthanides were exceedingly stable over a wide pH range; ten 
orders of magnitude more stable than their EDTA complexes (Table 6.2). 
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Ho1~"-- n ~(oH 0 eN NJ 0 
O N N:- II 
HO_.)V \_) ~"-...OH 
DOTA TRITA TETA 
Figure 6.2 Uacrocyclic tetraamine tetracarboxylic acids 
for 90 Y binding. 
Ln3+ DOTA EDTA DTPA 
Eu3+ 28.2 17.3 22.4 
Tb3+ 28.6 17.9 22.7 
Lu3+ 29.2 19.8 22.4 
Table 6.2 Stability constants (log K) of Lanthanide-POTA 
complexes1 5; 20 DC; 1=1.0 mol dm-3 
The stability of DOTA complexes increases with decreasing ionic radius 
of the metal ion. No stability constant for Y-DOTA has been reported 
but on the basis of its ionic radius, it might be expected to be similar 
to that of Tb-DOTA (28.6). DOTA behaves as a classical acyclic 
complexing agent; there being no metal ion diameter-cavity size 
correlation often associated with macrocyclic complexes. Indeed the 
metal does not reside within the macrocyclic cavity but sits above the 
N4 plane, with carboxylic groups completing a nearly spherical "cage-
like" structure16 . The square antiprismatic structure of the Eu-DOTA 
complex, Na+ (EuDOTA.H20)-.4H20 is shown in Figure 6.3. The coordinated 
ligand is able to adopt the same stable, rigid conformation which is 
found in the free ligand. Moreover 1H NMR studies have indicated that 
Ln-DOTA complexes adopt the same rigid, highly symmetrical structures In 
solution. This is highly unusual; lanthanides generally form highly 
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labile complexes in which Ln-oxygen bonds exchange very rapidly. Since 
the ligand undergoes little or no conformational change, the energy 
required for complexation is limited to that associated with desolvation 
of the metal 1on. Overall the enthalpy term is very favourable, thereby 
contributing to the high thermodynamic stability of these complexes. 
Figure 6.3 The crystal structure of (EuflOTA.H2D)-
It is reported17 that the rate of complexation of heavy lanthanides by 
DOTA is very slow below pH 7. This was associated with the unusual 
conformational properties of the ligand. The rate-determining step may 
involve the rearrangement of an intermediate complex, in which the metal 
is not coordinated to all the carboxylic groups, to one in which the 
metal is completely encapsulated. 
Lanthanide complexes of the [14]-membered system, TETA (Figure 6.2) 
18 have also been reported. However these complexes are much less 
thermodynamically stable by virtue of the conformation of the 
coordinated ligand being more highly strained. The six-membered chelate 
rings of TETA complexes are more sterically crowded than the five-
membered rings of DOTA complexes. The crystal structure of Tb111 -TETA 
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is shmm in Figure 6 .4. The ligand adopts a distorted dodecahedral 
structure which lacks the axial symmetry of DOTA complexes. 
Figure 6.4 The crystal structure of {TbTETA)-
The kinetics of association for Ln-TETA complexes are much more rapid 
than those of Ln-DOTA complexes presumably because the free ligand is 
less rigid and more easily distorts to accommodate the incoming metal 
ion. 
In view of the similar nature of yttrium and the lanthanides, DOTA 
should be preferred to TETA for binding 90Y in vivo. The rigid and 
symmetric structure of Y-DOTA is kinetically inert, resisting acid-
induced decomplexation. Hm~ever it was thought at the outset of this 
work, that its association kinetics at lm~ pH (necessary to prevent non-
specific 90Y binding) might be too slow for its use to be practicable at 
the tracer level. Thus a [13]-membered analogue, TRITA (Figure 6.2) was 
contemplated, which it was hoped would combine the high kinetic 
stability of DOTA complexes with the more rapid association kinetics of 
TETA complexes. With this hope in mind, a functionalised derivative of 
TRITA was synthesised (section 6.3.4). 
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It has smce transpired that Y-DOTA is formed more rapidly than had 
been expected on the basis of previous observations using lanthanides 
e.g terbium~ 9 In preliminary radiolabelling experiments at Harwell, it 
would appear that the rate of formation of 90Y-DOTA may actually be more 
rapid than that of 90Y-TRITA or 90Y-TETA; in which case its superior 
stability would make 90Y-DOTA the preferred choice for in vivo yttrium 
binding. 
6.3.4 The Functionalisation of TRITA 
The selection of a side-chain functionality for TRITA is some,~hat less 
critical than it was for unsubstituted tetraamine macrocycles (section 
2.1.1) since the necessity for acylation of the exocyclic amine to be 
selective does not arise; the TRITA ring being peralkylated. However it 
seemed sensible to employ the same aminomethyl group as before to enable 
the use of a similar conjugation procedure. 
The synthesis of the functionalised 13N4 cycle (28) has been 
described vide ante (section 2.3.4). Prior to alkylation of the 4 r1ng 
nitrogens, the exocyclic primary amine must be protected as an amide 
(59, Figure 6.5). Selective acylation was conducted under the same 
experimental conditions as the conjugation of (28) with the p-nitro-
phenyl ester of 2-vinylpyridine-methoxyacetic acid (section 2.6.4). 
A 2.7 fold excess of p-nitrophenyl acetate in p-dioxane was stirred 
with (28) in 11 Pipes 11 buffer (pH 6.8) for 3 days at room temperature. A 
large excess of ester was required to drive the reaction to completion. 
The amide could then be recovered as a clear oil (pure by 1H NMR) simply 
by extracting from aqueous base (KOH; pH 14) into chloroform. Attempts 
to peralkylate (59) directly using chloroacetic acid produced a crude 
mixture of partially alkylated products, from which the desired product 
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Pipes; pH 6.8 
(28) 
H0"--../'....1\ ~('"OH 
Ollc _.:.N NJ O 6N HCI )vN N, __ p~ 
HO OH 
( 61 ) 
(62) 
0 
II 
NHCCH3 
(59) 
BrCH2C~Et 
Cs2C03 
iPrOH 
0 
II 
NHCCH3 
(60) 
0 
II 
NHCCH3 
Figure 6.5 A Synthetic Route to a Functionalised TRITA Derivative 
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(61) could only be isolated by reverse phase HPLC. It was therefore 
more convenient to peralkylate (59) using ethyl bromoacetate, the 
product (60) being separable using conventional column chromatography 
(alumina), then hydrolyse the ester and amide groups simultaneously 
using 6N HCl. 
The reaction with ethyl bromoacetate is cleaner, giving a higher 
yield of the peralkylated product (60), if caesium carbonate is used as 
a base (rather than sodium carbonate which is less basic) and anhydrous 
iso-propanol is used as the solvent (rather than acetonitrile which is 
normally used for such reactions). Although a small amount of trans-
esterification (Et -. iPr) occurred, this was not problematical since the 
ester is hydrolysed in the next step anyway (the use of anhydrous 
ethanol as a solvent would prevent this). Two successive alumina 
columns were necessary to isolate (60) as a pure "off-white" solid. 
Deprotection proceeded smoothly in boiling 6N HCl to give the 
functionalised TRITA derivative (61) 1n a sufficiently pure form to be 
linked to a "trauted" Mab using the 2-vinylpyridine linker molecule 
whose synthesis is_described in section 2.5.2. 
A small amount of (61) was acetylated for future radiolabelling and 
biodistribution studies using 90v. On this occasion, selective 
acetylation was not necessary; pH 9 bicarbonate buffer being used 
instead of "Pipes". Follmving extraction of the excess ester and p-
nitrophenol, the amide was purified from inorganic salts using a cation 
exchange resin (Dowex 50W H+ form). 
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6.4 COPPER-67 FOR RADIOIMMUNOTDERAPY 
6.4.1 The Nuclear Properties of 67cu 
67cu is an attractive choice for radioimmunotherapy. In addition to 
abundant (J particles (max E: 0.577, 0.486, 0.395 MeV), 67cu delivers 
moderately abundant gamma rays of an energy (91, 93, 184 keV) suitable 
for imaging. It has a half-life (62h), which is almost identical to 
that of 90¥, and decays to give stable 67zn. In vieH of its much 
shorter (J particle range (0.2 mm), 67cu should inflict less damage upon 
healthy tissue at the edge of the tumour than 90¥. On the other hand, 
it is less suitable for the treatment of larger tumours especially those 
containing extensive "cold" regions. 
The requirement to produce 67cu in a linear accelerator makes this 
isotope four times more expensive than 90¥. It is produced from 68zn by 
a (p,2p) reaction: 
68zn + p ___, 67cu + 2p 
67cuC12 is available from the Los Alamos National Laboratory (NeH 
Mexico, USA) at a cost of "'£40 per mCi. 
6.4.2 The Chemical Properties of 67cu 
Of course, the chemical properties of 67cu are identical to those 
already outlined in connection with the imaging isotope 64cu (section 
1.5). It has already been established that antibody-bound cyclam and 
phenolic cyclam (2) form 64cu complexes which are stable in vivo 
(section 4.2.2). These ligands should be equally suitable for binding 
67cu to Mab's. 
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HO 
cyclam (~) 
6.4.3 The Labelling and Riodistribution of 67cu-Macrocycle-Antibody 
Conjugates 
A 67cu-mac-ab conjugate (mac=(~); ab=B72.3) was prepared from 67cu-
succinate (67CuC1 2 in succinate buffer) and the mac-ab according to the 
pH 4 labelling method which had worked so well for 64cu (section 4.3.4). 
After incubating for 30 minutes at 37°C,+ the labelled conjugate was 
washed with excess DTPA for 5 minutes to chelate the small amount of 
67cu which may have bound non-specifically. The conjugate was purified 
using size-exclusion HPLC to remove aggregated protein (the sample of 
mac-ab conjugate was several months old and substantial cross-linking 
had occurred). The purified 67cu-mac-ab conjugate was then injected 
intravenously into "Thy 1. 211 mice. The biodistribution profiles at 4, 
24 and 72 hours are given in Table 6.3 (see section 3.1.3 for a review 
of the interpretation of animal data). 67cu biodistribution data for 
b b d b Z20 . 1 . tumour- earing mice o taine y Meares et a . us1ng t1e tetraamine-
carboxylate macrocycle, TETA (section 1.5.2), conjugated to the Mab, 
"Lym-1" (anti-human B cell lymphoma), is given in Table 6.4 for 
+The higher temperature provides a kinetic enhancement over room 
temperature lvithout damaging the antibody. 
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comparison. 
--4 hours-- -- 24 hours -- -- 72 hours -_-
TISSUE %Dg-t %Dose %Dg-t %Dose %Dg-t %Dose 
BLOOD 28.8±1.9 70.5±4.5 19 .1±1. 2 46.0±5.3 18.1±0.9 46.8±4.3 
KIDNEYS 8.2±0.1 2.5±0.1 5. 9±0 .4 2.0±0.2 6.2±0.5 2.1±0.2 
LIVER 9 .3±0 .4 13.8±0.1 6.5±0.6 8 .6±1. 6 5.1±0.3 8.7±1.3 
LUNGS 10.1±0.1 1. 9±0 .1 7.7±0.8 1. 2±0.4 8.6±0.3 1. 7±0.1 
SPLEEN 5.9±0.2 0.6±0.0 4.1±0.5 0 .4±0 .1 4.9±0.5 0.6±0.2 
STOMACH 1.1±0. 0 0.6±0.1 1. 0±0. 2 
INTESTINES 5.1±0.7 4.6±0 .4 4.6±0.0 
Table 6.3 Biodistribution data for 67 Cu-mac-ab; p!l 4; conventional 
labelling; mac=(g); ab=B72.3; 2 mice for 4h and 72h time-
points, 7 mice for 24h time-point. 
-- 24 hours -- -- 72 hours -- -- 120 hours -
TISSUE %Dg-t %Dose %Dg-t %Dose %Dg-1 %Dose 
BLOOD 13.8±2.5 28.0±5.0 8.7±1.2 17.8±2.4 5 .8±1. 2 11. 8±2 .4 
TUMOUR 8.2±1.8 1.4±0 .3 14.7±4.5 2 .4±0. 7 13. 2±1. 9 2.2±0.3 
KIDNEYS 5 .1±0 .4 1. 5±0 .1 4. 9±1.8 1.5±0. 5 3.2±0.5 0.9±0.1 
LIVER 10.9±0.6 10.9±0.6 9 .4±2 .3 9 .4±2 .3 4.8±2.3 4.7±2.3 
LUNGS 5 .4±0. 5 0.8±0.1 4. 8±1. 6 0.7±0.2 2.9±0.7 0 .4±0.1 
SPLEEN 9.1±1.8 0.9±0.2 8.5±3.0 0.9±0.3 3.2±1.2 0.3±0.1 
STOMACH 2.7±0.6 0.4±0 .1 2 .4±0. 5 0.4±0.1 1.6±0 .4 0.3±0.1 
INTESTINES 4.7±0.5 4.9±0.5 3. 8±1.0 4.0±1.1 1. 7±0. 5 1.8±0. 5 
Table 6.4 Biodistribution data for HearesJ 6 7 Cu-mac-ab in tumour-
bearinG mice_: pH R.: r.n1111Pnfin'Tinl !~~'!!!~·'!'.:; (E!JTA ::._•::,:;.~); 
mac=TETA; ab="Lym-1". 
TETA was conjugated to the "trauted" Mab via its a-bromoacetamide 
derivative (section 1.7.2). Since the conjugated macrocycle was 
labelled at pH 8 (citrate), extensive non-specific 67cu binding 
occurred. Apparently a single wash with EDTA (10 ~!) successfully 
removed all non-specifically bound metal. The radiolabelled conjugate 
was purified using a gel centrifugation procedure (Sephadex G50) before 
being injected intravenously into tumour-bearing mice. 
Comparison of the two sets of animal data must be done with a 
degree of caution. Not only was a different strain of mice used by 
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Meares et al., but more importantly a xenograft was present; a tumour 
obviously alters the biodistribution of the radiolabel with respect to 
the other tissues. Therefore we cannot compare the tissue activities 
(g- 1) directly, since an implanted tumour removes from the blood 
activity bound by Mab's which recognise its associated antigens. 
However we can compare activity ratios: blood (g- 1):liver (g- 1). If 
there is no excess accumulation in the liver, such that its activity 
reflects only its blood content, the level of activity in the blood and 
liver will fall at essentially similar rates, as the radiolabelled Mab 
either accumulates in the tumour or is catabolised (i.e the blood:liver 
activity ratio will remain constant). 
Bet\>'een 24 and 72 hours, Meares reports a liver activity which 
falls much less rapidly than the blood level, such that the blood:liver 
ratio decreases from 1.27 to 0.93 (Table 6.4). This indicates retention 
of activity in the liver, over and above that expected from its blood 
content. 
With reference to our own set of animal data, the blood:liver ratio 
remains essentially constant between 24 and 72 hours (2.94 ~ 2.92), 
indicating that the liver activity is falling at almost exactly the same 
rate as that of the blood. This suggests that the activity in the liver 
can be attributed almost entirely to its blood content (roughly 30% by 
weight). Since there is no xenograft, the decrease in cardiovascular 
activity is simply due to normal Mab catabolism in the liver and 
radiolabel excretion (see Figure 3.2) rather than to tumour 
localisation. The apparent increase in the cardiovascular % initial 
dose between 24 and 72 hours is an artifact arising from the use of 
differently-sized animals for different time-points. 
The blood:organ ratios for the other tissues also do not change 
appreciably between 24 and 72 hours and are reasonably consistent with 
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their blood content (the apparent slight accumulation in the lungs and 
spleen at 72 hours may need further investigation). A further time-
point at 120 hours or more is advisable, since therapeutic isotopes such 
as 67cu remain highly active for several days. The blood:kidney ratio 
cannot be interpreted simply upon the basis of its blood content since 
it is also the organ of excretion (several timepoints are required). 
H01vever the fact that its activity appears to decrease at roughly the 
same rate as the blood (the blood:kidney ratios at 24 and 72 hours are 
broadly similar) suggests that there is no significant retention of the 
radiolabel in the kidneys. 
6.4.4 Biodistribution Conclusions 
On the basis of th'e evidence presented in section 6.4.3, it is readily 
apparent that our animal data is superior to that obtained by Meares et 
al. However this direct form of comparison is not entirely fair: our 
67Cu-mac-ab conjugate was purified by HPLC, which removes essentially 
all aggregated protein; Meares' conjugate was purified by gel 
chromatography (Sephadex G-50) which removes considerably less 
aggregated protein. Indeed Meares admits that the liver activity is too 
high and suggests that this may be due to cross-linked antibody 
molecules. Although 90% of the radiolabelled material had a molecular 
weight of N150000 D (i.e IgG), 9% was labelled molecules of N300000 D 
(i.e aggregates). 
On the other hand, it is possible that the high liver levels 
recorded by Meares et al. are not entirely explained by the presence of 
aggregates and may be exacerbated by the dissociation of non-
specifically bound copper (not removed by the EDTA wash) or by the loss 
of 67cu from TETA. (As an anionic complex, [Cu-TETA] 2- should be less 
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kinetically inert in vivo than [Cu-cyclam] 2+, see section 1.5.5). 
However we must await the publication of further biodistribution results 
from Meares et al., obtained using HPLC-purified conjugates, to 
establish which factors contribute to the high liver retention. In the 
meantime, it is hoped to determine the stability and localisation of our 
own conjugate in tumour-bearing animals. 
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CHAPTER SEVEN 
SYNTHETIC PROCEDURES 
- 231 -
7.1 APPARATUS AND CHARACTERISATION 
The chemical compounds reported in the procedural sections of this 
chapter have been characterised using a variety of analytical techniques 
in order of presentation: melting/boiling point, microanalysis, thin 
layer and high performance liquid chromatography, ultraviolet/visible 
spectroscopy, mass spectroscopy, infrared spectroscopy and proton and 
carbon-13 nmr spectroscopy. 
Chromatography 
Reported Rf values refer to silica gel TLC (~lerck.Art.5735, Kieselgel 60 
F254), with the eluent system indicated. All HPLC analyses and 
purifications were performed using a Varian Vista 5500/Polychrom 9060 
system fitted with a cation exchange column ("CM 30011 Synchropak). The 
tetraamine macrocycles were retained on the column to a greater or 
lesser extent depending on the degree of charge, allowing for example 
dipositively charged species to be separated from tripositively charged 
species. For each 20 minute run, the flow rate was 1.4 cm3 sec- 1 and 
the composition of the eluent, unless indicated otherwise, was varied as 
follows: 
TIME (mins) 
0 
20 
ZA 
70 
0 
Zl! 
10 
80 
Z!l 
20 
20 
The retention time (Rt) of the macrocycle under these conditions is 
specified, together with the pH of the eluent used. All column 
chromatography employed 11 gravity 11 silica (Merck.Art.7734, Kieselgel 60, 
0.063 - 0.200 mm) unless 11 flash 11 silica (Merck.Art.9385, Kieselgel 60, 
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0.040 - 0.063 mm) is specified. The "standard conditions" specified for 
the purification of macrocyclic amides and diamides were as follows: 
A= aqueous NH3 (0.890); B = CH30H; C = CH2Cl2 
TIME (hours) ZA Lill ZJl 
0 - 1 1 12 87 
1 - 3 2 23 75 
3 - 6 4 36 60 
6 + 6 44 50 
Ultraviolet/Visible Spectroscopy 
All spectra were recorded in water using a Perkin-Elmer Lambda 3 
spectrometer. ,\max is given in nanometres (nm). 
Mass Spectroscopy 
All spectra were obtained using a VG 7070E spectrometer. Samples were 
analysed using CI/DCI techniques (iso-butane, ammonia) except where 
otherwise indicated. FAB spectra were recorded in the positive ion mode 
using a water/glycerol matrix unless indicated to the contrary. 
Infrared Spectroscopy 
Spectra were recorded using a Perkin-Elmer 577 spectrometer. Samples 
were prepared either as a potassium bromide disc, in solution in 
chloroform (0.1 mm KBr cell) or as a thin film on a NaCl plate. 
Frequencies are quoted in cm-1. 
N.UR Spectroscopy 
A Brliker AC 250 spectrometer was used with its spectral frequency set at 
250.134 MHz for proton NMR and 62.896 Mllz for carbon-13 nmr. The 
chemical shifts are indicated in parts per million, to higher frequency 
of TMS at b = 0 ppm. For 1H NMR, CDC13 samples are referenced to 
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internal TMS at o = 0 ppm, CD30D samples to CD2HOD at o = 3.35 ppm and 
D20 samples to HOD at o = 4.80 ppm. For 
13c ~ffi, CDC13 and CD30D 
samples are referenced to solvent peaks at o = 77.00 and o = 49.00 ppm 
respectively, and D20 samples are referenced externally to TMS at o = 0 
ppm. The following abbreviations are used: Ar = Aromatic; Py = Pyridine; 
Ak = Alkene. Proton coupling constants (J) and 13c assignments are given 
for certain representative cycles. 
7.2 REAGENTS 
The follmving chemicals \vere purchased from the suppliers indicated and 
were used without further purification: 
a-Bromo-p-tolunitrile (Aldrich); n-Butyllithium (Aldrich); Caesium 
carbonate (Aldrich); Copper(!) cyanide (Aldrich); Coumarin (Lancaster); 
Cyclam (Aldrich); Diborane-DMS (Aldrich); Diborane-THF (Aldrich); 
Dicyclohexylcarbodiimide (Aldrich); Diethyl malonate (BDH and Aldrich); 
Ethyl bromoacetate (Aldrich); Manganese dioxide (Fluka); Methyl bromo-
acetate (Aldrich); 4-Nitrobenzyl bromide (Aldrich); 6-Nitrocoumarin 
(Lancaster); p-Nitrophenyl acetate (Aldrich); "Pipes" buffer (Aldrich); 
Pyridine dimethanol (Aldrich); 1,4,7,10-Tetraazadecane (Fluka); 
1,4,8,11-Tetraazaundecane (Strem); Trimethylsilylmethylmagnesium 
chloride (Aldrich). 
Solvents were dried using the following reagents: Methanol, Ethanol, 
Iso-propanol (Mg(OR) 2); Dichloromethane (CaH2); Tetrahydrofuran 
(Na/benzophenone); Acetonitrile (CaH2); Toluene (Na). 
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Water was pre-distilled, dimethylformamide (D~W) was of HPLC grade and 
all other solvents were of reagent grade. 
7.3 EXPERIMENTAL 
7.3.1 Functionalised Tetraamine Macrocycles 
5-{2-Hydroxy-5-nitrophenyl)-1,4,8,11-tetraazacyclotetradecane-7-one (1) 
Equimolar quantities of 1,4,8,11-tetraazaundecane (5g, 31.25 mmol) and 
6-nitrocoumarin (6g, 31.41 mmol) were reacted in methanol (150 cm3), 
under reflux for 5 days (argon atmosphere) 1. On cooling, the solvent 
was removed under reduced pressure and the residue was chromatographed 
on silica (standard conditions) to give the desired product as an orange 
solid (2.3g, 21%). Mpt: 150-152 °C; Anal: Calcd for C16H25N5o4.1.2 H20: 
C 51.51; H 7.40; N 18.78. Found: C 51.99; H 7.30; N 18.16; TLC: Rf 0.4 
(aq.NH3/CH30H/CH2Cl2 6:44:50); UV(H20): 400 nm; mfe: 353(~1+2)+; 352 
(M+1)+; 227; 203; 192; 186; 185; 162; 161; IR(KBr): 3260(NH); 3050(CH); 
2920(CH); 2840(CH); 1640(CO); 1590(Ar); 1550(NH); 1H NMR(D20) o 8.00(2H, 
mult,Ar); 6.50(1H,d,Ar); 4.29(1H,t,ArCHN); 3.56-2.48(14H,mult,CH2N 
+CH2CO); 1.84(2H,q,CH2C); 13c miR (D20) o 176.2; 174.4; 133.0;130.1; 
126.8; 124.4; 119.8; 53.9; 49.3; 47.4; 42.3; 38.7; 25.2. 
5-{2-Hydroxy-5-aminophenyl}-1,4,8,11-tetraazacyclotetradecane (~) 
The trihydrochloride salt of (1) was dissolved in dry THF (20 cm3) and 
refluxed with a 10 molar solution of diborane in methyl sulphide (4 cm3, 
40 mmol) for 9 days. The reaction mixture was cooled, quenched with 
methanol and the solvent removed under reduced pressure. The resulting 
aminoborane was hydrolysed with refluxing 6N hydrochloric acid (40 cm3) 
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for 3 hours to give the hydrochloride salt as a dark-coloured solid. 
13c ~IR (D20) 6 155.3; 126.9; 124.4; 122.2; 119.8; 118.0; 60.8; 54.6; 
45.1; 43.2; 42.0; 41.6; 38.9; 28.2. 
5-{2-Hydroxy-5-nitrophenyl}-1,4,8,11-tetraazacyclotetradecane (li) 
The amide group of (.1) (0.7g, 2 mmol) was selectively reduced using 
diborane-THF (15 cm3, 15 mmol) at reflux for 24 hours under nitrogen. 
On cooling, the excess diborane was quenched with methanol and 
evaporated in vacuo. The residue was then hydrolysed with 6N HCl (30 
cm3) for 3 hours and evaporated to dryness. A solution of the crude 
hydrochloride salt (187 mg) in distilled water (2 cm3) was basified with 
potassium hydroxide (1g) and extracted into chloroform (15 cni3). A 
yellow gum (21.4 mg) was recovered on evaporation of the solvent which 
was found to be highly impure by 1H NMR. Therefore a small amount (6 
mg) of pure product was separated by cation exchange HPLC. HPLC: Rt 21 
min (CM 300 "Synchropak"; Et3NH.HC03jH20 5-;99/95-;1); m/e (Neg.FAB): 
336(&1-1r; 257; 205; 183; 143; 1H NMR (D20) 6 7 .98(2H,mult,Ar); 6.49 
(1H,d,Ar); 4.22(1H,dd,ArCHN); 3.19-2.60(14H,mult,CH?.N); 2.27-2.00 
( 4H ,mult ,CH2C). 
6 A . . 2 - m~nocoumar~n 
To a suspension of 6-nitrocoumarin (30g, 157 mmol) in 0.5N hydrochloric 
acid (700 cm3) was added, in batches, iron powder (40g, 716 mmol) and 
stirred at 50-60 °C for 30 minutes. The reaction mixture was then 
refluxed for 5 hours to complete the reduction, then cooled and made 
alkaline with potassium bicarbonate. The solids were filtered off, 
dried in vacuo, then extracted repeatedly with hot chloroform. Having 
removed the chloroform under reduced pressure, the residue was dissolved 
in 0.2N HCl (500 cm3) and washed with chloroform (2 x 250 cm3) to remove 
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unreacted 6-nitrocoumarin. The dilute acid was then evaporated in vacuo 
to give the cream coloured hydrochloride salt of 6-aminocoumarin in 74% 
yield (22.8g). Mpt: 166-168 °C (Lit. 168 °C); Anal: Calcd for C9H7N02: 
C 67.08; H 4.38; N 8.69. Found: C 66.56; H 4.27; N 8.36; mfe: 163(M+2)+; 
162(M+1)+; 161(M)+; 133; 1H NMR (CDC13) 8 7.58(1H,d,Ak); 7.15(1H,d,Ar); 
6.88(1H,dd,Ar); 6.72(1H,d,Ar); 6.38(1H,d,Ak); 3.73(2H,br.s,NH). 
6-Cyanocoumarin 
The hydrochloride salt of 6-aminocoumarin (22.7g, 115 mmol) suspended in 
3N HCl (103 cm3) at 0 °C, was diazotised using a solution of sodium 
nitrite (8.36g, 121 mmol) in water (18 cm3) added dropwise to avoid 
over-heating. The reaction mixture was neutralised with sodium 
carbonate, then added, in 5 cm3 aliquots, to a cold (< 5 °C) aqueous 
solution (44 cm3) of copper(I) cyanide (12.3g, 137 mmol) and potassium 
cyanide (16.9g, 260 mmol). Chloroform (400 cm3) was added to prevent 
excessive foaming and the reaction mixture was allowed to warm to room 
temperature over a period of 3 hours. The diazotisation was completed 
by warming to 50 °C for 30 minutes. On cooling, a further 150 cm3 of 
chloroform was added, the solids were filtered off and the organic layer 
was separated. The solvent was removed to yield 6-cyanocoumarin as an 
orange solid (15.9g, 81%). Mpt: 214-215 °C; Anal: Calcd for c10H5No 2. 
0.2 H20: C 68.72; H 3.09; N 8.02. Found: C 68.29; H 2.80; N 8.01; TLC Rf 
0.10 (20% EtOAcfpetrol); mfe: 171(M)+; 143(M-CO)+; IR(KBr): 2225(CN); 
1730(CO) cm- 1; 1H NMR (CDC13) 8 7.85(1H,d,Ar); 7.79(1H,dd,Ar); 7.73(1H, 
d,Ak); 7 .43(1H,d,Ar); 6.55(1H,d,Ak); 13c NMR (CDC13) 8 159.0; 156.4; 
141.7; 134.7; 132.3; 118.8; 118.4; 117.5; 108.7. 
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11-{2-Hydroxy-5-cyanophenyl)-1,4,7,10-tetraazacyclotridecane-13-one (16) 
A solution of 1,4.,7,10-tetraazadecane (4.39g, 30.0 mmol) and 6-cyano-
coumarin (5.12g, 29.9 mmol) in dry methanol (165 cm3) was heated under 
reflux for 18 days. The methanol was evaporated and the crude residue 
was chromatographed on silica gel (standard conditions) to give the 
cyclic amide as an orange solid (1.57g, 17%). Mpt: 119-121 °C; TLC Rf 
0.27 (aq NH3/CH30H/CH2Cl2 5:45:50); Ace. Mass (DCI): C16H23N5o2 requires 
(M+1)+ 318.19298. Found: 318.23172; IR(KBr): 3250(NH); 3050(CH); 2930 
(CH); 2840(CH); 1640(CO); 1600(Ar); 1470; 1430; 1H NMR (CDC13) 6 7.69 
(1H,br.s, NHCO); 7.37(1H,d,Ar,J=8.6 Hz); 7.35(1H,s,Ar); 6.76(1H,d,Ar, 
J=8.3 Hz); 4.18(1H,d,ArCHN,J=11.5 Hz); 3.73-2.44 (18H,mult,CH2N+NH 
+CII2CO); 
13c NMR (D20) 6 175.3(CO); 169.6; 133.9; 131.8; 130.5; 122.8; 
120.2(Ar); 94.5(CN); 55.2(ArCHN); 47.7; 45.8; 45.1; 44.2; 43.0; 42.3; 
39.3(CH2N+CH2CO). 
11- {2-Hydroxy-5-aminomethy lpheny l}-1 ,4, 7,10- tetraazacyc lotridecane (18) 
The amide (16) (1.308g, 4.13 mmol) was reduced using molar diborane-THF 
(40 cm3, 40 mmol). After 60 hours under reflux, the solution was 
cooled, quenched with methanol (10 cm3) and evaporated to dryness. 
Following treatment with boiling 6N HCl (80 cm3), the acid was removed 
in vacuo and the hydrochloride salt was re-dissolved in water (35 cm3), 
washed with ether (100 cm3), basified (15g KOH) and extracted into 
chloroform (2 x 250 cm3) as the free amine (370 mg, 30%). HPLC: Rt 17.5 
min (pH 6.5); UV(H20): 276 nm; mfe: 310(M+2)+, 309(M+1)+; 292; 204; 147; 
1 H NMR (CDC13) o 7.01(1H,dd,Ar,J=8.2 Hz); 6.87(1H,s,Ar); 6.71(1H,d,Ar, 
J=8.3 Hz); 3.81(1H,dd,ArCHN,J=10.8 Hz,J=2.4 Hz); 3.72(2ll,s,ArCH2N); 
3.09-2.42(20H,mult,CH2N+NH); 2.03-1.70(2H,mult,CH2C); 13c NMR (CDC13) o 
156.8; 133.4(Ar); 126.8; 116.5(Ar,CH); 66.5(ArCHN); 49.6; 48.5; 48.1; 
47.5; 47.3; 46.7; 46.5; 46.0(CH2N); 36.1(CH2C). 
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5-(2-Hydroxy-5-cyanophenyl}-1,4,8,11-tetraazacyclotetradecane-7-one (17) 
This was prepared from 1,4,8,11-tetraazaundecane (9.68g, 60.5 mmol) in a 
similar manner to (16). Yield: 4.0g (20%); Mpt: 136-138 °e; TLC Rf 0.32 
(aq NH3/CH30H/CH2Cl2 5:45:50); UV(H20): 362 nm; Ace. Mass (DCI): 
C17H25N502 requires (M+1)+ 332.20865. Found: 332.21757; IR(KBr): 3040 
(CH); 2925(CH); 2830(CH); 2205(CN); 1635(CO); 1588; 1470; 1H NMR (D20) o 
7.42(1H,s,Ar); 7.40(1H,dd,Ar); 6.63(1H,d,Ar); 4.28(1H,dd,ArCHN); 3.55-
2.38(14H,mult,CH2N+CH2CO); 1.85(2H,q,CH2C); 
13c ~ffi (D20) o 174.9; 
170.3; 133.5; 131.3; 130.8; 122.8; 120.2; 93.5; 53.5. 
5-{2-Hydroxy-5-aminomethylphenyl)-1,4,8,11-tetraazacyclotetradecane (19) 
The amide (17) (2.87g, 8.67 mmol) was treated with molar diborane-THF 
(90 cm3, 90 mmol), under reflux for 48 hours, then quenched with 
methanol. The solvent was removed and the residue treated with boiling 
6N HCl (180 cm3) for 3 hours. The acid was evaporated in vacuo and the 
crude hydrochloride salt re-dissolved in distilled water (50 cm3). 
After washing with diethyl ether (150 cm3), the solution was basified 
(25g) and extracted into chloroform (2 x 400 cm3). The solvent was 
removed to give the free amine as a clear oil (1.93g, 69%). HPLC: Rt 
13.7 min (pH 7.4); UV(H20): 276 nm; Ace. Mass (DCI): c17n31N50 requires 
(M+1)+ 322.26069. Found: 322.33893; IR(CHC13): 3250(NH,OH); 2910(CH); 
2830(CH); 1600(Ar); 1H NMR (CDC13) o 7.04(1H,dd,Ar); 6.91(1H,s,Ar); 
6.73(1H,d,Ar); 3.81(1H,dd,ArCHN); 3.75(2H,s,ArCH2N); 3.11-
2.51(14H,mult,CH2N+Nll); 1.94-1.75(4H,mult,CH2C+NH); 
13c NMR (CDC13) o 
156.6; 133.5; 126.8; 126.6; 116.4; 66.8; 51.2; 51.0; 50.1; 49.7; 49.4; 
49.2; 47.4; 46.0; 36.4; 29.4. 
N-(4-Nitrobenzyl}-1,4,8,11-tetraazacyclotetradecane (20) 
A solution of 4-nitrobenzyl bromide (200 mg, 0.926 mmol) in chloroform 
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(10 cm3) was added dropwise to a solution of cyclam (2g, 10 mmol) in 
chloroform (100 cm3) in the presence of potassium carbonate (3g) at 0°C. 
The reaction mixture was allowed to warm to room temperature and stirred 
for 18 hours. Having removed the chloroform under reduced pressure, the 
residue was extracted with diethyl ether (3 x 100 cm3) and the excess 
cyclam was filtered off. This extraction procedure was then repeated to 
remove remaining traces of cyclam from the monoalkylated product (222 
mg, 70%). Anal: Calcd for c17n29N502: C 60.87; H 8.71; N 20.88. Found: 
C 61.07; H 9.08; N 19.92; mfe: 345(M+2)+; 344(M+1)+; 343(M)+; 1H NMR 
(CDC13) 8 8.08(2H,d,Ar); 7.50(2H,d,Ar); 3.58(2H,s,CH2Ar); 2.89-2.32(19H, 
mult,CH2N+NH); 1.80(2H,q,CH2C); 1.62(2H,q,CH2C); 
13c NMR (CDC13) 8 
147.1; 129.9; 129.5; 123.3; 57.6; 54.8; 53.5; 50.9; 49.3; 49.1; 48.6; 
47.8; 47.1; 28.2; 26.0. 
1 2 3 
N-(4-Nitrobenzyl)-N,N,N -trimethyl-1,4,8,11-tetraazacyclo-
tetradecane (21) 
The monoalkylated cyclam, (20) (79.2 mg, 0.24 mmol) was trimethylated 
using a mixture of 37% aqueous formaldehyde solution (2 cm3, 24.6 mmol) 
and formic acid (3.5 cm3). After refluxing for 20 hours, molar 
hydrochloric acid (10 cm3) was added and the solvent was removed in 
vacuo. The amine hydrochloride salt was then dissolved in water (12 
cm3) and a white insoluble material was filtered off. The filtrate was 
washed with dichloromethane (15 cm3), basified with sodium hydroxide 
(2.5g) 
amine. 
and extracted into dichloromethane (2 x 30 cm3) to gi~e the free 
1 H NMR (CDC13) 8 8.16(2H,d,Ar); 7.58(2H,d,Ar); 3.62(2H,s,ArCH2N); 
2.56-2.44(16ll,mult,CH2N); 2.25-2.21(9H,mult,CH3N); 1.67(4H,mult,CH2C). 
N-(4-Cyanobenzyl)-1,4,8,11-tetraazacyclotetradecane (23) 
This was synthesised in the same manner as (20) to yield a colourless 
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solid (0.257g, 82%). Mpt. 88-90 °C; Anal: Calcd for C18n29N5: C 68.53; 
H 9.27; N 22.20. Found: C 68.52; H 9.59; N 22.04; m/e: 317(M+2)+; 316 
(M+1)+; 199(M-C8H6N); IR(CHC13): 2920(CH); 2810(CH); 2235(CN); 
1H NMR 
(CDC13) 8 7.59(2H,d,Ar); 7.50(2H,d,Ar); 3.61(2H,s,ArCH2N); 2.86-2.45 
13 (19H,mult,CH2N+NH); 1.86(2H,q,CH2C); 1.71(2H,q,CH2C); C NMR (CDC13) 8 
144.9; 131.8; 129.3; 119.0; 110.5; 57.7; 55.1; 53.4; 50.1; 49.2; 49.0; 
48.6; 47.9; 47.1; 28.5; 26.1. 
N-(4-Aminomethylbenzyl}-1,4,8,11-tetraazacyclotetradecane (24) 
The nitrile group of (23) (200mg, 0.65 mmol) was reduced using diborane-
THF solution (7 cm3, 7 mmol), heated under refllL'< for 24 hours. After 
quenching with methanol, the solvent was removed and the residue treated 
with boiling 6N HCl (20 cm3) for 3 hours. The hydrochloride salt was 
then dissolved in water (10 cm3), basified (1g KOH) and extracted into 
dichloromethane (2 x 30 cm3). The free amine was recovered as a clear 
oil (177mg, 85%); m/e: 321(M+2)+; 320(M+1)+; 220; 1H N~tR (CDC13) 8 
7.22(2H,d,Ar); 7.16(2H,d,Ar); 3.76(2H,s,ArCH2N); 3.49(2H,s,ArCH2N); 
13 2.70-2.30 (21H,mult,CH2N+NH); 1.78(2H,q,CH2C); 1.60(2H,q,CH?C); C miR 
(CDC13) 6 141.9; 137.2; 129.4; 126.7; 57.4; 54.4; 53.3; 50.8; 49.4; 
49.2; 48.9; 47.9; 47.3; 45.2; 28.5; 25.2. 
Diethyl-4-cyanobenzylmalonate (25) 
A solution of diethyl malonate (20g, 125 mmol) in dry ethanol (50 cm3) 
was added dropwise under a nitrogen atmosphere to sodium ethoxide, 
prepared by dissolving sodium metal (1.5g, 65 mmol) in dry ethanol (125 
cm3). After stirring for 30 minutes at 20 °C, a solution of a-bromo-p-
tolunitrile (12g, 61 mmol) in dry miF (60 cm3) was added dropwise. The 
reaction mixture was heated under reflux for 24 hours. On cooling to 
room temperature, the reaction was quenched with distilled water (150 
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cm3). A white precipitate of dibenzylated malonate was filtered off and 
the filtrate was extracted with diethyl ether (440 cm3). The ether was 
removed under reduced pressure and the desired product, a clear oil, was 
distilled from the residue at 150 °C (0.1 mm). Yield: 7.84g (47%); TLC: 
Rf 0.26 (20% EtOAcfpetrol); mje: 277(M+2t; 276(M+1)+; 275(M)+; 230(M+1 · 
-EtOH)+; 184(M+1-2EtOH); IR(CHC13): 3010(CH); 2980(CH); 2235(CN); 1730 
(CO); 1H NMR (CDC13) 8 7.59(2H,d,Ar); 7.33(2H,d,Ar); 4.16(4H,mult,CH20); 
3.36(1H,t,CH); 3.27(2H,d,CH2); 1.22(6H,t,CH3); 
13c N~ffi (CDC13) 8 167.3; 
143.3; 132.1; 129.5; 116.5; 110.5; 61.6; 53.0; 34.4; 13.8. 
12-{4-Cyanobenzyl)-1,4,7,10-tetraazacyclotridecane-11,13-dione (26) 
The linear tetraamine, 1,4,7,10-tetraazadecane (4.18g, 28.6 mmol) was 
added to diethyl 4-cyanobenzyl malonate (7.84g, 28.5 mmol) in dry 
ethanol (58 cm3) and heated for 10 days under reflux. A white 
precipitate of the required diamide was filtered off and recrystallised 
from hot ethanol (1.404g, 15%). Mpt: 244-247 °C (dec); Anal: Calcd for 
C17H23N502.0.2 H20: C 61.31; H 7.08; N 21.03. Found: C 61.15; H 7.03; N 
20.79; TLC: Rf 0.27 (aq NH1 /CH1 0H/CH?Cl? 6:44:50); m/e: 331(M+2)+; 330 
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(M+1)+; 312; 286; IR(KBr): 3320(NH); 2930(CH); 2880(CH); 2810(CH); 
2225(CN); 1665(NH); 1640(CO); 1550; 1525; 1H NMR (CD30D) 8 7.63(2H,d,Ar, 
J=8.0 Hz); 7.41(2H,d,Ar,J=8.2 Hz); 3.64(2H,mult,CH2N); 3.47(1H,t,CHCO); 
3.26(2H,d,CH2Ar); 3.02(2H,mult,CH2N); 2.67(8H,mult,CH2N). 
12-(4-Aminomethylbenzyl)-1,4,7,10-tetraazacyclotridecane (28) 
The macrocyclic diamide (26) (1.3g, 3.95 mmol) was reduced with molar 
diborane-THF (80 cm3, 80 mmol) under reflux for 3 days. After treatment 
with boiling 6N HCl (100 cm3) for 3 hours, the hydrochloride salt was 
dissolved in distilled water (50 cm3), washed with ether (60 cm3), 
basified (8g KOII) and extracted into chloroform (2 x 70 cm3). A clear 
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oil was recovered upon removal of the solvent (1.19g, 99%). Anal: Calcd 
for C17H31N5.5HC1.4H20: C 36.47; H 7.92; N 12.51. Found: C 36.71; H 
7.82; N 12.11; mje: 307(M+2)+; 306(M+1)+; 305(M)+; 258; 1H NMR (CDC13) 8 
7.22(2H,d,Ar,J=8.0 Hz); 7.14(2H,d,Ar,J=8.0 Hz); 3.84(2H,s,ArCH2N); 2.84-
13 2.49(19H,mult,CH+CH2N+CH2Ar); 2.04(6H,br.s,NH); C NMR (CDC13) 8 140.7 
(Ar); 138.8(Ar); 128.9(Ar,CH); 126.8(Ar,CH); 54.6(ArCH2N); 48.8(CH2N); 
47.4(CH2N); 47.2(CH2N); 46.0(CH2N); 40.2; 38.3(CH2Ar+CHC). 
6-{4-Cyanobenzyl}-1,4,8,11-tetraazacyclotetradecane-5,7-dione (27) 
A solution of 1,4,8,11-tetraazaundecane (2.768g, 17.3 mmol) and diethyl 
4-cyanobenzyl malonate (4.75g, 17.3 mmol) in dry ethanol (35 cm3) was 
heated under reflux for 5 days. The solvent was evaporated and the 
diamide was isolated from the residue through silica gel column 
chromatography (standard conditions) in 19% yield (1.1g). Mpt. 209-
2110C; Anal: Calcd for c18H25N5o2.H20: C 59.80; H 7.53; N 19.38. Found: 
C 60.06; H 7.17; N 18.68; TLC: Rf 0.25 (aq NH3/CH30H/CH2Cl2 6:44:50); 
mfe: 345(M+2)+; 344(M+1)+; 326; 309; 308; IR(KBr): 3290(NH); 2910(CH); 
2805(CH); 2225(CN); 1638(CO); 1530; 1H ~ffi (CDCl~) 8 7.56(2H,d,Ar); 7.33 
(2H,d,Ar); 6.65(2H,br.s,NH); 3.50(2H,mult,CH2Ar); 3.25(5H,mult,CH2NCO 
+CHCO); 2.82-2.57(8H,mult,CH2N); 1.78(2H,br.s,NH); 1.65(2H,mult,CH2C); 
13c NMR (CD30D) 8 171.2; 146.3; 133.3; 131.1; 119.7; 111.3; 56.5; 50.9; 
39.4; 35.1; 28.3. 
6-{4-Aminomethylbenzyl}-1,4,8,11-tetraazacyclotetradecane (29) 
The diamide, (27) (0.969g, 2.82 mmol) was reduced by stirring with 
diborane-THF (47 cm3, 47 mmol) for 24 hours under reflux. Once cool, 
the reaction was quenched with methanol and the solvent evaporated in 
vacuo. The residue was treated with boiling 6N HCl (60 cm3) for 3 hours 
to convert the aminoborane to an amine hydrochloride salt. The acid was 
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removed under reduced pressure and the residue was re-dissolved in 
distilled water (45 cm3). The aqueous solution was washed with diethyl 
ether (60 cm3), basified with sodium hydroxide (2.5g) and extracted into 
chloroform (2 x 120 cm3). The crude macrocycle was recrystallised from 
toluene in 83% yield (0.75g). Mpt. 149 °C; Anal: Calcd for c18H33N5.H20: 
C 64.05; H 10.45; N 20.75. Found: C 64.61; H 10.16; N 20.10; mje: 321 
(M+2)+; 320(M+1)+; 1H NMR (CDC13) 8 7.22(2H,diAr); 7.14(2H,d,Ar); 3.83 
(2H,s,ArCH2N); 2.40-2.85(19H,mult,CH2N+CH2Ar+CHCH2Ar); 2.20(6H,br.s, 
NH); 1.71(2H,q,CH2C); 
13c NMR (CDC13) 8 140.9; 139.0; 129.1; 127.0; 
55.8; 50.7; 49.3; 46.2; 40.8; 38.6; 29.3. 
7.3.2 Vinyl Pyridine Linker Molecule 
2-flimethoxytrityloxymethyl-6-hydroxymethyl-pyridine (32) 
A solution of 2,6-bis(hydroxymethyl)-pyridine (16.1g, 116 mmol) in dry 
pyridine (200 cm3) was added to a solution of dimethoxytrityl chloride 
(39.2g, 116 mmol) in pyridine (120 cm3), dropwise over 4 hours. The 
reaction mixture was stirred for a further hour, then concentrated by 
evaporation in vacuo. The residual solution was then dissolved in 
dichloromethane (400 cm3), washed with saturated sodium bicarbonate 
solution (400 cm3), separated and dried. The solvent was removed under 
reduced pressure and the crude residue was purified by ''flash" 
chromatography (diethyl ether/hexane 8:2) to give the mono-protected 
alcohol as a yellow glass in 61% yield (31.2g). Mpt. 38-40 °C; TLC: Rf 
0.20 (diethyl ether/hexane 8:2). 
2-Hydroxymethyl-6-methylmethoxyacetate pyridine (33) 
The mono-protected alcohol (32) {30.96g, 70.2 mmol) was dissolved in dry 
TIIF {200 cm3) and n-butyl lithium (48 cm3, 1.6M solution in hexane, 77.2 
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mmol) was added by syringe at -78 °C under nitrogen. The brown 
suspension thus formed was added via a cannula to a solution of methyl 
bromoacetate (26.85g, 175mmol) in dry THF (50 cm3) at -78 °C. The 
reaction mixture was allowed to warm to room temperature and stirred for 
18 hours. The THF solution was poured into saturated sodium bicarbonate 
solution (250 cm3) and extracted into dichloromethane (500 cm3). The 
organic layer Has separated, dried (MgS04) and evaporated to dryness in 
vacuo. The crude residue Has re-dissolved in dry dichloromethane (300 
cm3) and zinc bromide (78.7g, 350 mmol) was added as a solid. After 
stirring for 15 minutes at room temperature, the reaction mixture was 
poured into saturated disodium EDTA solution (300 cm3). The aqueous 
layer was separated, basified with sodium bicarbonate and extracted into 
chloroform (3 x 500 cm3). The solvent was removed under reduced 
pressure to give the alcohol (3.0g) in 20% overall yield. TLC: Rf 0.46 
(CH30H/CH2Cl2 1:9); Ace. Mass (DEI): c10n13N04 requires (M)+ 211.08446. 
1 Found 211.08082; H N~ffi (CDC13) o 7.72(1H,t,Py); 7.41(1H,d,Py); 7.18(1H, 
d,Py); 4.76(4H,s,PyCH20); 4.22(2H,s,CH20); 3.75(3H,s,CH30); 3.07(1H, 
13 br.s,OH); C NMR (CDCl::\) o 158.3; 156.3; 137.5; 120.2; 119.4; 73.9; 
67.9; 63.9; 51.9. 
2-Formyl-6-methylmethoxyacetate pyridine (34) 
The alcohol (33) (2.6g, 12.3 mmol) was dissolved in dry dichloromethane 
(50 cm3) and oxidised with manganese dioxide (25g, 288 mmol). After 
stirring at room temperature for 15 hours, the excess oxidant was 
filtered off (using "Celite") and the filtrate evaporated in vacuo. The 
aldehyde was purified by silica gel "flash" chromatography, eluting with 
ether/hexane (8:2). Yield: 1.3g (51%); Anal: Calcd for c10H11N04: C 
57.41; H 5.30; N 6.70. Found: C 56.59; H 5.00; N 6.39; TLC: Rf 0.45 
(ether/hexane 4:1); Ace. Mass (DEI): c10H11 N04 requires (M+l)+ 
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210.07663. Found 210.07255; 1H NMR (CDC13) 8 10.05(1H,s,CHO); 7.90(2H, 
mult,Py); 7.78(1H,dd,Py); 4.86(2H,s,PyCH20); 4.29(2H,s,CH20); 3.80(3H, 
13 s,CH30); C NMR (CDC13) 8 193.2; 158.4; 152.0; 137.7; 125.9; 120.6; 
73.7; 68.0; 51.9. 
2-Vinyl-6-methoxyacetic acid pyridine-methyl ester (35) 
To a solution of the aldehyde (34) (1. 3g, 6. 22 mmol) in dry THF (20 cm3) 
was added by syringe, a molar solution of trimethylsilylmethylmagnesium 
chloride in ether (6.84 cm3, 6.84 mmol) at -78° C under nitrogen. After 
stirring for 15 minutes at -78 °C, the reaction mixture was allowed to 
warm to 0 °C and thionyl chloride (0.81g, 6.81 mmol) was added dropwise. 
The solution was stirred at 0 °C for 20 minutes, then warmed to room 
temperature, cautiously basified with saturated sodium bicarbonate 
solution and extracted into dichloromethane. The solvent was dried 
(MgS04) and evaporated, and the residue "flash" chromatographed on 
silica (ether/hexane 1:1) to give the vinyl pyridine in 71% yield 
(0.91g). TLC: Rf 0.19 (Et20jhexane 1:1); mfe (DEI): 208(M+1)+; 207(M)+; 
206(M-1)+; 1H NMR (CDC13) 8 7.68(1H,t,Py); 7.41(1H,d,Py); 7.29(1H,d,Py); 
6.82(1H,dd,Ak); 6.19(1H,d,Ak); 5.49(1H,d,Ak); 4.76(2H,s,PyCH20); 4.25 
13 (2H,s,CH20); 3.78(3H,s,CH30); C NMR (CDC13) 6 170.6; 163.0; 156.4; 
137.2; 136.6; 122.2; 120.3; 118.4; 73.9; 67.9; 51.8. 
2-Vinyl-6-methoxyacetic acid pyridine-4-nitrophenyl ester (36) 
The methyl ester (35) (0.80g, 3.87 mmol) was hydrolysed with lithium 
hydroxide (0.175g, 7.31 mmol) in a mixture of methanol (40 cm3) and 
water (13 cm3). After stirring for 15 minutes at room temperature, the 
reaction mixture was concentrated by evaporation in vacuo and passed 
down a pyridinium cation exchange column (20g Dowex 50W), eluting with 
pyridine. The UV active fractions were combined and the solvent removed 
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under reduced pressure. To a solution of the pyridinium salt in dry 
dichloromethane (50 cm3) was added p-nitrophenol (840mg, 6 mmol) as a 
solid, and dicyclohexylcarbodiimide (DCC) (830mg, 4 mmol) as a solution 
in dry dichloromethane (25 cm3). Having stirred the reaction mixture for 
60 minutes at room temperature, the white precipitate of dicyclohexyl-
urea was filtered off and the solvent evaporated under reduced pressure. 
The active ester was purified by silica gel "flash" chromatography, 
eluting with ether/dichloromethane (1:40). Yield: 0.81g (63%). TLC: Rf 
0.32 (etherfCH2Cl2 1:40); Ace. Mass (DCI): c16H14N205 requires (M+1)+ 
315.09809. Found 315.09810; 1H ~ffi (CDC13) 8 8.28(2H,d,Ar); 7.76(1H,t, 
Py); 7.41(2H,mult,Py); 7.32(2H,d,Ar); 6.84(1H,dd,Ak); 6.18(1H,dd,Ak); 
5.53(1H,dd,Ak); 4.84(2H,s,PyCH20); 4.51(2H,s,CH20). 
7.3.3 Macrocycle-Vinyl Pyridine Conjugation 
2-Vinyl-6-methoxyacetic acid pyridine-12-{4-amidomethylbenzyl)-1,4,7,10-
tetraazacyclotridecane (39) 
The ·following procedure is generally applicable to the acylation of 
exocyclic primary amines using the active ester (36). The macrocycle 
(28) (10.5mg, 34.4 mmol) was dissolved in 0.5M "Pipes" buffer (1 cm3) at 
pH 6.8 ("Pipes"= 1,4-piperazinebis(ethanesulphonic acid)). A solution 
containing a 2-fold excess of the active ester (36) (21mg, 69 pmol) 1n 
p-dioxane (1 cm3) was added dropwise to the aqueous solution of the 
macrocycle and stirred at 40 °C for 4 hours. Exhaustive extraction of 
the reaction mixture with chloroform removed the unreacted p-nitrophenyl 
ester and the majority of the p-nitrophenol liberated in the acylation. 
Purification of the macrocycle-vinylpyridine conjugate was by cation 
exchange HPLC, the adduct eluting after 13 minutes (pH 6.5) in 55% yield 
(9mg); mfe(FAB): 482(M+1)+; 481(M)+; 243; UV(H20): 281 nm; 
1H NMR (D20) 
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8 7.82(1H,t,Py,J=7.9 Hz); 7.54(1H,d,Py); 7.36(1H,d,Py); 7.22(4H,s,Ar); 
6.79(1H,dd,Ak); 6.09(1H,d,Ak,J=17.7 Hz); 5.56(1H,d,Ak,J=11.0 Hz); 
4.70(2H,s,PyCH20); 4o38(2H,s,CH20); 4.20(2H,s,ArCH2N); 3.09-2.59(18H, 
mult,CH2N+CH2Ar); 2.21(1H,mult,CHCH2); 1.89(6H,s,CH3COO-). 
2-Vinyl-6-methoxyacetic acid pyridine-6-(4-amidomethylbenzyl}-1,4,8,11-
tetraazacyclotetradecane (40) 
Yield: 80%. HPLC: Rt 13 min (pH 6.5); mje(FAB): 495(M+1)+; 494(M)+; 304; 
185; 115; lN(H20): 280 nm; 1H NMR (D20) 8 7.76(1H,t,Py); 7.48(1H,d,Py); 
7.30(1H,d,Py); 7.17(4H,br.s,Ar); 6.74(1H,dd,Ak); 6.03(1H,d,Ak); 5.50(1H, 
d,Ak); 4.64(2H,s,PyCH20); 4.33(2H,s,CH20); 4.14(2H,s,ArCH2N); 2.98-2.32 
(19H,mult,CH2N+CH2Ar+CHCH2); 1.84(2H,mult,CH2C). 
2-Vinyl-6-methoxyacetic acid pyridine-11-{2-hydroxy-5-amidomethyl-
phenyl}-1,4,7,10-tetraazacyclotridecane (37) 
Yield: 50%. HPLC: Rt 12.01 min (pH 6.5); m/e(FAB): 484(M+1)+; 483(M)+; 
1 453; 378; 325; UV(H20): 280 nm; H NMR (D20) 8 7.79(1H,t,Py); 7.52(1H, 
d,Py); 7.32(1H,d,Py); 7.07(2H,mult,Ar); 6.86(1H,d,Ar); 6.72(1H,dd,Ak); 
6.05(1H,d,Ak); 5.53(1H,d,Ak); 4.67(2H,s,PyCH20); 4.31(2H,s,CH20); 4.18 
(2H,s,ArCH2N); 4.06(1H,dd,ArCHN); 3.32-2.54(14H,mult,CH2N); 2.14-1.89 
(8H,mult,CH2C+CH3COO-). 
2-Vinyl-6-methoxyacetic acid pyridine-5-{2-hydroxy-5-amidomethylphenyl)-
1,4,8,11-tetraazacyclotetradecane (38) 
Yield: 70%. HPLC: Rt 11.2 min (pH 6.5); UV(H20): 280 nm; 1H NMR (D20) 8 
7.78(1H,t,Py); 7.51(1H,d,Py); 7.30(1H,d,Py); 7.07(2H,mult,Ar); 6.85(18, 
d,Ar); 6.71(1H,dd,Ak); 6.04(1H,d,Ak); 5.52(1H,d,Ak); 4.66(2H,s,PyCH20); 
4.29(2H,s,CH20); 4.12(3H,mult,ArCHN); 3.31-2.60(14H,mult,CH2N); 2.12-
1.80(10H,mult,CH2C+CH3COO-). 
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7.3.4 Selective Acetylation of Functionalised Macrocycles 
12-(4-Acetamidomethylbenzyl)-1,4,7,10-tetraazacyclotridecane (59) 
A solution of (28) (0.8g, 2.62 mmol) in 0.5M "Pipes" buffer (35 cm3, pH 
6.8) was added to a solution of p-nitrophenyl acetate (1.3g, 7.2 mmol) 
in p-dioxane (35 cm3) and stirred for 3.5 days at room temperature. 
Having washed the reaction mixture with ether (2 x 150 cm3), the aqueous 
layer was made basic with KOH (5g) and extracted into chloroform (2 x 
200 cm3), to give the free amine as a clear oil in 70% yield (0.636g). 
IR(film): 3260(NH); 3060(CH); 2915(CH); 2830(CH); 1650(CO); 1550; 1460; 
1295; m/e: 350(M+3)+; 349(M+2)+; 348(M+1)+; 1H NMR (CDC13) 8 7.17(2H,d, 
Ar,J=8.1 Hz); 7.11(2H,d,Ar,J=8.1.Hz); 6.97(1H,br.s,NHCO); 4.35(2H,d, 
ArCH2N,J=5.6 Hz); 2.80-2.41(23H,mult,CH2N+CHCH2+CH2Ar+NH); 1.97(3H,s, 
CH3); 
13c N~ffi (CDC13) 8 170.0; 139.5; 135.9; 129.1; 127.7; 54.8; 48.8; 
47.4; 43.2; 40.3; 38.3; 23.0. 
6-(4-Acetamidomethylbenzyl)-1,4,8,11-tetraazacyclotetradecane (52) 
Synthesised using the same method as (59). Yield: 75%; 1H ~m (AcO-
salt, D2U) b 7.26(4H,mult,Ar); 4.33(2H,s,ArCH2N); 3.10-2.75(16H,mult, 
CH2N); 2.63(2H,d,CH2Ar); 2.23(1H,mult,CHCH2); 2.02(3H,s,CH3); 1.89(8H, 
mult,CH2C+CH3COO-). 
5-{2-Hydroxy-5-acetamidomethylphenyl)-1,4,8,11-tetraazacyclo-
tetradecane (51) 
Synthesised in a similar manner to (59) and (52). Yield: 51% (after 
recrystallisation from CH3CN); Mpt. 151-153 °C; Anal: Calcd for 
C19H33N502.1.3H20: C 58.97; H 9.27; N 18.10. Found: C 59.02; H 9.04; N 
17.87; UV(H20): 285 nm (phenol); .296 nm (phenolate); mje: 365(M+2)+; 
364(M+1)+; IR(KBr): 3240(NH); 3050(CH); 2925(CH); 2880(CH); 2820(CH); 
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1632(CO); 1545; 1500; 1460; 1270; 1H NMR (CDC13) 8 7.00(1H,d,Ar); 6.87 
(1H,s,Ar); 6.71(1H,d,Ar); 5.80(1H,br.s,NHCO); 4.29(2H,d,ArCH2N); 3.79 
(1H,dd,ArCHN); 3.05-2.49(18H,mult,CH2N+NH); 2.00(3H,s,CH3); 2.00-1.70 
13 (4H,mult,CH2C); C NMR (CDC13) 8 157.5; 157.3; 128.2; 127.8; 127.7; 
126.8; 116.5; 66.7; 51.2; 51.0; 50.1; 49.6; 49.3; 49.1; 47.4; 43.4; 
36.3; 29.3; 23.3. 
7.3.5 Parent Tetraamine Macrocycles 
1,4,7,10-tetraazacyclotridecane-11,13-dione (63) 
A solution of 1,4,7,10-tetraazadecane (20g, 0.137 mmol) and diethyl 
malonate (21.92g, 0.137 mmol) in dry ethanol (250 cm3) was stirred under 
reflux for 2 weeks under nitrogen. On cooling a precipitate was 
deposited which was filtered off and found by TLC to be baseline 
material. The filtrate was evaporated to dryness and chromatographed on 
silica (standard conditions) to give the desired diamide as a white 
solid (5.57g, 19%). Mpt. 168-170°C (dec); TLC: Rf 0.38 (aq NH3/CH30H/ 
CH2Cl2 5:45:50); Acc.Mass (DCI): C9H18N4o2 requires (M+1)+ 215.15080. 
Found ~15.16653; IR(KBr): 3310(NH); 3040(CH); 2950(CH); 2930(CH); 
2895(CH); 2830(CH); 1655(CO); 1532; 1440; 1H N~IR (CDC13) 8 7.64(2H, 
br.s,NHCO); 3.40(4H,q,CH2NCO); 3.22(2H,s,CH2CO); 2.74(4H,t,CH2N); 
2.70(4H,s,CH2N); 1.73(2H,s,NH); 13c mtR (CDC13) 8 168.2; 47.7; 46.7; 
46.4; 39.4. 
1,4,7,10-tetraazacyclotridecane (13N4) 
The cyclic diamide (63) (4.814g, 22.5 mmol) was dissolved in molar 
diborane-THF (180 cm3, 180 mmol) and refluxed for 36 hours. After 
quenching the excess diborane with methanol, the solvent was removed and 
the residue treated with 6N HCl (230 cm3) at 100 °C for 3 hours. The 
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crude hydrochloride salt was then re-dissolved in distilled water (75 
crn3), washed with ether (200 crn3), basified (22g KOH) and extracted as 
the free amine into chloroform (2 x 300 cm3) in 76% yield (3.2g). Mpt. 
40-41.5 °C (Lit. 40-41 °C) 3; Anal: Calcd for c9H22N4.0.6H20: C 54.84; H 
11.86; N 28.43. Found: C 55.01; H 12.39; N 28.10; mje: 188(M+2)+; 187 
(M+1)+; 99; 1H NMR (CDC13) 6 2.76-2.66(16H,rnult,CH2N); 2.05(2H,br.s,NH); 
1.67(2H,q,CH2C); 
13c ~IR (CDC13) o 49.8; 48.7; 47.5; 47.2; 28.8. 
11-{2-Hydroxyphenyl}-1,4,7,10-tetraazacyclotridecane-19-one (64) 
A solution of 1,4,7,10-tetraazadecane (12.7g, 86.8 rnmol) and coumarin 
(12.7g, 86.9 mmol) in dry methanol (420 crn3) was boiled for 14 days. 
The solvent was removed and the desired amide was separated using the 
standard chromatographic conditions in 16% yield (3.989g). The 
trihydrochloride salt was recrystallised from ethanol/HCl. Mpt. 165-
1670C; Anal: Calcd for c15H24N402.3HC1.2H20: C 41.15; H 7.14; N 12.80. 
Found: C 40.90; H 7.07; N 12.29; TLC: Rf 0.54 (aq NH3/CH30H/CH2Cl2 
10:40:50); m/e: 294(M+2)+; 293(M+1)+; 276(M+1-NH3); 275(M-NH3); 213; 
171; IR(KBr): 3260(NH); 3050(CH); 2920(CH); 2840(CH); 1635(CO); 1450 
(NH); iH NMR (CDC13) o 7.42(1H,br.s,NHCO); 7.13(1H,t,Ar,J=8 Hz); 7.05 
(1H,d,Ar,J=7.5 Hz); 6.78(2H,mult,Ar); 4.46(3H,br.s,NH); 4.21(1H,dd, 
ArCHN); 3.88-2.47(15H,mult,CH2N+CH2CO); 
13c NMR (CDC13) o 172.0; 157.1; 
128.4; 128.3; 125.4; 119.1; 116.5; 60.3; 47.9; 47.3; 46.3; 45.3; 44.7; 
43.6; 39 .1. 
11-{2-Hydroxyphenyl}-1,4,7,10-tetraazacyclotridecane (56) 
The cyclic amide (64) (3.95g, 13.5 mmol) was reduced using molar 
diborane-THF (130 cm3, 130 mmol), under reflux for 36 hours. The 
residue, after quenching (CH30H) and removal of solvent, was hydrolysed 
with boiling 6N HCl (200 cm3) for 3 hours. The hydrochloride salt was 
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dissolved in distilled water (50 cm3), washed with ether (80 cm3), 
basified (12g KOH) and the free amine extracted into chloroform (2 x 200 
cm3) in 49% yield (1.833g). Mpt. 69-71°C (Lit. 72-74 °C) 4; Anal: Calcd 
for c15H26N40.1.7H20: C 58.29; H 9.59; N 18.13. Found: C 58.26; H 9.32; 
N 18.19; mje: 281(M+2)+; 280(M+1)+; 147; 85; 1H NMR (CDC13) 6 7.11 (1H,-
t,Ar,J=7.9 Hz); 6.92(1H,d,Ar,J=7.3 Hz); 6.75(2H,mult,Ar); 3.83(1H, dd,-
13 ArCHN); 3.11-2.60(19H,mult,CH2N+NH); 2.02-1.71(2H,mult,CH2C); C NMR 
(CDC13) 6 158.7; 158.1; 128.1; 118.7; 116.7; 66.4; 49.6; 48.5; 48.1; 
47.5; 46.7; 46.5; 36.1. 
5-(2-Hydroxyphenyl}-1,4,8,11-tetraazacyclotetradecane-7-one (65) 
Synthesised in a similar manner to (64). Yield: 1. 68g (17%); TLC: Rf 
0.35 (aq NH3/CH30H/CH2Cl2 5:45:50); mje: 308(M+2)+; 307(M+1)+; 164; 147; 
1 H ~IR (CDC13) 6 7.78(1H,br.s,NHCO); 7.11(1H,t,Ar); 7.03(1H,d,Ar); 6.80-
6.73(2H,mult,Ar); 4.20(1H,dd,ArCHN); 3.84-2.45(20H,mult,CH2N+CH2CO+NH); 
13 1.73(2H,mult,CH2C); C NMR (CDC13) 6 171.6; 156.6; 128.2; 125.5; 119.0; 
116.1; 59.0; 49.6; 48.9; 47.8; 45.3; 42.9; 38.2; 28.1. 
5-(2-Hydroxyphenyl}-1,4,8,11-tetraazacyclotetradecane (~) 
Synthesised in a similar manner to (56), then recrystallised from CH3CN. 
Yield: 520mg (55%); Mpt. 141-143 °C (Lit. 142-143 °C)4; Anal: Calcd for 
C16H28N40.H20: C 61.90; H 9.74; N 18.05. Found: C 61.79; H 9.26; N 
17.97; m/e: 294(M+2)+; 293(M+1)+; 161; 131; 130; 1H ~IR (CDC13) 6 
7.10(1H,t,Ar); 6.93(1H,d,Ar); 6.74(2H,mult,Ar); 3.81(1H,dd,Ar); 3.09-
2.45(18H,mult,CH2N+NH); 1.93(2H,mult,CH2C); 1.74(2H,mult,CH2C); 0.75(18, 
13 br.s,OH); C NMR (CDC13) 6 157.7; 127.8; 126.5; 118.5; 116.2; 66.5; 
51.1; 50.8; 49.9; 49.5; 49.2; 49.1; 47.2; 36.2; 29.2. 
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7.3.6 Modified Phenol-Pendent Macrocycles 
5-{2-ffydroxy-3-sulphonic acid-5-aminomethylphenyl)-1,4,8,11-tetraaza-
cyclotetradecane (55) 
A solution of (19) (84mg) in 98% H2so4 (1 cm
3) was heated to 100 °C for 
1 hour. On cooling, the darkened solution was poured onto crushed ice 
(15g) and the pH was adjusted to 3-4 with sodium hydroxide. On addition 
of excess methanol, sodium sulphate was precipitated and was filtered 
off. Remaining sodium sulphate was removed by evaporating the solution 
to dryness, then extracting the macrocycle into methanol. The required 
monosulphonated product was separated from unreacted starting material 
using cation exchange HPLC: Rt 10.0 min (pH 7.4); m/e(FAB): 402(~1)+; 
1 - . 389; 346; H miR (AcO salt,D20) 6 7.66(1H,d,Ar,J=2.2 Hz); 7.31(1H,d,Ar, 
J=2.1 Hz); 4.19(1H,dd,ArCHN); 4.06(2H,s,ArCH2N); 3.23-2.71(14H,mult, 
CH2N); 2.40-1.87(4H,mult,CH2C+CH3COO-). 
5-{2-Hydroxy-3-nitro-5-aminomethylphenyl)-1,4,8,11-tetraazacyclotetra-
decane (54) and 5-{2-hydroxy-3,5-dinitrophenyl)-1,4,8,11-tetraazacyclo-
tetradecane (53) 
A solution of (19) (180mg, 0.56 mmol) in trifluoroacetic anhydride (2 
cm3) was stirred at room temperature for 15 hours. The excess anhydride 
was then evaporated in vacuo and the residue dissolved in ethyl acetate/ 
chloroform/dichloromethane (2:1:1). After stirring for 2 hours in the 
presence of water (10 cm3), the organic layer was washed with more water 
(2 x 6 cm3) and the solvent removed under reduced pressure. Diethyl 
ether was added to precipitate a white solid (263mg) which was filtered 
off. The nitration of the protected pentaamine (263mg) was carried out 
with a mixture of concentrated nitric (0.9 cm3, 75%) and sulphuric (0.55 
cm3, 98%) acids. After stirring for 4 hours at room temperature, the 
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reaction mixture was poured into distilled water (25 cm3) and a yellow 
precipitate was filtered off. The solid (203mg) was treated with a 
mixture of molar sodium hydroxide in water (1.2 cm3) and methanol (5 
cm3) for 20 hours at room temperature. After evaporating the solvent in 
vacuo, molar acetic acid (5 cm3) was added to the residue producing a 
yellow precipitate of the acetate salt of (53) which was filtered off. 
Overall yield: 45mg (16%); Mpt. 215-217°C; m/e(Neg.FAB): 382(M)-; 381 
(M-1)-; 365; 249; UV(H20): 261 nm (pH 2,phenol); 372 nm (pH 10, 
1 phenolate); H NMR (D20) 8 8.81(1H,d,Ar); 8.08(1H,d,Ar); 4.16(1H,dd, 
ArCHN); 3.32-2.61(14H,mult,CH2N); 2.27-1.87(4H,mult,CH2C). 
The aqueous layer was evaporated to dryness and the residue was twice 
recrystallised from water to remove further dinitro-compound. Cation 
exchange HPLC was used to remove further impurities, including sodium 
acetate. The acetate salt of (54) was isolated as a yellow-orange 
solid. Overall yield: 7mg (2.3%); HPLC: Rt 15 min (pH 6.5); UV(H20): 236 
nm (pH.4,phenol); 411 nm (pH 9.2,phenolate); 1H ~ffi (AcO- salt,D20) 8 
8.10(1H,d,Ar,J=2.1 Hz); 7.50(1H,d,Ar,J=2.1 Hz); 4.23(1H,dd,ArCHN); 4.10 
(2H,s,ArCH2N); 3.30-2.67(14H,mult,CH2N); 1.92(13H,mult,CH2C+CH3COO-). 
7.3.7 Functionalised Yttrium Binder 
1 2 3 
12-(4-Acetamidomethylbenzyl}-1,4,7,10-tetraazacyclotridecane-N,N,N,N-
tetraacetic acid, ethyl ester (60) 
The monoprotected amine (59) (300mg, 0.86 mmol) was dissolved in dry 
isopropanol (15 cm3). Caesium carbonate (1.173g, 3.6 mmol) was added as 
a solid, ethyl bromoacetate (600mg, 3.6 mmol) as a solution in dry 
isopropanol (2 cm3). After stirring for 18 hours at 55-60 °C, the 
solids were filtered off and the solvent evaporated. The residue was 
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re-dissolved in chloroform (50 cm3), washed with water (20 cm3) and 
dried over potassium carbonate. The chloroform was removed under 
reduced pressure to give a crude oil (476mg). The crude material was 
chromatographed on alumina, eluting with 2% methanoljdichloromethane, to 
give the pure tetracarboxylate ester in 35% yield (205mg). Two 
successive columns were necessary to remove all remaining traces of 
baseline material. TLC: Rf 0.45 (ethyl acetate); mfe(EI): 694(M+2)+; 
693(M+1)+; 680; 679; 666; 665; IR(film): 3270(NH); 3050(CH); 2980(CH); 
2930(CH); 2825(CH); 1735(CO); 1655(CO); 1542; 1450; 1375; 1200; 1H NMR 
(CDC13) 8 7.22(2H,d,Ar); 7.15(2H,d,Ar); 5.21(1H,br.s,NHCO); 4.40(2H,d, 
ArCH2N); 4.15(8H,mult,CH20); 3.39-2.30(27H,mult,CH2N+COCH2N+CHCH2+ 
CH2Ar); 2.05(3H,s,CH3CO); 1.26(12H,t,CH3C); 
13c NMR (CDC13) 8 171.8; 
171.3; 140.7; 135.4; 129.5; 127.8; 60.1; 57.5; 55.2; 52.3; 51.5; 50.6; 
43.5; 39.6; 37.8; 21.9; 14.3. 
1 2 3 
12-{4-Aminomethylbenzyl)-1,4,7,10-tetraazacyclotridecane-N,N,N,N -tetra-
acetic acid (61) 
Treatment of (60) (110mg, 0.16 mmol) with 6N HCl (10 cm3) for 24 hours 
hydrolysed the amide and ester functionalities simultaneously. The acid 
was removed in vacuo to give the tetraacid as a glassy solid (110mg, 
96%); .m/e(FAB): 538(M+1)+; 494(M+1-C02)+; 480; 462; 1H NMR (D20) 8 
7.36(2H,d,Ar); 7.30(2H,d,Ar); 4.11(2H,s,ArCH2N); 4.00-3.70(8H,mult, 
NCH2C02H); 3.60-2.40(19H,mult,CH2N+CH2Ar+CHCH2); 
13c NMR (D20) 8 173.6; 
141.5; 133.8; 132.4; 131.8; 62.4; 56.3; 55.8; 53.7; 51.4; 45.3; 38.9; 
34.7. 
. 1 2 3 12-(4-Acetamzdomethylbenzyl)-1,4,7,10-tetraazacyclotridecane-N,N,N,N-
tetraacetic acid (62) 
The exocyclic amino group of (61) (110mg, 0.153 mmol) in water (1 cm3) 
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was acetylated using excess p-nitrophenylacetate (76mg, 0.42 mmol) in p-
dioxane (4 cm3). The reaction mixture was neutralised with sodium 
carbonate and stirred for 3 days at room temperature. The solution was 
then acidified (pH 4) with molar acetic acid and washed with ether (2 x 
50 cm3) to remove excess ester and p-nitrophenol. The solvent was then · 
removed under reduced pressure. The amide was separated from inorganic 
salts by passing down a cation exchange column (Dowex 50W H+ form), 
eluting with 0.5M ammonium hydroxide. The alkaline fractions were 
collected and combined, and the solvent removed to give a glassy solid 
(55mg, 62%); 1H NMR (D20) o 7.27(4H,mult,Ar); 4.35(2H,s,ArCH2N); 3.70-
2.20(27H,mult,CH2N+CH2CO+CH2Ar+CHCH2); 2.04(3H,s,CH3). 
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APPENDIX 1 
RESEARCH CfiLLOQUIA, SEMINARS AND lECTURES 
The following lectures were organised by the Department of Chemistry 
during the course of my three years of research (October 1985 -
September 1988); "*"indicating the authors's attendance: 
17.10.85 Dr. C.J. Ludman (Durham) 
"Some Thermochemical Aspects of Explosions" 
24.10.85 Dr. J. Dewing (1Th1IST) 
"Zeolites - Small Holes, Big Opportunities" 
30.10.85 Dr. S.N. Whittleton (Durham) 
"An Investigation of a Reaction \Hndow" 
31.10.85 * Dr. P. Timms (Bristol) 
"Some Chemistry of Fireworks" 
05.11.85 *Prof. M.J. O'Donnell (Indiana-Purdue University, USA) 
"New Methodology for the Synthesis of Amino Acids" 
07.11.85 Prof. G. Ertl (Munich, W. Germany) 
"Heterogeneous Catalysis" 
14.11.85 * Dr. S.G. Davies (Oxford) 
"Chirality Control and Molecular Recognition" 
20.11.85 Dr. J.A.H. McBride (Sunderland Polytechnic) 
"A HPt.Prnrurl ir 1'n11r nn !I Oicd·nr+orl 'l'r;,...,,...l,,, 
- -" ----- ---- --- ........ -~- ......... - .... .....-- ................ ....,J ..... ~ ...... 
- Biphenylene" 
21.11.85 Prof. K.H. Jack (Newcastle) 
"Chemistry of Si-Al-0-N Engineering Ceramics" 
28.11.85 *Dr. B.A.J. Clark (Kodak Ltd.) 
"Chemistry & Principles of Colour Photography" 
28.11.85 
15.01.86 
23.01.86 
29.01.86 
Prof. D.J. Waddington (York) 
"Resources for the Chemistry Teacher" 
Prof. N. Shephard (East Anglia) 
"Vibrational and Spectroscopic Determinations of the 
Structures of Molecules Chemisorbed on Metal Surfaces" 
Prof. Sir Jack Lewis (Cambridge) 
"Some more Recent Aspects in the Cluster Chemistry of 
Ruthenium and Osmium Carbonyls" 
Dr. J.H. Clark (York) 
"Novel Fluoride Ion Reagents" 
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30.01.85 *Dr. N.J. Phillips (Loughborough) 
"Laser Holography" 
12.02.86 
12.02.86 
13.02.86 
Dr. J. Yarwood (Durham) 
"The Structure of Water in Liquid Crystals" 
Prof. O.S. Tee (Concordia University, Montreal) 
"Bromination of Phenols" 
Prof. R. Grigg (Queen's, Belfast) 
"Thermal Generation of 1,3-Dipoles" 
19.02.86 *Prof. G. Proctor (Salford) 
"Approaches to the Synthesis of some Natural Products" 
20.02.86 *Dr. C.J.F. Barnard (Johnson Matthey Group) 
"Platinum Anti-Cancer Drug Development" 
26.02.86 
27.02.86 
05.03.86 
Miss C. Till (Durham) 
"ESCA and Optical Emission Studies of the Plasma 
Polymerisation of Perfluoroaromatics" 
Prof. R.K. Harris (Durham) 
"The Magic of Solid State NMR" 
Dr. D. Hatlway (Durham/ 
"Herbicide Selectivity' 
05.03.86 * Dr. M. Schroder (Edinburgh) 
"Studies on Macrocyclic Complexes" 
06.03.86 * Dr. B. Iddon (Salford) 
"The Magic of Chemistry" 
12.03.86 
14.05.86 
09.06.86 
23.06.86 
16.10.86 
Dr. J.M. Brown (Oxford) 
;;l.!helate I.Jontrol in Homogeneous Catalysis" 
Dr.P .R. R. Langridge-Smi th (Edinburgh) 
"Naked Metal Clusters - Synthesis, Characterisation and 
Chemistry" 
Prof. R. Schmutzler (Braunschweig, W. Germany) 
"Mixed Valence Diphosphorus Compounds" 
Prof. R.E. Wilde (Texas Technical University, USA) 
"Molecular Dynamic Processes from Vibrational 
Band shapes" 
Prof. N.N. Greenwood (University of Leeds) 
"Glorious Gaffes in Chemistry" 
23.10.86 *Prof. H.W. Kroto (University of Sussex) 
"Chemistry in Stars, between Stars and in the 
Laboratory" 
29.10.86 * Prof.E.H. Wong (University of New Hampshire, USA) 
"Coordination Chemistry of P-0-P Ligands" 
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05.11.86 Prof. D. Dopp (University of Duisburg) 
"Cyclo-additions and Cyclo-reversions Involving 
Captodative Alkenes" 
06.11.86 * Dr. R.M. Scrm~ston (University of Hull) 
"From Myth and Magic to Modern Medicine" 
13.11.86 *Prof. Sir G. Allen (Unilever Research) , 
"Biotechnology and the Future of the Chemical Industry" 
20.11.86 *Dr. A. Milne and Mr. S.Christie (International Paints) 
"Chemical Serendipity: A Real Lite Case Study" 
26.11.86 
27.11.86 
03.12.86 
08.12.86 
22.01.87 
28.01.87 
Dr. N.D.S. Canning (University of Durham) 
"Surface Adsorption Studies of Relevance to 
Heterogeneous Ammonia Synthesis" 
Prof. R.L. Williams (Metropolitan Police Forensic 
Science) 
"Science and Grime" 
Dr. J.J. Miller (Dupont Central Research, liSA) 
"Molecular Ferromagnets; Chemistry and Physical 
Properties" 
Prof. T. Dorfmuller (University of Bielefeld~ 
"Rotational Dynamics in Liquids and Polymers' 
Prof. R.H. Ottewill (University of Bristol) 
"Colloid Science a Challenging Subject" 
Dr. W. Clegg (University of Newcastle-upon-Tyne) 
"Carboxylate Complexes of Zinc; Charting a Structural 
Jungle" 
04.02.87 *Prof. A. Thomson (University of East Anglia) 
"Metalloproteins and Magneto-optics" 
05.02.87 
11.02.87 
Dr. P. Hubberstey (University of Nottingham) 
"Demonstration Lecture on Various Aspects of Alkali 
Metal Chemistry" 
Dr. T. Shepherd (University of Durham) 
"Pteridine Natural Products; Synthesis and Use 1n 
Chemotherapy" 
12.02.87 * Dr. P.J. Rodgers (I.C.I. Billingham) 
"Industrial Polymers from Bacteria" 
17.02.87 * Prof.E.H. Wonrr (University of New Hampshire, USA) 
"Symmetrical §hapes from Molecules to Art and Nature" 
19.02.87 * Dr. M. Jarman (Institute of Cancer Research) 
"The Design of Anti Cancer Drugs" 
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04.03.87 Dr. R. Newman (University of Oxford) 
"Change and Decay: A Carbon-13 CP/MAS NMR Study of 
humification and Coalification Processes" 
05.03.87 *Prof. S.V. Ley (I~perial College) 
"Fact and Fantasy in Organic Synthesis" 
09.03.87 
11.03.87 
12.03.87 
17.03.87 
18.03.87 
Prof. F.G. Bordwell (Northeastern University, USA) 
"Carbon Anions, Radicals, Radical Anions and Radical 
Cations" 
Dr. R.D. Cannon (University of East Anglia) 
"Electron Transfer in Polynuclear Complexes" 
Dr. E.M. Goodger (Cranfield Institute of Technology) 
"Alternative Fuels for Transport" 
Prof. R.F. Hudson (University of Kent) 
"Aspects of Organophosphorus Chemistry" 
Prof .. R.F. Hudson (University of Kent) 
"Homolytic Rearrangements of Free Radical Stability" 
03.04.87 *Prof. G. Ferguson (University of Guelph, Canada) 
"X-Ray Crystallography for the Organic Chemist" 
06.05.87 
07.05.87 
11.05.87 
27.05.87 
Dr. B. Bartsch (University of Sussex) 
"Low Co-ordinated Phosphorus Compounds" 
Dr. M. Harmer (I.C.I. Chemicals & Polymer Group) 
"The Role of Organometallics in Advanced Materials" 
Prof. S. Pasynkiewicz (Technical University,Warsaw) 
"Thermal Decomposition of Methyl Copper and its 
Reactions with Trialkylaluminium" 
Dr. AI. Blackburn (University of Sheffield) 
"Phosphonates as Analogues of Biological Phosphate 
Esters" 
24.06.87 *Prof. S.M. Roberts (University of Exeter) 
"Synthesis of Novel Antiviral Agents" 
26.06.87 
15.10.87 
Dr. C. Krespan (E.I. Dupont de Nemours) 
"Nickel(O~ and fron(O) as Reagents in Organofluorine 
Chemistry' 
Dr. M.J. Winter (University of Sheffield) 
"Pyrotechnics" (Demonstration Lecture) 
22.10.87 *Prof. G.W. Gray (University of Hull) 
29.10.87 
04.11.87 
"Liquid Crystals and their Applications" 
Mrs. S. van Rose (GeoloRical Museum) 
"Chemistry of Volcanoes 
Mrs. M. Mapletoft (Durham Chemistry Teachers' Centre) 
"Salters' Chemistry" 
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05.11.87 Dr. A.R. Butler ~University of St.Andrews) 
"Chinese Alchemy' 
12.11.87 *Prof. D. Seebach (E.T.H. Zurich) 
"From Synthetic Methods to Mechanistic Insight 11 
26.11.87 * Dr. D.H. Williams (University of Cambridge) 
"Molecular Recognition" 
.11.87 Dr. J. Davidson (Herriot-\vatt University) 
"Metal Promoted Oligomerisation Reactions of Alkynes" 
03.12.87 *Dr. J. Howard (I.C.I. Wilton) 
"Chemistry of Non-Equilibrium Processes" 
10.12.87 
16.12.87 
Dr. C.J. Ludman (Durham University) 
"Explosives" 
Mr. R. M. S\..rart (I. C. I.) 
"The Interaction of Chemicals with Lipid Bilayers 11 
19.12.87 *Prof. P.G. Sammes (Smith, Kline and French) 
"Chemical Aspects of Drug Development" 
21.01.88 *Dr. F. Palmer (University of Nottingham) 
"Luminescence" (Demonstration Lecture) 
28.01.88 
09.02.88 
11.02.88 
18.02.88 
25.02.88 
. 03.03.88 
07.03.88 
16.03.88 
Dr. A. Cairns-Smith (Glasgmv University) 
"Clay Minerals and the Origin of Life" 
Mr. Lacey (Durham Chemistry Teacher's Centre) 
"Double Award Science" 
Prof. J.J. Turner (University of Nottingham) 
"Catching Organometallic Intermediates" 
Dr. K. Borer (Univ.of Durham Industrial Research Labs.) 
"The Brighton Bomb - A Forensic Science View)" 
Prof. A. Underhill (University of Bangor) 
"Molecular Electronics" 
Prof. W.A.G. Graham (University of Alberta, Canada) 
"Rhodium and Iridium Complexes in the Activation of 
Carbon-Hydrogen Bonds 
Prof. H.F. Koch (Ithaca College, U.S.A.) 
"Does the E2 Mechanism Occur in Solution" 
L. Bossons (Durham Chemistry Teachers' Centre) 
"GCSE Practical Assessment" 
07.04.88 * Prof. M.P. Hartshorn (Univ.of Canterbury, New Zealand) 
"Aspects of Ipso-Nitration" 
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13.04.88 
18.04.88 
Mrs. E. Roberts (SATRO Officer for Sunderland) 
Talk - Durham Chemistry Teachers' Centre 
"Links between Industry and Schools" 
Prof. C.A. Nieto De Castro (University of Lisbon and 
Imperial College) 
"Transport Properties of Non-Polar Fluids" 
25.04.88 * Prof. D. Birchall (I.C.I. Advanced Materials) 
"Environment Chemistry of Aluminium" 
27.04.88 Dr. R. Richardson (University of Bristol) 
"X-Ray Diffraction from Spread Monolayers" 
27.04.88 *Dr. J.A. Robinson (University of Southampton) 
"Aspects of Antibiotic Biosynthesis" 
28.04.88 Prof. A. Pines (Univ. of California, Berkeley, USA) 
"Some Magnetic Moments" 
11.05.88 * Dr. W.A. McDonald (I.C.I. Wilton) 
"Liquid Crystal Polymers" 
11.05.88 
08.06.88 
29.06.88 
29.06.88 
06.07.88 
Dr. J. Sodeau (University of East Anglia) 
Durham Chemistry Teachers's Centre: 
"Spray Cans, Smog and Society" 
Prof. J.-P. Majoral (Universite Paul Sabatier) 
"Stabilisation by Complexation of Short-Lived 
Phosphorus Species" 
Dr. M.E. Jones (Durham Chemistry Teachers' Centre) 
"GCSE Chemistry Post-mortem" 
Prof. G.A. Olah (University of Southern California) 
"New Asnects of Hvdrocarbon Chemistrv" 
- . 
Dr. M.E. Jones (Durham Chemistry Teachers' Centre) 
"GCE Chemistry A-Level Post-mortem" 
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